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Abstract 
 The recent advancements in stem cell biology have allowed for new and exciting 
opportunities to use stem cells in clinical and industrial applications. Stem cells have the 
unique ability to self-renew and differentiate into any specialized cell type found in the 
body. Using certain mechanical and biochemical cues, stem cells can be directed to become 
any specific cell type, such as hepatocytes. A robust and efficient process for expansion 
and differentiation to generate large quantities of functional hepatocytes from stem cells 
will be essential to establishing a stem cell bioprocess in the future for therapeutic and 
industrial applications of hepatocytes.  
 In this study, a differentiation protocol with soluble growth factors and cytokines 
was used to mimic the key signaling cues during embryonic development. However, most 
directed differentiation processes have run into issues with limited scalability and lack of 
functionality in the differentiated cells. In an effort to bring stem cell therapy closer to 
reality, our strategy was to use a systems-based approach to enhance the quality and yield 
of stem cell-derived hepatocytes.  
 To achieve higher cell yield, we modified an existing differentiation protocol to 
incorporate a cell expansion stage to facilitate simultaneous differentiation and cell growth. 
Using transcriptome analysis and mass cytometry, we showed how the population of cells 
changed over time on both the transcript and protein level. Both analyses revealed that with 
the new expansion stage, we obtained a higher quantity of hepatocytes within the same 
time frame compared to the conventional method of differentiation. We then showed the 
capability to scale up our differentiation for larger scale cultures by adapting the expansion 
stage onto Cytodex 3 microcarriers. Using the same culture volume as a tissue plate culture, 
we demonstrated the ability to achieve up to a 5-fold increase in cell number with a final 
cell density in the range of 4-5x106 cells/ml. These strategies show that the demand for 
large quantities of hepatocytes can be met by translating the conventional method of 
differentiation to suspension microcarrier differentiation.  
 Encouraged by our ability to yield higher cell density using microcarrier culture, 
we explored assessing the functional maturity of our stem cell-derived hepatocytes using 
transcriptome analysis. We showed that stem cell-derived hepatocytes are still clearly 
different when compared to primary hepatocytes at the transcriptome level. In addition to 
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evaluating cells using transcriptome analysis, we wanted to be able to compare the current 
in-vitro processes to embryonic liver development to understand the genetic roadblocks. 
The transcriptome data from hESCs hepatocyte differentiation was integrated with mouse 
liver development using principal component analysis and batch corrections. This allowed 
us to create a unified developmental scale to compare samples from different species and 
in-vitro to in-vivo platforms. The meta-analysis revealed that stem cell-derived hepatocytes 
are equivalent to the functional maturity of developing cells at E15 in mouse development.  
 From the transcriptome analysis, we observed many different genes in energy 
metabolism with dynamic behavior over the course of differentiation. We sought to 
understand the effect of changes in different metabolic genes and the impacts on metabolic 
transition during differentiation. We characterized the energy metabolism of hESCs and 
assessed the metabolic demand of cells at different stages of differentiation.  hESCs and 
early differentiated cells exhibited a high glycolytic flux. transitioning towards an oxidative 
metabolism as the differentiation progressed. Furthermore, using confocal microscopy, we 
also characterized the activity and morphology of the mitochondria in the cells at different 
stages of differentiation. Using the consumption rates of different nutrients as an input to 
our metabolic flux model along with our transcriptome findings, we were able to gain a 
deeper understanding of the metabolic behavior of cells during differentiation. Our analysis 
revealed that cells consume lower amounts of glucose over the course of the differentiation 
but become more efficient at transporting pyruvate into the mitochondria leading to 
increased oxidative phosphorylation. However, our metabolic and transcriptome data 
revealed that our stem cell-derived hepatocytes are not capable of mature metabolic 
functions such as gluconeogenesis, supporting the immature phenotype that has been 
described in literature.  
 Together, these studies reveal that stem cells can provide a renewable and scalable 
source of hepatocytes for therapeutic applications. These cells demonstrate some 
phenotypic and functional properties of primary hepatocytes but have some contrasting 
elements compared to their in-vivo counterparts that will need further genetic intervention 
to enhance their maturation before cellular therapy can become a reality. However, this 
work is invaluable as it contributes to the current status of the field and facilitates the 
translation of laboratory practices of stem cell culture into a scalable technology.  
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Chapter 1 : Introduction 
1.1 Introduction 
The liver is the largest internal organ inside the human body. This organ is responsible 
for many important functions including drug metabolism and detoxification, protein 
synthesis, energy metabolism, synthesis of biochemical for digestions, and many more 
functions that are necessary for maintaining homeostasis within the organism. Many of 
these functions are carried out by the parenchymal cells found in the liver, commonly 
referred to as hepatocytes, which make up 70-85% of the liver mass.  
Although the liver is inherently capable of regeneration following any acute injury, 
typical liver disorders and end-stage liver diseases can compromise the regenerative 
capability and result in liver failure and ultimately death. Currently, there are many options 
to alleviate the effects of liver failure. However, there is only one viable treatment option 
through liver transplantation. As of 2016, there are currently over 14,000 people on the 
waitlist for liver transplantation in the United States alone and half of those patients will 
die annually due to the shortage of donors (1). Thus, the shortage of donor organs and risks 
present with liver transplantation presents serious limitations to the liver transplantation 
approach that will need to be addressed.  
There have been alternative solutions that have been proposed to address these issues. 
Hepatocyte transplantation has shown to have promising results especially in liver-based 
congenital and metabolic disorders. Bioartificial liver devices which rely on using 
hepatocytes from a variety of cell source (e.g. porcine, human, stem cell derived, etc.) can 
use the mechanical and cellular components of the device to provide temporary assistance 
until a donor organ is available. In these alternative treatment options, primary human 
hepatocytes are the preferred cell source due to its lower risk in immunogenicity and exact 
match with the human physiology. However, primary hepatocytes have limited 
proliferation and the availability of donor liver for isolation of liver cells is still far below 
what is demanded.  
With the recent advances in developmental biology and the emergence of stem cell 
therapy, many have attempted to use stem cells as an alternative cell source for obtaining 
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hepatocytes. Using our understanding of embryonic liver development, many groups 
including our own have developed a differentiation protocol to use different biochemical 
and/or mechanical cues to mimic the embryonic development for generating hepatocytes 
from stem cells.  Through the sequential stages of different growth factors and cytokines, 
stem cells can be guided through different developmental stages to give rise to cells, 
referred to as hepatocyte-like cells, that are functionally and phenotypically similar to 
primary hepatocytes.  
Stem cell fate determination is typically the result of very complex processes through 
the combination of soluble signals, physical stimuli, and cell-cell interaction. Embryonic 
stem cells are isolated from the inner cell mass during embryonic development. It can be 
hypothesized then that the differentiation of stem cells towards the hepatic lineage will 
follow similar progression as in-vivo liver development. In recent history, stem cell 
research has made tremendous strides in using different strategies to generating 
hepatocytes from different stem cell and progenitor cell populations. The simplicity of the 
culture systems developed for in-vitro differentiation will need to be well thought out to 
meet the demands in the complexity of embryonic development. In addition, the issue of 
being able to design different platforms for generating hepatocyte cells in a scalable manner 
to meet the demand for hepatocytes in clinical and industrial applications will also have to 
be kept in mind.  
1.2 Research Objectives 
The goal of this study is to establish a robust platform for the generation of functional and 
mature stem cell-derived hepatocytes in a scalable manner for clinical and industrial 
applications. The key objectives in meeting this goal are: 
Objective 1: To improve the cell yield of the directed differentiation of hESCs to 
hepatocytes by incorporating an endodermal expansion stage to mimic the embryonic 
development 
Objective 2: To develop a microcarrier based culture system for scalable expansion 
and differentiation of endodermal cells towards the hepatic lineage 
3 
 
Objective 3: To perform a systems-based study using transcriptome data to understand 
the transcriptional control of different gene expression that are vital to generating 
hepatocyte-like cells 
Objective 4: To understand the metabolic changes that hESCs undergo during the 
differentiation to hepatocyte-like cells and characterize the nutrients demand of cells 
at different stages of differentiation for future studies using environmental monitoring 
and control 
1.3 Scope of Thesis  
 A detailed literature review is presented in Chapter 2. The first part of this chapter 
serves as an introduction to using stem cells and its defining characteristics to address liver 
failure. The second part of the chapter provides background information on our current 
understanding in the metabolic profile of stem cells and hepatocytes. This has been utilized 
to gauge the progression of stem cells towards the hepatic lineage and identify the ability 
of stem cells to adopt the metabolic elements of a hepatocyte. The final part of this chapter 
highlights the current status in in stem cell technologies and the options that are available 
for generating hepatocytes from stem cells in a bioprocess manner.  
 Chapter 3 presents a detailed list of all the materials and universal methods that are 
employed in the different studies in this thesis. Chapter 4 focuses how cell yield can be 
improved by utilizing an endodermal cell population and comparing it to the conventional 
method of differentiation at the transcriptomic and protein level. Chapter 5 presents a 
comprehensive study between in-vitro differentiation and in-vivo development to 
understand the progression of stem cells towards the hepatic lineage and what further steps 
need to be taken to improve the maturity of stem cell-derived hepatocytes. Chapter 6 
focuses on understanding the metabolic profile of our cells during the differentiation 
process and how to use different cell culture conditions to improve the maturity of our 
differentiation for future scalable reactor studies. We also  describe the studies that were 
conducted to improve the scalability of differentiation by adapting our protocol described 
in chapter 4 to being carried out on microcarriers.  Finally, in Chapter 7, a conclusion 
summarizing the findings and their relevance to the field of stem cell is presented along 
with potential routes for the future work that still need to be investigated further.  
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Chapter 2. Background 
2.1 An Introduction to Stem Cells 
 Stem cells are a unique cell type defined by their ability to self-renew, to 
differentiate into different cell types, and to functionally reconstitute tissue in-vivo. These 
capabilities make stem cells an attractive candidate in the field of regenerative medicine 
and tissue engineering. With the emergence of stem cells and as our understanding on stem 
cells continue to grow, we can begin asking fundamental questions on the mechanisms 
behind the self-renewal and different differentiation processes to become specialized cell 
types that make up our body. Currently, the field has already begun to evaluate the potential 
of stem cells in different applications for studying different diseases and drug toxicity 
studies. As our knowledge in stem cell biology improves, we can begin to evaluate the 
possibility of using stem cell based therapy to treating diseases like diabetes, liver cirrhosis, 
Parkinson’s disease, and many others.  
 Stem cell technology will play a key part in the utilization of stem cells not only for 
the purposes of research and fundamental biology but also for the pharmaceutical industry 
in therapeutical settings as well as for drug screening studies. The hopes of the next 
revolution of medicine with stem cells will rely heavily on our understanding of the biology 
and mechanisms regulating stem cells and its properties. In these next few sections, we will 
be discussing the different properties of stem cells and the impact it can have for 
regenerative medicine especially for liver failure. Finally, we will explore the status of 
generating hepatocytes from different types of stem cells and the properties of those stem 
cell-derived hepatocytes. 
2.2 Properties of Stem Cells 
 A cell is characterized as a stem cell for fulfilling three unique characteristics: self-
renewal, potential for multi-lineage differentiation, and in-vivo reconstitution of certain 
tissues.  
2.2.1 Self-Renewal 
 Self-renewal is typically the first property that is used to define a stem cell. 
Normal somatic cells can only undergo a limited number of cell division before 
senescence occurs. This phenomenon is typically referred to as the Hayflick’s limit (2). 
Unlike somatic cells however, stem cells have the capability to self-renew in its potency 
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state through large numbers of cell division giving rise to more daughter cells with the 
same genetic properties as the parental cell.  Although the mechanisms of self-renewal 
still remain a major topic of research, it has long been accepted that the immortal 
proliferative capacity of tumor and cancerous cells have been linked to the activity of the 
enzyme, telomerase, and maintenance of the telomere length (3, 4). Thus, there have been 
many studies and debates on the activation of the telomerase in playing a role for the self-
renewal capability in stem cells. Recently, there is growing evidence that telomerase is 
activated in different stem cells and the level of activation is dependent on the type of 
stem cells which gives rise to the different rates at which senescence occur at (5). It 
should be noted that the activation of telomerase to relieve telomere shortening is a 
necessary step for the onset of cancer and have resulted in heavy investigations between 
the mechanisms between self-renewal and the mechanisms of cancer. There are still 
ongoing debates as to whether the activation of telomerase and slowing down of 
telomeres will be the key to longevity but how that is balanced with the onset of tumor 
remains to be seen. Through these efforts, a different type of stem cells is believed to 
exist within different tumors and cancer that is now commonly referred to as “cancer” 
stem cells. These cancer stem cells are believed to be the reason for metastasis of cancer 
even after different cancer treatments but the existence of these cells are still under heavy 
debate that is beyond the scope of this thesis. Nonetheless, the reasons behind the self-
renewal behavior of stem cells and the factors regulating this process will be critical for 
the purposes of obtaining large numbers of cells in a renewable manner for the different 
clinical and industrial applications envisioned for regenerative medicine and tissue 
engineering (6). 
2.2.2 Potency 
 The second property that stem cells possess that will be described in this chapter is 
the ability of stem cells to differentiate into specialized cell types that make up the human 
body. The differentiation potential of a stem cell is defined as its potency. The regulation 
of potency and self-renewal typically go hand in hand and recent studies have shown that 
the mechanisms behind the degree of potency and self-renewal might be more closely 
related than previously thought. Stem cells can remain uncommitted for long periods of 
time generating new daughter cells with the same potency. It is because of these behaviors 
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that stem cells has become a key renewable cell source for regenerative medicine. Several 
transcription factors have been found to be important regulators in maintaining the 
undifferentiated state of a stem cell along with different chromatin-modifying enzymes, 
regulatory RNA molecules, and signal-transduction pathways (7-11). Three major 
transcription factors (Oct4, Sox2, Nanog) have been found to be essential in promoting the 
expression of genes to maintain pluripotency while also repressing genes that induce 
differentiation (12). The importance of these transcription factors was further demonstrated 
when somatic cells were transfected with these factors were found to become induced 
pluripotent stem cells (iPSCs).  
There are different degrees of potency that is generally designated based on the 
number of cell types that the stem cell can differentiate into. Typically, potency can be 
divided into four major classes: totipotency, pluripotency, multipotency, and unipotency. 
Totipotent cells can become any cell type of embryonic and extraembryonic origin found 
in the organism (13). These cells are typically found after the fusion between a sperm cell 
and an egg cell. Pluripotent stem cells are stem cells designed as capable of differentiating 
into any of the three germ layers: endoderm, ectoderm, and endoderm (13) . The most 
commonly found pluripotent stem cells are embryonic stem cells or iPSCs. Multipotent 
stem cells are typically capable of differentiating into a limited number of cell types 
typically to a subset of cells found such as cells found within the hematopoietic system 
(13).  Unipotent stem cells are the least potent type of stem cells that can give rise to only 
one particular specialized type but is still capable of self-renewal. These types of cells are 
typically referred to as precursor cells such as hepatic precursor cells or cardiac precursor 
cells (14, 15).  
2.3 Types of Stem Cells 
2.3.1 Pluripotent Stem Cells 
 Embryonic stem cells (ESCs) are pluripotent stem cells derived from the inner cell 
mass during the blastocyst stage of development. These type of stem cells are still the most 
widely studied in stem cell research. Mouse ESCs were first isolated in 1981 and were 
found to have the remarkable capability to re-enter embryogenesis after injection into a 
pre-implantation embryo and functionally contribute to all the tissues and organs of a new 
mouse (16). Due to the pluripotent nature of cells, they emerged as promising potential 
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tools for clinical applications. These isolated mouse ESCs were then injected into animal 
models and pre-implantation embryo and found capable of forming teratomas consisting 
of tissues from all three germ layers. Then, in 1998, Thomson et al. was able to successful 
derive human ESCs from human blastocysts showing remarkably similar properties as 
mouse ESCs. Both human and mouse ESCS were further characterized by the expression 
of the transcription factors, Oct4, Nanog, Sox2, Rex, and the surface markers SSEA-1 (17). 
The expression profile of pluripotent cells were universally defined by the presence and 
expression of these key genes that are now commonly referred to as pluripotent genes.  In 
addition to the phenotypic expression profile, ESCs were found to have unlimited 
proliferative capacity along with a high nucleus to cytoplasm ratio (18, 19).  These cells 
were initially isolated and routinely cultured on a layer of irradiated mouse embryonic 
fibroblasts (MEFs) in the presence of serum. The MEFs were found to release certain 
growth factors and cytokines that help maintain the pluripotent nature of ESCs (19, 20). 
Although, for the purposes of clinical and industrial applications, there will need to be 
extensive studies to try and replace MEFs and serum to have more defined media 
components either using various cytokines or other sources of feeder layer from human 
(21). In addition, the research of ESCs had a period of controversy if it was ethical to 
conduct research that involved the development, use, and destruction of human embryos. 
In addition, there was issues raised whether ESCs-derived cells for cellular therapy would 
trigger an immune response since ESCs were derived from embryos with a specific 
immunogenic state and not designed to specifically match the immunogenic state of the 
patient (22-25). Nonetheless, as the stem cell and regenerative medicine field begin to 
advance, studies have shown that ESCs can be used to treat certain disorders and diseases 
in numerous clinical trials. 
 However, at the time due to these concerns, in 2006 a research group in Japan 
discovered a new pluripotent population called induced pluripotent stem cells(12). These 
cells showed the pluripotent nature but was generated through a process termed “cellular 
reprogramming”. Through the expression of a combination of different key transcription 
factors involved in pluripotency, somatic cells could be reprogrammed to a stem cell-like 
fate and exhibit many pluripotent characteristics simply through the transfection of Oct4, 
SOX2, KLF4, and C-myc. These factors are now known as the Yamanaka factors to credit 
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the scientist that had discovered them. Since iPSCs can be derived from any somatic cells 
isolated from an individual, they not only bypass the need for embryos but it can be thought 
of as personalized medicine by using an autologous cell source that should not have the 
risk of immune rejection. To demonstrate the therapeutic concept of using iPSCs, a group 
used fibroblasts from a humanized sickle cell anemia model mice and reprogrammed them 
into iPSCs. The diseases iPSCs were corrected by using gene targeting and differentiated 
to hematopoietic progenitor cells to be transplanted back into the diseased mice showing 
rescue of the mice with the corrected iPSC-derived hematopoietic cells (26).  
 Pluripotent stem cells can be directed to differentiate towards any lineage of the 
three germ layers. There are a number of differentiation strategies that utilizes different 
mechanical or biochemical cues to mimic the embryonic development. One strategy is to 
allow stem cells to spontaneously differentiate and select for the desired cell type by sorting 
or selecting those that have the desired phenotype. However, this method can result in very 
heterogeneous culture with typically very low yield in desired cell type along with tedious 
labor to obtain the cell of interest. Thus, more recently as our understanding in 
developmental biology continues to improve, strategies of using directed differentiation 
through the addition of various cytokines and growth factors to mimic the signaling of in-
vivo development along with co-culture with certain cell types found in development can 
achieve in much higher cell yield and cell quality. Thus, while ESCs have the versatility to 
be used in a number of different applications, there are still many obstacles and unknowns 
that need to be sorted out before clinical therapies in human can be reached.  
2.3.2 Adult Stem Cells 
 Adult stem cells are typically derived from the tissues of post-natal or adult animals. 
These cells typically have a lower potency and limited self-renewal capability compared 
to pluripotent stem cells.  The most studied adult stem cells to date have been isolated from 
the bone marrow and are typically involved in the hematopoietic system. Adult stem cells 
have been believed to exist in every organ but exist at very low numbers and only resides 
in a stem cell ‘niche’ that favor’s their quiescent state. Once activated, they can proliferate 
and give rise to more adult stem cells and daughter cells that will differentiate towards a 
cell lineage. Although these properties are still being studied today, it is intuitive that these 
cells remain in an inactive state as they have limited proliferative capability but become 
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activated to replenish the cell population after the native population undergoes senescence. 
Once activated, these adult stem cells can proliferate and their daughter cells can either 
remain as stem cells or differentiate to the other specialize cell types. There are a number 
of different adult stem cells found in different organs and niches. Hematopoietic stem cells 
found in the bone marrow are the most well-known and well-studied adult stem cells. 
Neural stem cells are isolated from the brain and can give rise to the different populations 
that are found in the brain.  Mesenchymal stem cells are of the stromal origin that can be 
isolated from many of different tissues including lung, bone marrow, adipose, and molar.  
2.3.2.1 Liver Stem Cells 
 In our study, we were interested in generating hepatocytes from embryonic stem 
cells for the purposes of different liver applications. Thus, we considered the different 
populations of liver stem cells. Hepatocytes in the adult liver are capable of inherent 
regeneration upon acute liver injury. The isolation of hepatocytes from an adult mouse 
model have shown to be capable of up to 70 doublings and still engraft in the liver mass 
through serial isolation and transplantation (27). However, in certain incidents where there 
is chronic liver failure or severe liver injury, the regenerative capability of hepatocytes 
become compromise and the resident hepatic stem cells can proliferate and repair the liver 
in a process known as ductular reaction (28). There are still many debates and questions 
that remain as to how this process occurs and the mechanisms that trigger this process.  
However, many researchers and clinicians have referred to the proliferative hepatic stem 
cells that participates in regeneration as oval stem cells.   
Both populations of hepatocytes and the hepatic stem cells in the adult liver are 
capable of proliferation and reconstitution of the liver mass. Such potential can potentially 
be harnessed for in vitro culture and clinical applications.  However, our current culture 
systems have resulted in the lost of proliferative capacity as well as functional activity for 
hepatocytes. With the advances in our understanding of the nature of liver stem/progenitor 
cells, our ability to isolate and culture liver stem cells or progenitor cells has enhanced 
greatly in the past few years and will be key in translating this knowledge to differentiating 
hESCs into hepatocytes.  
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Study of liver stem/progenitor cells often employs partial hepatectomy or treatment 
with drugs like acetylaminofluoren in rodents. By BrdU labeling of proliferative cells in 
regenerating livers of rodents after induced acetaminophen injury, the region that stem cells 
reside and their niches were identified. Four differently labeled  stem cell populations were 
identified, namely periductal mononuclear cells and peribiliary hepatocytes along with 
cells in the canal of Hering and intralobular bile ducts (29). While most have accepted 
hepatoblasts as a key contributor to liver regeneration, Kuwahara’s finding raises the 
interesting notion that there may be multiple sources of this cell source that may be 
responsible for liver regeneration.  
The availability of genomic data and the enhanced capability to identify genes 
differentially expressed under different differentiation states helped identified markers 
suitable for cell isolation. The markers identified in rodents enabled selective isolation of 
the rodent counter parts in human liver and revealed interesting similarity between embryo 
liver development and adult liver regeneration in terms of delineation of liver cell 
differentiation (30-32).  
EPCAM has been a key marker for enriching both fetal and adult liver 
stem/progenitor cells in rodents as well as human(33-36).  Recently, the detection of high 
level expression of aldehyde dehydrogenase using a fluorescent substrate,  adult liver stem 
cells  from both mice and human liver were isolated without using any chemical stimuli to 
enrich their population (32). This methodology could possibly provide a readily robust 
method of isolating a relatively homogenous population of hepatic progenitor cells.  A 
recent review by Turner et al. summarizes current state of understanding of the locale of 
liver stem cells in liver lobule, their characteristics in human (37).  Readers are also referred 
to a more detail overview of the fetal and adults liver stem cells (38).  
Turner et al. presented a comprehensive descriptive progression of liver stem cell during 
the development of the liver. It is postulated that the hepatic stem cells reside in the 
periportal region of the liver, specifically the canal of Hering. As these cells proliferate 
“older” cells migrate along the cell plate toward central vein and grow more committed 
and mature; first becoming bipotential, then becoming proliferative hepatocytes, and 
mature hepatocyte. As they move toward central vein, they also become larger in size. 
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Further details regarding the origin and repair mechanisms are described elsewhere (37-
39) 
The hepatic stem cells have been isolated from both fetal liver and adult liver; 
whereas the mesonendodermal cells have only been reported from human fetal liver. Both 
precede the hepatoblast; although both share many markers of hepatoblasts including 
EPCAM, E-cadherin, CK8, CK18, CK19, both are also AFP and albumin negative. A 
distinction between hepatic stem cells and hepatoblast cells is their NCAM/ICAM-1 
expression; ++/- and -/++ for hepatic stem cell and hepatoblast respectively.  
Hepatic stem cells isolated from human adult liver are about 7-10 µm in diameter 
(32, 37); somewhat smaller than hepatoblasts in both adult and fetal liver (10-12 µm). They 
exhibit a high nucleus to cytoplasm ratio. Hepatoblasts are abundant in fetal liver (~80%), 
but decreases after birth to less than 0.01% in adult liver. In contrast, hepatic stem cells 
remain relatively stable comprising of about 0.5 to 1.5% of the liver cell mass throughout 
(40). 
In addition to growth factors, surface properties also affect the outcome of cell fate. 
Turner et al. reported that the both hepatic stem cells and hepatoblasts grew out from 
EPCAM sorted cell population when plated on plastic surface, but only hepatic stem cell 
colonies emerge when plated on STO feeder layer or a surface treated with ECMs like 
collagen I collagen III or angioblast feeder layer for hepatic stem cells and collagen IV, 
laminin or stromal feeder cells for hepatoblasts (30, 31, 33).   
2.4 Differentiation of Stem Cells to Hepatic Lineage 
 Because of the liver’s high regenerative capacity there has been a long history of 
research on liver stem/progenitor cells and on their in vitro expansion. Those attempts aim 
to expand cells already committed to a developmental path. This contrasts with the effort 
initiated after the isolation of embryonic stem cells, which seek to direct uncommitted cells 
to endoderm lineage and further down to hepatic path. Embryonic stem cells have huge 
self-renewal and differentiation capacity. If they can be expanded and guided to liver 
lineage a potentially unlimited supply of hepatocytes may ensue. The emergence of iPSCs 
only amplified the effort.    
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2.4.1 Differentiation of Hepatic Stem Cells 
Hepatoblasts and liver stem cells isolated from fetal and adult livers have been 
shown to differentiate to hepatocyte-like cells in culture. A combination of growth factors, 
HGF, EGF, Oncostatin and Dexamethasone administered over one week was used to 
induce hepatic differentiation for mouse hepatoblasts (32). Recently it was shown that the 
liver progenitor cells isolated from human adults can be expanded and differentiated to 
hepatocyte-like cells with many liver functions including urea synthesis, albumin secretion 
and CYP activity. Human hepatic stem cells were expanded in a medium known as 
Kubota’s medium which is a serum free medium composition with no copper and low 
calcium. These cells were induced to differentiate by supplementing Kubota’s medium 
with calcium, copper, glucagon and tri-iodothyronine. In this study, decellularized liver 
biomatrix was used as an ECM thereby reducing the need of commonly used growth factors 
HGF and EGF (41).  
The development of liver in vivo entails the specification to definitive endoderm 
(about E8.5 in mouse), followed by commitment to hepatoblast and formation of liver bud, 
and finally fully differentiated hepatocytes and the emergence of bile ducts. The 
progression of the development is guided by a number of inductive signals dynamically. 
The early differentiation to mesoendoderm and subsequent distinction of mesenchyme and 
endoderm is driven by Nodal ,BMPs, and Activin signaling  (42-44). Further signaling 
from the FGF and BMP family, specifically BMP4, FGF1, FGF2,FGF4 and FGF8, induce 
differentiation to hepatoblast. Liver bud formation is guided by the inductive signal of HGF 
and oncostatin which stimulate the hepatoblasts to differentiate towards hepatocytes.  
Most efforts in guiding the differentiation of pluripotent stem cells to hepatic lineage 
deploy growth factors to mimic the temporal dynamics of cues in hepatogenesis in-vivo. 
However, it should be noted that the development of the liver and any other tissue in vivo 
is a continuous process, whereas our efforts to replicate these processes tends to be in 
discrete stages. Each various protocol for guiding the differentiation of stem cells to hepatic 
lineage are segmented into different differentiation stages. Thus, each protocol may 
implement different numbers of stages, and different corresponding duration and medium 
composition.  Representative protocols used for differentiation to hepatic lineage in vitro 
are listed in Figure 2-1. 
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Figure 2-1. Hepatic Differentiation Protocols for iPSCs and ESCs. 
Most hepatocyte differentiation protocols start with Activin and Wnt3a for a 3-5 
day period to induce definitive endoderm commitment (42, 45-47). FGF and BMP plays a 
significant inductive role in promoting endodermal progenitor maintenance and expansion 
during the second stage of directed differentiation (48). Further treatment with a mixture 
of FGFs facilitates the commitment to hepatic fate or the equivalent of hepatoblast state in 
liver development.  The last stage often entails the use of oncostatin or follistatin and 
hepatocyte growth factor (HGF). It was previously reported that oncostatin-treated stem 
cells would lead to an increased activity level of STAT3 (49). HGF, shown to contribute 
to liver development in a STAT3-independent manner, is also often used in the last stage 
of directed differentiation toward hepatic lineage (49).  
2.4.2 Differentiation of Stem Cells using Gene Transfection 
A number of laboratories have demonstrated the differentiation of iPSCs to 
hepatocyte-like cells using the protocols developed for ES cells. It appears that the 
protocols developed for embryonic stem cells are mostly applicable to iPSCs. This opens 
the possibility of personalized hepatocyte-like cells for drug screening and even for 
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therapy.  However, deriving iPSC is a lengthy process.  Recently the feasibility of directly 
inducing fibroblastic cells to hepatic lineage through gene transfection mediated 
reprogramming was demonstrated in mice models. A combination of Hnf4a with Foxa1, 
Foxa2 or Foxa3 was used to transfect and reprogram adult mouse fibroblasts to 
hepatocytes-like cells which are called iHEP cells (50). The efficiency was about 1 in 1000 
of initially transfected embryonic fibroblasts. Interestingly the resulting iHep cells possess 
a very high proliferative potential, unlike the hepatocyte-like cells derived from from 
pluripotent cells which appear to die off in prolonged culture. In another study the over 
expression of Gata4, Hnf1α and Foxa3 along with p19Arf inactivation enabled mouse 
fibroblasts to become iHep cells (51). In this case inactivation of p19Arf suppressed 
senescence to enhance the chance of isolating reprogrammed cells.  
The reprogrammed iHep cells expressed key hepatic genes and other liver functions and 
successful engraftment was shown in animal models. The obvious question then is why 
does the resulting iHep cells have a higher proliferative potential compared to the 
hepatocyte-like cells derived from pluripotent cells. The differences and similarities 
between the different types of hepatocyte-like cells derived from stem cells along with 
primary hepatic stem cells have yet to be studied extensively. However, the approach will 
certainly see many in vitro applications if it can be shown to work in reprogramming human 
cells. 
2.5 Current Technology of Stem Cell Culture  
 With the recent advancements in stem cell biology and potential of stem cells for 
different applications, there has been an increasing interest in the development of stem cell 
bioprocess. In this area, researchers are focused on developing new ways for scalable 
expansion and differentiation of stem cells to meet the demand of different cells for 
different applications. However, current stem cell practices are routinely carried out on 
tissue culture plates where it does not come close to the scale that would be needed for 
tissue engineering and regenerative medicine. In addition, the need to have a robust 
bioprocess to have consistent and reproducible processes is very difficult to achieve in a 
tissue culture plate. As stem cells is very susceptible to slight changes in different culture 
environments, the inability to monitor and control the culture conditions poses a severe 
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problem to achieving well-defined outcomes. Thus, there has been large focus on using 
different bioreactor configurations to address the demand for large quantities of cells and 
have well-defined culture conditions to scale-up cultures with the ability to achieve 
continuous monitoring and control of the microenvironment of the cells.  In this section, 
we will be focused on the recent studies that has been carried out on translating laboratory 
stem cell practices to a technology.  
The most common cell culture practice carried out today is used for the 
manufacturing of different therapeutic proteins in the biopharmaceutical industry. For 
these biological processes, the end goal is to use a variety of cells (e.g. insect cells, Chinese 
Hamster Ovary Cells) to secrete the protein of interest in large tank reactors in a scalable 
manner. But as we discussed earlier before, the fundamental difference between future 
stem cell processes and current biological processes is that future stem cell bioprocess will 
require the separation and purification of the cells themselves from the process. To this 
end, we are interested in the generation and harvesting of the cells itself which will be our 
product. Thus, when designing a cell culture process for manufacturing stem cells we need 
to keep in mind what our product and objective is. 
2.5.1 Reactor Configurations for Stem Cell Culture  
Typical cell culture processes use different bioreactor systems for cell cultivation 
for a more scalable process. There are many different bioreactor configurations that are 
used in the industry to meet the demands of cells and the particular process in mind. 
However, the fundamental bioprocess engineering principles that include bioreactor design 
and process control that have been established for the traditional pharmaceutical industry 
can still be translated to stem cell cultivation.  
The most commonly used reactor system used today is the stirred reactor system 
where an impeller is use to mix the culture to achieve a homogenous environment and 
effective nutrient delivery. Most reactor systems used today can be coupled with automated 
programs to allow for continuous monitoring of the environment and different feedback 
controls to regulate the various chemical and physical parameters in the bioreactor (52, 53) 
Simple stirred reactors are easy to operate and facilitate larger quantity of cells with access 
to continuous information of  the process run. However, the presence of an impeller to 
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ensure homogenous conditions also poses hydrodynamic shear stress to the cells. A 
sufficiently high agitation rate should be established to ensure a homogenous environment 
and prevent agglomeration and microcarrier bridging without introducing too much shear 
stress. Although the simplicity and ease of stirred tank bioreactors have pushed it to the 
forefront of the bioreactor configurations for scalability, there are still many effects that 
have not been examined and other reactor configurations that can also meet the demand for 
scalability. 
The wave bioreactor is another bioreactor design that have been used in expanding 
cells especially in the area of cellular therapy for small to medium scales (54). These 
reactors are typically consisted of a disposable bag that is inoculated with media and cells 
that can be connected to several probes for monitoring. The wave reactor allows for ease 
of use and lower risk of contamination because of the pre-sterilization and one-time use. 
These culture bags can be placed on an apparatus to allow a rocking motion to create waves 
at the air-liquid interface in the bag, hence the name wave reactors. This will ensure a 
homogenous environment without the introduction of mechanical agitation seen in stirred 
tank reactors. However, this configuration has proven to be higher in cost and the 
demonstration of scalability is still limited.  
 
 In the field of bioprocess manufacturing, there has been a recent push toward 
continuous process with an emphasis of using perfusion systems. Currently, most reactor 
cultures are done in batch settings and scaled up from the seed train at smaller scales all 
the way to the manufacturing scale. However, this approach only harvests the product of 
interest at the largest scale where there are debates whether this is done in the most 
economical and efficient manner. In a perfusion setting, there would be a continuous 
process of harvesting and maintenance. Current reactor configurations can be modified to 
operate in a perfusion culture with continual exchange of media as fresh or recycled media 
is introduced (55). Currently, there are other bioreactor configurations that are designed 
specifically to serve a perfusion run; fixed bed, fluidized bed, and hollow fiber.  
One of the biggest difficulties in scaling stem cell culture is the ability to adapt stem 
cells to suspension culture for the different reactor configurations. Typically, most cells 
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grown in reactor systems can be grown as single cells or aggregates in suspension to allow 
for scalability. For non-adherent cells, single cells or aggregates are likely to be cultured 
in stirred tank to prevent the agglomeration and homogenous environment. As mentioned 
before, stem cells however, face very low viability and spontaneous differentiation when 
cultured as single cells.  There are some exception to certain stem cells such as 
hematopoietic stem cells which have been demonstrated to be viable as a suspension 
culture(56). Otherwise, most stem cells are unable to survive as dissociated single cells in 
a suspension culture (57). Thus, currently there are three cultivation formats that have been 
used for stem cell processes for scalability: i) non-adherent suspension culture ii) adherent 
layer culture and iii) aggregate culture.  Although most studies with stem cells are in the 
late phases of research and clinical trials, the current trend points towards the need to 
develop a platform to establish high cell doses for therapeutic purposes after the clinical 
trial phase.  
 For therapies that would require large quantities of cells, a lot of studies have relied 
on using the traditional stirred tank bioreactors. For instances, a lot of work have been 
focused on establishing the feasibility of maintaining and expanding mesenchymal stem 
cells (58-61), pluripotent stem cells (62-66), and hematopoietic stem cells (56, 67) in stirred 
tank bioreactors. These studies have established the foundation of using bioreactor systems 
to propagate undifferentiated cells in a scalable manner for inducing differentiation to a 
large quantities of cells towards a particular lineage. Most of these studies use microcarriers 
to provide a solid substrate for stem cells to adhere to for growth and survival. 
Microcarriers have long been used in the biopharmaceutical industry especially in the field 
of virus production (68-72). Because of the demonstration and understanding through 
current processes that use microcarriers in large scale settings, we believe that 
microcarriers are a viable option for scaling stem cell culture practices. The success of 
using microcarriers for stem cell culture practices will depend largely on the separation 
process which still pose as a critical issue for stem cell bioprocessing. There has been 
extensive research that are still ongoing regarding the design for isolation and purification 
that can be found in this comprehensive review (73).  
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 In addition to the different configurations of bioreactor systems, there are a number 
of different microcarriers that are out on the market that can be used for stem cell processes. 
The most commonly used microcarriers are solid microcarriers that are made of cross-
linked dextran, cellulose or polystyrene. These microcarriers allow for cell attachment and 
growth on the surface of the beads. Macroporous microcarriers are another type of 
microcarriers that are made of either gelatin or collagen that have pores that reach into the 
beads to provide additional surface area for further attachment and growth.  
Table 2-1. Attachment Efficiency of Human Embryonic Stem Cells on Different 
Microcarriers. [Modified from Thakur et al. 2015]  
Microcarrier Material 
Cell 
Attachment 
Cell 
Viability 
Cytodex 1 
Cross-linked dextran with N,N 
diethylaminoethyl groups Fair Poor 
Cytodex 3 
Cross-linked dextran immobilized with 
denatured collagen  Fair Fair 
Culti-sphere S 
Crosslinked pharmaceutical grade porcine 
gelatin Fair Poor 
Solo Hill F102 
Crosslinked polystyrene modified with 
cationic gelatin Poor N/A 
Solo Hill C102 
Crosslinked polystyrene modified with 
gelatin Poor N/A 
Solo Hill PP102  Cationic crosslinked polystyrene   
Poor N/A 
 
2.5.2 Media Design for Stem Cell Culture 
 One of the biggest market and influential scientific aspects in the stem cell industry 
is the media development. The current market for the stem cell industry was valued to be 
at $8.8 billion US dollars as of 2016 (74). Approximately a third of that value is estimated 
to come from stem cell products such as media and the different components. As our 
interest and potential of using stem cell grows, investment into this sector is expected to 
continue to grow at an exponential rate. Overall, we must harness our understanding of the 
different pathways and its effect on stem cell behavior in order to move the field forward. 
Without the proper medium and signaling cues, stem cells cannot behave the way we 
expect them to. In the past few decades, the focus of media development have been 
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optimized for the industrial mammalian cell culture processes for biologics. With the 
growing importance of stem cell research, the focus of medium design has been extended 
to enhancing stem cell behavior and growth.  Most cell types share a basic nutritional 
requirement to promote survival and growth. However, stem cells are more susceptible to 
varying levels of nutrients and the need for different growth factors and cytokines 
increasing the complexity of the design. In order to continue our progress in this sector, we 
must also improve in our techniques to meet the demand to grow and differentiate stem 
cells. In this section, we will focus on the different nutritional needs of stem cells that are 
known and how it will influence the translation of current stem cell research into a 
technology.  
 Most optimal medium are designed to mimic the chemical environment of the 
native environment of the cell origin. Although the native chemical environment has been 
proven to be feasible to maintain and promote survival of different cells, studies continue 
to provide us with additional information on the effect of different components on cell 
physiology and behavior. Depending on the objective of the process, a cell culture medium 
can vary its composition to meet the demand of the cells. Typical cell culture media 
contains small molecular weight components that are found in the interstitial fluid of the 
body. Although, the chemical composition may vary from tissue to tissue, there is a general 
composition of sugar, amino acids, vitamins, nucleotides, salts, and trace elements that 
compose the interstitial fluid.    
 The most common supplemented sugar in cell culture medium is glucose. Glucose 
is the basic component found in cell culture medium to provide fuel to the cells in the form 
of high energy phosphate bonds in ATP, hydrogen atoms associated through the co-
enzymes NADP and NAD as well as other nucleotide triphosphate (75, 76).  There are 
other forms of simple sugars such as fructose, mannose, and galactose that can provide 
energy to cells as well. However, the utilization of the sugar is dependent on the presence 
of the corresponding sugar transporter. GLUT is the transmembrane protein responsible 
for enabling transport of different sugars into the cell for metabolism. However, the 
different sugars are uptake and transported depending on which isozyme of GLUT is 
expressed. In most mammalian cells, GLUT1 is the predominant isozyme. Although 
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GLUT1 is predominantly responsible for transporting glucose, it has also been shown to 
transport other sugars such as galactose, mannose, and glucosamine (77). In stem cells 
where glycolysis is known to promote maintenance and growth, GLUT1 and GLUT3 are 
known to be the predominant isozyme (78, 79). Both isozymes have a fairly low Km making 
it have a higher affinity to glucose compared to the other GLUT transporters (80, 81). As 
a result, most mammalian cell culture utilize glucose as the major sugar for carbon in its 
medium. The physiological concentration of glucose in interstitial fluid is approximately 
1g/L. As a result, most cell culture medium is present from 1g/L to 5g/L depending on the 
application. The conventional wisdom is that the presence of higher glucose levels can lead 
to larger uptake of the glucose facilitating faster growth and lead to higher production of 
different proteins. However, recent studies have shown that high glucose can have 
detrimental effects on stem cells and its behavior (82, 83). However, the inherent glycolytic 
metabolism of stem cells requires that its medium be consist of high levels of glucose to 
prevent starvation of glucose and meet the demand of its high glycolytic state.  
 Nucleosides are another basic component present in basal medium that provide the 
cells with the basic building blocks to RNA and DNA. Nucleosides consists of adenosine, 
cytidine, guanosine, and uridine. The supplementation of nucleosides either through serum 
or exogenous nucleosides in serum-free medium can promote cell growth (84). When 
replication stress occurs in highly proliferative cells such as stem cells, nucleosides can be 
supplemented to prevent DNA damage (85).  In a recent study, the addition of nucleosides 
have shown to have an important role in stem cell reprogramming by reducing the number 
of genomic rearrangements during the reprogramming of somatic cells (86). Although the 
importance of nucleosides have been demonstrated, the presence of nucleosides are 
typically at very low quantity as they also make up only 5-10% of the cell mass (87).  
 In most cell culture processes, amino acids are typically the most varied depending 
on the cell type and cell stage. Amino acids are categorized into essential and non-essential 
amino acids. In some cells, they lack the biosynthetic pathways to make certain amino 
acids and are specified as essential amino acids that must be supplemented to meet the 
cell’s demand for it. This is key in medium design to understand the type of cell you have 
in culture and its biosynthetic capability. In certain tissues in-vivo, there are transport of 
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amino acids from one tissue to the next but in a more homogenous population of cells, they 
are limited by the biosynthetic pathways that are expressed in the cells. For instances, 
glutamine synthetase is typically expressed in cells in animals but after isolation this 
enzyme decreases after culture. As a result, the level of glutamine synthesis goes down 
requiring supplementation of glutamine into many cell culture media.  Glutamine is an 
essential amino acid that must be provided as it is typically the highest consumed amino 
acids of all the 20 amino acids present in the cell culture media. In culture, they are known 
to consume roughly 1/10 of the consumption rate of glucose. Through carbon tracing 
experiments, glutamine has been found to contribute to the TCA cycle as well as through 
lactate production. Although glutamine is a critical amino acid for energy source and 
nucleoside synthesis as well, excess glutamine can lead to detrimental effects as it is known 
to degrade in aqueous solution and release ammonium which is toxic to cells. Thus, the 
balance between cellular demand and supply must be planned out carefully in order to 
reduce the potential fatal effects to cells.  
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Chapter 3: Materials and Methods 
3.1 Human Embryonic Stem Cell Culture 
 The hES cell line H9 was predominantly used in all the experiments described in 
this thesis. However, it should be noted that there were other cell lines, HSF6 and HES3, 
that were also cultured to validate our findings but the results will not be present in this 
thesis. Therefore, all methods described was specifically carried out on the H9 cell line.  
 The human embryonic stem cell (hESC) line H9 was cultured using 80% Knockout 
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco/BRL), supplemented with 20% 
Knockout Serum Replacement (Gibco), 2.0 mM glutamine, 0.1mM nonessential amino 
acids (Gibco), 55 mM β-mercaptoethanol, and basic fibroblast growth factor (FGF2; 10 
ng/mL; R&D Systems). The cells were cultured on irradiated E13-E14 CF-1 mouse 
embryonic fibroblasts (MEFs; Charles River Laboratories, Wilmington,MA), at 37°C in 
10% CO2. The cells were passaged on a regular basis every 2–3 days using 0.1% (w/v) 
Collagenase Type IV (Gibco) in Knockout DMEM after reaching ~50% to 70% 
confluency. 
 In the metabolic studies, hESCs were cultured in feeder-free conditions to 
minimize the effects of feeder cells. hESCs were harvested/collected using 0.5mM EDTA 
(Corning) and cultured on 2% Matrigel® (BD Biosciences) coated plates in TeSR™-E8™ 
media (STEMCELL-Technologies).  
3.2 Hepatocyte Differentiation 
 H9 cells were plated in 12-well plates coated with 2% Matrigel_ (BD Biosciences) 
in mTeSR medium (STEMCELL Technologies) for 24 h or until confluency was reached. 
Differentiation was initiated by switching to differentiation medium consisting of a 60/40 
(v/v) mixture of low glucose DMEM (Gibco) and MCDB-201 (Sigma), supplemented with 
26 µg/mL ascorbic acid 3-phosphate (Sigma), linoleic acid and bovine serum albumin (LA-
BSA; Sigma; 0.25µg/mL BSA and 2.35 µg/mL linoleic acid), insulin-transferrin-selenium 
(ITS; Sigma; 2.5 µg/mL insulin, 1.38 µg/mL transferrin, 1.25 ng/mL sodium selenite), 0.4 
µg/mL dexamethasone (Sigma), 4.3 µg/mL b-mercaptoethanol (Hyclone), 100 IU/mL 
penicillin, and 100 mg/mL streptomycin (Gibco). Two percent fetal bovine serum was 
added to the media (v/v) in Stage I for the first 6 days and 0.5% (v/v) for the remaining 
period. The differentiation medium was supplemented with stage specific growth factors: 
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Stage 1, Activin A (100 ng/mL) and Wnt3a (50 ng/mL); Stage 2, FGF2 (10 ng/mL) and 
BMP4 (50 ng/mL); Stage 3, FGF8b (25 ng/mL), FGF1 (50 ng/mL), and FGF4 (10 ng/mL); 
and Stage 4, HGF (20 ng/mL) and Follistatin (100 ng/mL). Differentiations were carried 
out at 21% O2 and 5% CO2 with a 50% media change every 2 days during differentiation. 
A complete media change was performed when changing the stages of differentiation (ie, 
day 6, 10, and 14).  
3.3 Endodermal Differentiation on Microcarriers 
Cytodex 3, a crosslinked dextran bead with a thin layer of denatured collagen was 
used for providing a matrix for the growth and differentiation of adherent cells. Cytodex 3 
(GE Healthcare) was purchased as dry powder and prepared by washing 2g of microcarrier 
powder with PBS for 3 times. Swollen beads were suspended in 500 ml PBS and sterilized 
by autoclaving.  Different coating materials were used to coat Cytodex 3 and 
Matrigel™ was found to give the highest attachment efficiency for endodermal cells (Data 
not shown). Prior to differentiation, sterile microcarriers were coated with Matrigel™ for 
1h at 37°C. Coated microcarriers were washed with low glucose DMEM (Gibco) twice and 
incubated with Stage 2 medium. Differentiated endodermal cells were washed with PBS 
and harvested using 0.1% (w/v) Collagenase Type IV (Gibco) in Knockout DMEM (Gibco) 
as described previously (78). Endodermal cells were suspended in Stage 2 medium and 
added to 12mg/ml of Cytodex 3 at the concentration of 1 x 106 cells/ml in a 1.7 ml tube 
(Corning). The mixture was incubated for 3 hours at 37°C to allow for initial cell 
attachment to the beads with occasional shaking of the tube every half an hour. The cell 
suspension was transferred to an ultra-low attachment plate (Corning) at a starting cell 
concentration of 1 x 106 cells/ml with 2 mg/ml Cytodex 3 microcarriers. After three days 
of differentiation and expansion in stage 2 medium, cells were further differentiated  
towards hepatocytes as described previously (raju et al. 2016) 
3.4 Endodermal Cell Harvest and Expansion 
 For endodermal cell expansion, cells were harvested on Day 6 after the initiation of 
hepatocyte differentiation using 0.1% (w/v) Collagenase Type IV (Gibco) in Knockout 
DMEM and plated onto Matrigel pre-coated plates in Stage 2 medium containing FGF2 
(10 ng/mL) and BMP4 (50 ng/mL). A day after plating, the media was completely 
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replenished with Stage 2 medium to remove any unattached cells. On the 3rd day after 
plating, the cells were passaged again using 0.1% (w/v) Collagenase Type IV onto Matrigel 
coated plates in Stage 2 medium. This was demonstrated to be capable of up to 3 passages 
without dedifferentiation of endodermal cells into fibroblastic cells. Three days after the 
second passaging, the medium was changed to Stage 3 medium to continue the 
differentiation. 
3.4 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Total RNA was obtained from cell lysates using the RNAeasy Micro Kit (Qiagen). 
Briefly, cells in culture are lysed directly on the tissue culture dish surface or in a 15 ml 
Falcon tube for cells not attached. The lysing procedure involves aspirating the media, 
rinsing the cells once in PBS, and finally lysing the cells using RLT lysis buffer + 1% βME, 
as prescribed by Qiagen. Each sample is collected in 350 µL of lysis buffer, vortexed for 
30 second to homogenize the sample, and finally stored in a –80°C freezer for later 
processing. 
Complementary DNA (cDNA) was synthesized using the Superscript III Reverse 
Transcriptase Kit (Invitrogen) according to manufacturer’s instructions. Transcript 
abundance levels of a sample were normalized to the housekeeping gene, GAPDH. Gene 
expression is quantified relative to a housekeeping gene, typically GAPDH, and is typically 
expressed as either expression relative to GAPDH, log2(expression relative to GAPDH), 
fold change relative to a reference, or log2(expression relative to a reference). The 
following formulas are used to calculate these values:  
∆𝐶𝑡𝑡,𝑔𝑒𝑛𝑒 = 𝐶𝑡𝑡,𝑔𝑒𝑛𝑒 − 𝐶𝑡𝑡,𝐺𝐴𝑃𝐷𝐻 
Fold change relative to GAPDH = 2−(∆𝐶𝑡𝑡,𝑔𝑒𝑛𝑒) 
∆∆𝐶𝑡𝑡,𝑔𝑒𝑛𝑒 = ∆𝐶𝑡𝑡,𝑔𝑒𝑛𝑒 − ∆𝐶𝑡𝑡=𝑡𝑖,𝑔𝑒𝑛𝑒 
Fold change relative to time ti = 2−(∆∆𝐶𝑡𝑡,𝑔𝑒𝑛𝑒) 
 Sequences for the primers of the different genes used in this study are listed in 
Table 3-1. For comparison among cells at different stages of differentiation, some values 
were then transformed to be expressed as log10 (Expression level relative to hESC) instead 
of log2.  
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Table 3-1. Primer Sequence 
Genes Forward sequence Reverse sequence 
AAT (H9) TTTAAAGGCAAATGGGAGAG CCTAAACGCTTCATCATAGG 
AAT (HSF6) GTCAAGGACACCGAGGAAGA TATTTCATCAGCAGCACCCA 
AFP (H9) CCTACAATTCTTCTTTGGGCT AGTAACAGTTATGGCTTGGA 
AFP (HSF6) AAATGCGTTTCTCGTTGCTT GCCACAGGCCAATAGTTTGT 
ALB TGGCACAATGAAGTGGGTAA CTGAGCAAAGGCAATCAACA 
CXCR4 AACTTCAGTTTGTTGGCTGC GAAACAGGGTTCCTTCATGG 
CYP3A4/5/7 AAGTCGCCTCGAAGATACACA AAGGAGAGAACACTGCTCGTG   
CYP3A7 TGCTTTGTCCTTCCGTAAGGG CAGCATAGGCTGTTGACAGTC 
CYP7A1 CTGAGGCTTTCCAGTGCCT AGGTAGTCTTTGTCTTCCCGT 
E-CADHERIN 
(HSF6) 
CGAGAGCTACACGTTCACGG GTGTCGAGGGAAAAATAGGCTG 
E-CADHERIN (H9) CGAACTATATTCTTCTGTGAGAGG GATAGATTCTTGGGTTGGGTC 
FOXA2 ATTGCTGGTCGTTTGTTGTG TACGTGTTCATGCCGTTCAT 
G6PC GTGTCCGTGATCGCAGACC GACGAGGTTGAGCCAGTCTC 
GAPDH (H9) TGGTATCGTGGAAGGACTCATGAC ATGCCAGTGAGCTTCCCGTTCAGC 
GAPDH (HSF6) GAGTCAACGGATTTGGTCGT GACAAGCTTCCCGTTCTCAG 
GSC TCTCAACCAGCTGCACTGTC CCAGACCTCCACTTTCTCCTC 
HAND1 CCATGCTCCACGAACCCTTC CCTGGCGTCAGGACCATAG 
HNF1 GTGGCGAAGATGGTCAAGTCC CCCTTGTTGAGGTGTTGGG 
HNF1 AGGCCACAATCTCCTCTCAC TTGCTGGGGATTATGGTGGGA 
HNF4 TGTACTCCTGCAGATTTAGCC CTGTCCTCATAGCTTGACCT 
MIXL1 GGATCCAGGTATGGTTCCAG CATGAGTCCAGCTTTGAACC 
NKX6.1 TCAGGTCAAGGTCTGGTTCC TCAACAGCTGCGTGATTTTC 
OCT4 (H9) GATGGCGTACTGTGGGCCC TGGGACTCCTCCGGGTTTTG 
OCT4 (HSF6) CTTCGCAAGCCCTCATTTC CCTTGGAAGCTTAGCCAGGT 
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SOX17 CGCACGGAATTTGAACAGTA GGATCAGGGACCTGTCACAC 
SNAI2 CGAACTGGACACACATACAGTG CTGAGGATCTCTGGTTGTGGT 
TTR (H9) AAACCAGTGAGTCTGGAGAG CTGTGAATACCACCTCTGCA 
UGT1A1 CAACTGCCTTCACCAAAATCCA GCAAGATTCGATGGTCGGGTT 
MPC1 ACT ATG TCC GAA GCA AGG ATTTC CGCCCACTGATAATCTCTGGAG 
MPC2 TACCACCGGCTCCTCGATAAA TATCAGCCAATC CAG CAC ACA 
HK1 GCTCTCCGATGAAACTCTCATAG GGACCTTACGAATGTTGGCAA 
HK2 GAGCCACCACTCACCCTACT CCAGGCATTCGGCAATGTG 
HK3 GGACAGGAGCACCCTCATTTC CCTCCGAATGGCATCTCTCAG 
GCK CCTGGGTGGCACTAACTTCAG TAGTCGAAGAGCATCTCAGCA 
GLS2 AACGAATCCCTATCCACAAGTTCA GCAGTCCAGTGGCCTTTAGTG 
GLS1 TGGTGGCCTCAGGTGAAAAT CCAAGCTAGGTAACAGACCCTGTT T 
 
 
3.5 Immunofluorescence   
 Cells were either grown on tissue culture plates or on glass coverslips that were 
placed inside tissue culture plates in the cases of higher magnification microscopes. The 
presence of proteins are visualized under a fluorescent microscope by marking the proteins 
of interest with fluorescent dyes attached to specific antibodies or secondary antibodies 
that interact with primary antibodies for the proteins. Cells in culture are washed once with 
PBS and then fixed for 15 minutes at room temperature with 4% formalin. 
 Fixed cells were washed with PBS once and then blocked with phosphate buffered 
saline (PBS) containing 0.2% Triton X-100, and 1% donkey serum or BSA (Sigma) at 
room temperature for 1 h. After blocking, samples were incubated with primary antibodies 
AFP (1:1,000; Dako), ALB (1:1,000; Dako), SOX17 (1:20; R&D Systems), Forkhead Box 
A2 (FOXA2; 1:1,000; Abcam), AAT (1:,1000, Abcam) and DAPI (1:500; Life 
Technologies) overnight at 4°C. The cells were then incubated with secondary antibodies 
[anti-mouse IgG1 Alexa Fluor 488 labeled (1:500 dilution;Molecular Probes), anti-rabbit 
IgG Alexa Fluor 488 (1:500 dilution; Molecular Probes), or anti-mouse IgG Alexa Fluor 
555 (1:500 dilution; Molecular Probes)] for 30 min at room temperature. Negative controls 
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were cells incubated with only the relevant isotype control and secondary antibody. 
Dilutions and vendor of each antibody are provided in Table 3-2. Images were taken using 
an Olympus FluoView FV1000 BX2 confocal microscope at the University Imaging 
Center (Minneapolis, MN) or a Zeiss AxioVert 200M inverted fluorescence microscope at 
the Stem Cell Institute.  
Table 3-2. Antibody Concentration and Vendor Information 
Name  Company  Catalog no.  Dilution  Type  
AFP  Dako  A0008  1:1000  Primary  
ALB  Dako  A0001  1:1000  Primary  
FOXA2  Abcam  ab40874  1:1000  Primary  
SOX17  Abcam  ab84990  1:20  Primary  
AAT Abcam Ab9373 1:1000 Primary 
Goat IgG  Jackson 
Immunoresearch  
005-000-003  Same as primary  Isotype  
Rabbit IgG  Jackson 
Immunoresearch  
011-000-003  Same as primary  Isotype  
Donkey anti-goat 
Alexa 555 (red)  
Invitrogen  A-21432  1:500  Secondary  
Goat anti-rabbit 
Alexa 555 (red)  
Invitrogen  A-21429  1:500  Secondary  
Goat anti-rabbit 
Alexa 488 (green)  
Invitrogen  A-11008  1:500  Secondary  
Goat anti-mouse 
Alexa 488 (green) 
Invitrogen A-21121 1:500 Secondary 
Hoechst 33258 Sigma  33258  1:500  Secondary  
 
3.6 Mass Cytometry 
 Antibodies were purchased from R&D systems and conjugated with different 
elemental isotopes with different masses according to the manufacturer’s protocol using 
the MaxPar® antiobidy labeling kit (Fluidigm). The concentration of the metal conjugated 
antibodies was measured using the absorbance reading at 280nm and diluted to 0.5 mg/mL 
in antibody stabilizer PBS (Candor Biosciences) with 0.05% sodium azide and stored in 
4°C until further use.  
 Lyophilized antibodies for FOXA2, SOX17, AFP, ALB, DLK1, A1AT and HNF4α 
proteins were obtained from R&D systems. About 200 μg of antibodies were conjugated 
with a selected panel of heavy metal isotopes. The antibodies were eluted in 50 μl PBS 
instead of W buffer provided in the kit and this was found to improve antibody recovery. 
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Metal conjugated CXCR4 and CD44 were directly obtained from DVS Sciences. Cells 
were dissociated into single cells by treatment with 0.1% collagenase in DMEM and 
trypsin as described previously.  About 500,000 cells per time point were fixed using 10% 
formalin for 20 minutes at room temperature. The cells were washed with PBS, centrifuged 
and each cell pellet were suspended in 5 μL Human TruStain FcX™ (BioLegend, 422302) 
and 95 μL PBS at room temperature for 10 minutes for blocking. The cells were first 
incubated in a cocktail of metal conjugated antibodies targeting surface markers in 100 μl 
of PBS for 30 minutes at room temperature. The concentration for each marker used is 
provided in Table 3-2.Cells were washed twice with PBS and incubated with a second 
cocktail of antibodies targeting intracellular proteins suspended in 100 μl SAP buffer (PBS 
with 0.1% (w/v) saponin (Sigma, 47036) and 0.05% (w/v) sodium azide (Sigma, 438456) 
for 30 minutes at room temperature. After washing the cells twice with SAP buffer, cells 
were incubated with MaxPar® Intercalator-Ir 125 μM (DVS Sciences, 201192A) at a 
dilution of 1:1000 in 1 ml of SAP buffer overnight at 4°C. Cells were washed twice, 
suspended in 500 μl water and passed through cell strainer and were run on the CyTOF2 
instrument (DVS Sciences). During titrations, an antibody cocktail was made at 8 μg/ml 
and serially diluted twofold to achieve a wide range of concentrations. The negative control 
used was hESCs. It was critical to run a negative control for every titration as well as 
experiment in case of changes in antibody activity. Data was analyzed using the Cytobank 
software and visualized in Spotfire (Tibco). 
 
Table 3-3: Antibodies for Mass Cytometry 
Antigen  Vendor  Catalog 
number  
Metal 
Conjugated  
Concentration  
SOX17  R&D  AF1924  Sm154  4 μg/ml  
FOXA2  R&D  AF2400  Gd156  4 μg/ml  
AFP  R&D  AF1369  Nd143  4 μg/ml  
DLK1  R&D  MAB1144  Tm169  4 μg/ml  
ALB  R&D  MAB1455  Er166  4 μg/ml  
A1AT  R&D  AF1268  Tb159  4 μg/ml  
CXCR4  DVS  3175001B  Lu175  2 μg/ml 
CD44 DVS 3171003B Yb171 2 μg/ml 
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3.7 Analysis of Mass Cytometry using Spanning-Tree Progression Analysis of 
Density Normalized Events (SPADE)  
 FCS files were obtained for each sample from the CyTOF2 and reanalyzed in the 
FlowJo software. For further analysis of mass cytometry and carry out clustering at the 
single cell level, each fcs file for each sample was concatenated and normalized by 
assigning the same DNA intercalator median intensity value for each sample. A metal-
encoded DNA intercalator, Ir191 and Ir193, was used to label nucleated cells. Events with 
very low intercalator reading (<20) or very high (>5000) were removed to exclude cell 
debris and cell aggregates. The normalized fcs files were analyzed and visualized further 
using the Cytobank software (Fluidigm). For Spade analysis, arcsinh was used to transform 
the intensity and cluster into 75 nodes. Because SPADE analysis is clustering based on the 
value of intensity, the SPADE tree can be annotated in a quantitative manner by labeling 
high, moderate, and low expression for certain markers. The SPADE trees were then 
overlaid for each sample to show the population distribution for that particular sample.  
3.8 Functional Analysis of HLCs  
 Several functional assays were carried out to determine the functional maturity of 
HLCs. Albumin secretion was measured using a quantitative ELISA kit (Bethyl 
Laboratory) following the manufacturer’s instructions. An internal standard, provided with 
the kit, was used to obtain a four-parametric equation to enable the best estimation of the 
albumin concentration in our samples. The albumin concentration in the sample was then 
subtracted from the amount present in the fresh media to quantify the amount secreted by 
the cells after 1 or 2 days of incubation. The cell number was measured by trypan blue 
exclusion and the albumin secretion was reported as pg/cell/day.  
 Urea secretion was also measured by using an QuantiChrom Urea Assay Kit 
(BioAssay Systems) according to the manufacturer’s instruction. Briefly, cells were rinsed 
with PBS and then grown in the hepatocyte differentiation media with 1mM ammonia-
bicarbonate with 0.5% FBS for 24 h. Supernatant was collected and measured using the kit 
and reported on a per cell basis as well.  
 Periodic Acid-Schiff staining was performed using a kit from Sigma Aldrich by 
immersing the cells in the Periodic acid solution for 5 mins and then in the Schiff’s reagent 
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for 15 minutes. The cells were then washed with PBS before taking it to microscopy for 
visualization.  
 To test for the function of drug metabolism, several CYP450 enzymes were 
measured at the transcript level after induction through the exposure of rifampicin. Cells 
were washed with PBS and then immersed in media with 50 µM rifampicin (Gold 
Biotechnology. The transcript levels of CYP2A6, CYP2C8, and CYP2C9 were measured 
using qRT-PCR. 
3.9 Transcriptome Analysis 
 Total RNA was extracted from different samples during hESC differentiation at 
different time points of differentiation as well as endodermal cell expansion using the 
RNease Mini kit. Samples were hybridized to the Illumina HT12 bead array v3 (Illumina 
Inc). CEL files were processed using RMA summarization and transcriptome data from 
over 34,000 probes representing about 20,000 genes were obtained. Data was processed 
using the lumi pacakage in R. First, intensity values were condensed to a single value based 
on common ENSEMBL ID. Next, data was normalized using either linear or quantile 
normalization in MatLAB where the linear normalization was set to have 500 as the median 
intensity. Briefly, principal component analysis (PCA), hierarchical clustering, and NMF 
was performed in R. The algorithm and criteria will be described more in depth in later 
sections.  
3.10 Western Blot  
 Cells were washed with cold PBS before being harvested and lysed using cold 
RIPA buffer (Abcam) with a cold plastic cell scraper. Cells were stored on ice in RIPA 
buffer and centrifuged in a microcentrifuge at 4°C for 30 min at 12,000 rpm. The 
supernatant was transferred to a fresh new tube and stored on ice, where the cell pellet was 
discarded. Protein quantification was carried out using the Pierce™ BCA Protein assay kit 
(Thermo #23227) following the manufacturer’s instructions. To reduce and denature the 
sample, NuPage™ LDS Sample buffer (4X, Thermo) was added depending on how much 
protein to load along with 1ul of β-mercaptoethanol. Each cell lysate was boiled in the 
buffer at 100°C for 5 min. 15 ug of protein were separated using Bolt™ 4-12% Bis-Tris 
Plus gels (Thermo). The primary antibody used were anti-COX1(1:5000, Cell Signaling 
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Technology), anti-COX2(1:5000, Cell Signaling Technology),anti-COX3 (1:2000, 
Abcam) , and anti-βActin (1:1000,Cell Signaling Technology). The secondary antibody 
used was goat anti-rabbit IgG HRP (1:50,000, Santa Cruz). For signal development, the 
SuperSignal West Pico Chemiluminescent Substrate kit (Thermo Scientific) was used. 
3.11 Mitochondria Biogenesis 
 Mitochondria DNA was measured using a Mitochondria DNA isolation kit 
(AbNova KA0895). Briefly, cells were harvested using Collagenase Type IV and 
centrifuged at 600g for 5 minutes at 4°C. Cells were resuspended in 1X Cytsol Extraction 
Buffer and incubated on ice for 10 min. Cells were homogenized using a tissue grinder. 
The homogenate was centrifuge at 600g at 10 min at 4°C. The supernatant was transferred 
to a new tube and centrifuged at 10,000g for 30 min at 4°C. The pellet was resuspended in 
1ml 1X Cytsol Extraction Buffer and centrifuged at 10,000g for 30 mins at 4°C. The 
supernatant is removed and the pellet is lysed with mitochondria lysis buffer and kept on 
ice. Enzyme B was added and incubated at 50°C until solution becomes clear and then 
absolute ethanol is added and stored in -20°C for 10 min. The solution is centrifuged and 
the pellet can be resuspended in water for quantification using a nanodrop at 250nm.  
3.12 Metabolite Measurement  
 Supernatant was collected every other day for assessing the concentration of 
different metabolites.  
3.12.1 Glucose Measurement 
Glucose was measured using Infinity Glucose Hexokinase (Thermo) following the 
manufacturer’s instruction. Briefly, for glucose concentration measurements, 196 µL of 
the hexokinase reagent solution (containing NAD, ATP, HK, G-6-PDH) was pipetted into 
a 96 well plate.  4 µL of distilled water (for blank), standard solution (1-0.0125 g/L 
glucose), or sample was then added, the plate was shaked to allow the mixture to mix. The 
reaction was allowed to be completed for 5 minutes at room temperature and the 
absorbance was measured at 340 nm against distilled water as reference. The glucose 
concentration of the unknown sample was then given by: 
sample blank
std blank
A A
    .
A A
dilution Std Conc

 

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where 
finalinitial AAA   
The control solution contained 1 g/L substrate and was serially diluted to create a standard 
curve.  
3.12.2 Lactate Measurement 
Lactate measurements were carried out using a lactate assay kit (Sigma) following 
the manufacturer’s instruction. Briefly, a lactate standard was created using the 100nmol/µl 
lactate standard and diluted with lactate assay buffer to create a 1nmol/µl solution. The 
reaction mix containing lactate assay buffer, lactate enzyme mix, and lactate probe was 
mixed with the sample and allowed to incubate in the dark at room temperature for 30 min. 
The reading was measured at 570nm and the concentration was determined based on the 
equation from the standard curve.  
3.12.3 Amino Acid Measurement 
Amino acid concentration was measured by HPLC (Agilent) using a 4.6 x 150mm 
Zorbax Eclipse Plus C-18 column (Agilent) with the derivatization reagents, 
OPA(Agilent) and FMOC (Agilent). Cysteine, tryptophan and proline cannot be 
measured by the OPA method and thus FMOC was purchased to resolved the remaining 
amino acids. The mobile phases consist of: 
Mobile Phase A: 
 10mM Na2HPO4  (pH 8.2)    
 10mM Na2B4O7       
 5mM NaN3    
 
Mobile Phase B: 
 Acetonitrile     45% v/v 
 methanol     45% v/v 
 water      10% v/v 
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 The flow rate of the mobile phase was maintained at 1.0 mL/min and the gradient 
profile was as follows: 
                     Table 3-4. HPLC Gradient Profile. 
Time (minutes) % A % B 
 0 – 0.5 98 2 
0.5  98  2 
20 43  57 
20.1   0 100 
23.5 0 100 
23.6 98 2 
25 End end 
The exact concentration of the amino acids was determined by comparing the observed 
peaks with those generated from fresh media and its known amino acid concentration.  
3.12.4 Ammonia Measurement 
Ammonia was measured using an ammonia diagnostic kit (Sigma, St. Louis, MO 
for the determination of ammonia concentration for each sample.  The assay is based on 
reductive amination of 2-oxoglutarate, using glutamate dehydrogenase (GLDH) and 
nicotinamide adenine dinucleotide phosphate (NADP) as follows: 
  GLDH32-oxoglutarate NH NADPH  glutamate NADP     
The decrease in absorbance at 340 nm due to disappearance of NADPH is proportional to 
the ammonia concentration. 
150 µL of ammonia assay solution (containing 2-oxoglutarate and NADPH) was pipetted 
into several wells of a 96 well plate.  10 µL of distilled water (for blank), control solution 
(for standard), or sample was added.  The cuvettes were allowed to equilibrate for 5 minutes 
at room temperature.  The initial absorbance of each cuvette at 340 nm was measured 
against distilled water as reference.  5 µL of GLDH solution was then added to each well 
and the reaction was allowed to occur for 5 minutes after gentle shaking.  The final 
absorbance was again measured at 340 nm against distilled water as reference.  The 
ammonia concentration was then given by: 
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..ConcStddilution
AA
AA
blankstd
blanktest 


 
where 
finalinitial AAA   
The control solution used had a concentration of 5 mg/L and a standard curve was 
generated through serial dilution. 
3.12.5 Oxygen Consumption Measurement 
 Oxygen consumption was measured with the NeoFox Software viewer using the 
NeoFox-GT fluorimeter coupled with the FOSPOR-R Oxygen Sensor probe (NeoFox). 
Cells were harvested and submerged in an Eppendorf tube with no air bubbles to allow for 
oxygen diffusion. The change in oxygen level would be due purely to oxygen consumption 
by the cells.  
3.12.6 Specific Consumption/Production Rates 
Metabolic consumption/production rates were calculated based on the cell count 
for each day. The viable and total cell concentration was measured by trypan blue dye 
exclusion using a hemacytometer. 1ml of the sample was vortex to ensure homogenous 
mixing and then 10µL of the sample was diluted with 10 µL of the 0.1% trypan blue 
solution. The mixture was transferred to the hemacytometer and viewed under the 
microscope. The cell count is given by: 
(number of cells x dilution) / (number of 1 mm2 box) x 104 (cells/ml)  
 The specific consumption/production rates were determined by: 
Consumption rate = 
𝑆𝑡𝑉𝑡−𝑆𝑡𝑜𝑉𝑡𝑜
𝛥𝑡∗𝐶𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟
 where S is the substrate concentration and V is the 
volume of media 
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Chapter 4: Endodermal Cell Expansion During Hepatocyte 
Differentiation 
 
4.1 Introduction 
 Pluripotent stem cells possess the ability to provide a renewable source of 
hepatocytes upon differentiation overcoming the issues of donor shortages. In our 
laboratory, we had established a protocol capable of differentiating pluripotent stem cells 
to the hepatic lineage using a sequential treatment of growth factors and cytokines that 
mimic embryonic liver development. In the past few years stem cell research has made 
significant advances; stem cells and progenitors cells isolated from various sources can 
now be expanded in cell number and differentiated towards the liver lineage in vitro.  This 
has brightened the prospect of generating large numbers of functional hepatocytes for 
applications in hepatic cell transplantation, extracorporeal liver-assist devices and in liver 
tissue engineering. Because of the prevalence of liver diseases, the severity of liver failure 
and its lack of curative treatments, it is imperative that we further advance stem cell based 
regenerative medicine for liver disease treatment. In addition to liver failure treatment, 
many congenital liver disease will also benefit from stem cell based therapy.  
 Our understanding of liver development has aided in different groups in developing 
different strategies to obtaining HLCs from stem cells (88-90). The differentiated cells by 
the end of every differentiation process result in cells with remarkably similar properties 
as primary hepatocytes. However, with the promises of stem cell in the field of regenerative 
medicine especially for chronic liver failure or liver diseases, low cell yield from a current 
differentiation is still a major hurdle that needs to be addressed. It is anticipated that any 
therapeutic applications requiring hepatocytes would be in the order of 109–1010 
cells/treatment. To derive HLCs currently, stem cells are expanded to the required quantity 
before undergoing differentiation toward the hepatocyte lineage. An alternative strategy to 
circumvent this issue would be to not only expand stem cells in their pluripotent state but 
also devise a methodology to expand PSC-derived progeny during their differentiation 
toward hepatocytes. We hypothesized that with the appropriate signaling cues, it may be 
37 
 
possible to expand the number of cells during the process of in vitro hepatocyte 
differentiation by mimicking the native proliferation that occurs naturally in vivo. 
 To date, there has not been a report of simultaneous in vitro proliferation and 
differentiation of PSC-progeny, just like in vivo fetal liver development. There have been 
multiple reports on selective surface markers that could be used for isolation of renewable 
hepatocyte progenitor cells (91-93). In one study, hepatocyte progenitor cells were 
enriched using the surface markers EpCAM or N-cadherin and, subsequently, expanded on 
stromal feeder layers (93). In addition, a self-renewing endodermal cell line was reported 
where CXCR4+/CD117+ cells were sorted and expanded on mouse embryonic feeders (48). 
During liver development, cells can undergo extensive proliferation using the signaling 
cues from their surrounding environment to increase the liver mass. In this chapter, we 
demonstrated the expansion of an early stage of endodermal intermediates without the need 
for cell sorting or relying on feeder cells that were previously described in other studies. 
This method was still able to show the ability to achieve higher yields of HLCs after 
subsequent differentiation of these endodermal intermediates from the same starting cell 
number of hESCs. 
4.2 Results 
4.2.1 Expansion of Endodermal Cells 
 In this study, we showed that during hepatocyte differentiation from hESCs, an 
intermediate population could be expanded similar to in-vivo development and 
simultaneously differentiated to the hepatic lineage to give larger quantities of HLCs as 
shown in Figure 4-1. hEScs were differentiated to the definitive endoderm stage using a 
medium containing Activin and Wnt3a to reach cell densities of 2.5 x 105 cells/cm2 in six 
days. The resulting endoderm cells were then detached by 0.1% collagenase treatment and 
passaged at ~6 x104 cells/cm2 onto Matrigel coated plates in Stage 2 medium containing 
FGF2 (10ng/ml) and BMP4 (50ng/ml). The morphology of the cells immediately after 
plating and before passaging are shown in Figure 4-2. Cells adhered to the surface a few 
hours after plating and expanded up to 4-fold in viable cell number after 3 days. Cells were 
then passaged again in Stage 2 medium containing FGF2 and BMP4, which have been 
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reported to provide the necessary proliferative cues to endodermal cells during embryonic 
liver development (94).  
 The endodermal cell population expanded approximately eightfold after two 
passages as shown in Figure 4-3. These populations will be referred to as EN1 and EN2 
where the number denotes the passage number that these cells have undergone. Further 
passages beyond the second passage were carried out, resulting in cell expansion up to 15-
fold; however, we detected an increasing population of cells with a fibroblastic morphology 
that would overtake the native population. By contrast, when we tracked the cell expansion 
during Stage 2 of the conventional differentiation method without passaging, we observed 
that the cell expansion was limited only up to twofold as shown in Figure 4-3. Thus, by 
implementing two passaging steps during the hepatic endoderm commitment stage, we 
could induce an eightfold expansion by providing additional surface area with the signaling 
cues of Stage 2 medium.  
4.2.2 Expression of Hepatic Genes and Protein Levels During Expansion Process 
 We evaluated the expression of pluripotency, endoderm, and hepatic endoderm 
related genes in cells during the expansion by qRT-PCR and immunostaining. Expression 
of Octamer-binding transcription factor 4 (OCT4), a master regulator of the pluripotency 
network in hESCs (95), decreased about 1,000-fold during the course of endodermal 
expansion as shown in Figure 4-4. The endodermal transcription factor, goosecoid 
homeobox (GSC), a key marker for differentiating definitive and visceral endoderm (96), 
and CXCR4, a surface marker coexpressed with GSC (96), were both highly expressed in 
the D6 population, but decreased in the EN1 and EN2 populations (Figure 4-4). Our 
hypothesis was that similar to in vivo development, ESC-derived DE cells can proliferate 
while at the same time differentiate to hepatic endoderm. In addition, we saw a higher 
expression of endodermal markers and lower expression of pluripotent markers in the new 
expansion protocol possibly due to the preferential attachment of endodermal fated cells 
compared to undifferentiated hESCs.  
 We also evaluated the expression of the genes indicative of maturation to hepatic 
committed endoderm and hepatoblasts. In line with our hypothesis, the decrease in DE 
marker gene transcripts was accompanied by almost 1,000- fold increase of the transcript 
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level of alpha-fetoprotein (AFP) and albumin (ALB) over the expansion period (97). These 
dynamics of gene expression suggest the gradual transition of an endodermal-committed 
phenotype toward a more hepatic phenotype during the expansion process. 
We also compared the transcript levels of hepatic endoderm/ hepatoblast genes in 
the EN1 and EN2 populations to cells obtained at the end of Stage 2 (D10) and Stage 3 
(D14) from the conventional differentiation process without cell expansion. Expression 
levels of OCT4, CXCR4, and GSC in EN1 and EN2 cells were similar to those in D10 and 
D14 cells, respectively (Figure 4-4). Levels of the hepatic transcripts, AFP and ALB, 
increased more gradually in the conventional method of differentiation (D10 and D14), 
compared to cells undergoing cell expansion (Figure 4-4). 
The transition from an endoderm to a more hepatic stage was also examined by 
immunostaining in both the conventional and expansion method as shown in Figure 4-5. 
FOXA2 and SRY (Sex determining Region Y)-Box 17 (SOX17), key transcription factors 
in the establishment of DE, were prominent in the D6 stage, but diminished by the EN2 
and D14 stage. In contrast, AFP was absent in the D6 stage and became more prominent 
in both the EN2 and D14 population consistent with the transcript levels observed. The 
results suggest that cells undergoing expansion are differentiating simultaneously. 
4.2.3 Mass Cytometry and SPADE Analysis 
 To identify whether the increase in transcript for hepatic endoderm/hepatoblast 
marker genes and proteins during expansion was restricted to a differentiated 
subpopulation of cells, or was occurring in most of the population, we used mass cytometry 
to examine coexpression of a panel of endodermal and hepatic markers at a single cell 
resolution (98). Cells undergoing differentiation were labeled with stable isotopes of 
lanthanide heavy metal conjugated with antibodies against endodermal marker proteins 
(CXCR4, FOXA2, and SOX17) and hepatic marker proteins (DLK1, CD44, AFP, ALB, 
and AAT). 
 Similar to flow cytometry, the antibody-labelled cells were dissociated into single 
cells and analyzed at a single cell resolution for multiple markers at a time. However, 
instead of detecting using various fluorescent tags, the sorted cells are vaporized to leave 
the stable isotope tags to be analyzed by a time of flight (TOF) mass spectrometry. In the 
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TOF analysis, different antibody tags will give sharp and distinctive signatures 
corresponding to its conjugated metal isotope, allowing for quantification of each labelled 
antibody without the need of resolving spectrum spillover or overcoming auto-fluorescence 
that normally occurs in multiple parametric flow cytometry. 
 Due to the complexity of the many markers that was used to label a particular cell, 
three-dimensional (3D) diagrams were used to efficiently plot the different marker 
expression levels. During the course of differentiation, various combinations of marker 
expressions were plotted as 3D diagrams with three markers represented along the X, Y, 
and Z axes and CD44 represented as a color gradient as shown in Figure 4-6 and 4-7. Still, 
with such plots it is not easy to gain a global view of the evolution of the population during 
the directed differentiation. Thus, we used the expression level of all eight markers to 
characterize the co-expression in the different populations using SPADE, which groups the 
cells into a defined number of clusters based on its expression pattern (99). 
The SPADE analysis utilizes a combined dataset that consists of all the markers’ 
expression level for cells of different differentiation stage during the directed 
differentiation as well as the expansion stages. The dataset was then clustered into 75 nodes 
based on the expression level of the eight markers for each cell, and the clustering results 
are shown as a tree diagram (Figure 4-8). Each node constitutes a cluster of cells with a 
similar pattern of expression for all eight markers. Because eight markers are used, eight 
tree diagrams are used to present the results for each marker (Figure 4-8).  
Based on the expression pattern of the different lineage specific markers, certain 
nodes can then be assigned to one of three subpopulations: (A) endodermal cells, (B) 
hepatic endoderm/hepatoblasts, and (C) hepatoblasts/hepatocytes (Figure 4-8(a-h)). The 
designation of the different subpopulation is based on the expression pattern of the different 
markers. The following expression patterns were used to classify the subpopulations: (A) 
(CXCR4++/+ ∪ FOXA2++/+ ∪ SOX17++/+) ∩ DLK1- ∩ AFP- ∩ ALB1- ∩ AAT- (“++/+” 
denotes ranging from ++ to +, and “∪” and “∩” represent union and intersection, 
respectively). (B) encompasses three subclasses: (i) (CXCR4++/+ ∪ FOXA2++/+ ∪ 
SOX17++/+) ∩ (DLK1++/+ ∪ AFP++/+ ∪ ALB++/+ ∪ AAT++/+), (ii) CXCR4++/+/- ∩ 
FOXA2++/+/- ∩ SOX17++/+/- ∩ (DLK1++/+ ∪ AFP++/+) ∩ ALB+/- ∩ AAT+/-, or (iii) 
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CXCR4++/+/- ∩ FOXA2++/+/- ∩ SOX17++/+/- ∩ DLK1++/+/- ∩ AFP++/+/- ∩ (ALB+ ∪ AAT+). 
(C) CXCR4- ∩ FOXA2- ∩ SOX17- ∩ DLK1++/+/- ∩ AFP++/+/- ∩ ALB++ ∪ AAT++. The 
threshold for determining -/+/++ are described more in detail in the figure legend of Figure 
4-8. The nodes of the same subpopulation are encircled in a dashed line. However, not all 
nodes were assigned to a subpopulation, especially those with low expression levels of 
most markers which we believe to be non-hepatic or endodermal committed cells.  
To validate our classification of the nodes into the different subpopulations, we 
performed k-means clustering on the 75 nodes using the median intensity of each marker 
for each node. The clear majority of the nodes for subpopulations A (endodermal cells) and 
C (hepatoblast/hepatocytes) were assigned to its own distinct clusters. The majority of 
nodes in subpopulation B (hepatic endoderm/hepatoblasts) were mainly scattered across 
the two clusters (Figure 4-8i). The results of the k-means clustering illustrated that the 
majority of the nodes within a subpopulation were grouped to the same clusters supporting 
our classification of the 75 nodes into 3 subpopulations. 
The mass cytometry data for each stage of differentiation was then mapped to the 
previously made SPADE tree diagram to illustrate the heterogeneity of the different 
subpopulations within each stage. The fraction of cells that were classified to a node for a 
particular stage will then be illustrated by the size and color of the node (Figure 4-9). Using 
the fraction of cells for each subpopulation, we can then quantitatively determine the 
heterogeneity at each stage of the differentiation/expansion. On D6, 51% of the cells were 
definitive endodermal cells, expressing CXCR4, SOX17, or FOXA2. During the expansion 
stage (EN1 and EN2), the definitive endodermal cells decreased to less than 10% while the 
early hepatic endoderm/hepatoblasts increased steadily to over 50%. The decrease of 
definitive endodermal cells and increase of hepatic endoderm/hepatoblasts was similar to 
what we observed in cultures without expansion (from D6 to D14). At the end of the 
directed differentiation, a similar percentage of HLCs was obtained with cell expansion 
(75%) or without (76%). However, considering that the cell number had increased 
significantly at the EN2 stage compared to D14 of differentiation, the total number of 
hepatocytes obtained is substantially higher with cell expansion. 
42 
 
We also used immunostaining to examine key differentiation markers (costaining 
of AFP and ALB or FOXA2 and SOX17) to confirm the results of mass cytometry 
measurements. The percentage of cells that were positive for those markers were compared 
to that obtained using mass cytometry for different populations (Figure 4-10). Images of 
multiple microscopic fields for each population sample were randomly taken, and the 
number of all nucleated cells and fluorescently stained cells were quantified using 
CellProfiler (100). Some differences were observed between the percentage of cells stained 
and percentage through mass cytometry. However, these small differences in percentages 
between the two approaches were likely caused by the chosen threshold values of mass 
cytometry data classifying positive and negative cells. Nevertheless, the overall trend of 
the dynamics of marker expression was still the same in both immunostaining and mass 
cytometry results. 
4.2.4 Differentiation Potential and Functional Activity of Expanded Endodermal 
Cells 
The results of the mass cytometry studies suggested that the majority of the 
expanded cells (EN2) can differentiate to HLCs. To confirm that HLCs derived with or 
without cell expansion were of the hepatic phenotype, both populations were 
immunostained and shown to be positive for the hepatic marker, ALB (Figure 4-11). We 
evaluated he transcript level of key hepatocyte marker genes in D20-HLCs and in EN2-
HLCs, including phosphoenolpyruvate carboxykinase (PEPCK), alpha-1 antitrypsin 
(AAT), AFP, and ALB. The EN2-HLC population expressed all the hepatocyte transcript 
levels 102–105 higher compared to hESCs, similar to D20-HLCs (Figure 4-12a).     
Further characterization of the HLCs and EN2-HLCs were carried out by measuring 
the activity of drug metabolism. Drug exposure to hepatocytes often induces specific 
CYP450 enzymes involved in its metabolism. Following exposure to rifampicin, we could 
detect increased transcript levels of its corresponding CYP450 enzymes (CYP2C8, 
CYP2C9, and CYP2A6) in D20-HLCs and EN2-HLCs (Figure 4-12b) (101). The level of 
increase was comparable between EN2-HLCs and D20-HLCs. In addition to drug 
metabolism, albumin synthesis and urea secretion for both D20-HLC and EN2-HLC 
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populations were also measured and shown to be comparable (Figure 4-13a-b) (102). 
Glycogen synthesis was evident in both D20-HLC and EN2-HLC cells as assessed by 
Periodic acid-Schiff staining (Figure 4-13c). 
4.2.5 Comparative Transcriptome Analysis of Expansion and Differentiation 
The transcriptome of cells at different stages of directed differentiation was 
evaluated and subjected to PCA. The first two principal components (PCs) representing 
90% of the variance among all samples were chosen to plot all the samples in a two-
dimensional PC space as shown in Figure 4-14. ESC, D6, D10, D14, and D20-HLC lined 
up chronically in order according to their differentiation stages, with the least and most 
mature cells on the two separate ends of the plot. EN1, EN2, and D10 cells, all exposed to 
Stage 2 medium, cluster in a similar region, with EN1 and EN2 lying between D6 and D10 
cells. Both EN2-HLC and D20-HLC colocalize in the same region, almost overlapping one 
another, confirming their similarity despite the differences with respect to cell expansion. 
The gene expression dynamics of cells undergoing directed differentiation from both 
protocols was compared and plotted in groups of similar functional classes. Overall, the 
gene expression profiles show that, regardless of whether cells were expanded during the 
endodermal stage, their gene expression dynamics was very similar. The transcript level of 
pluripotent genes POU5F1, NANOG, SOX2, ZIC3, SALL4, and LIN28 decreased from 
the beginning of differentiation as expected (Figure 4-15). Endodermal genes EOMES, 
CXCR4, GSC, and SOX17 increased in the first stage of differentiation, then decreased in 
the following stages either accompanied by cell expansion or not (Figure 4-16).  
In the presence of Stage 2 medium, a gradual increase in the transcripts of 
hepatoblast and hepatic genes is seen during the course of differentiation, including 
transcripts for AFP, DLK1, TTR, and KRT8 (hepatoblast specific markers), as well as 
ALB, PEPCK, PCK2, transferrin (TF), and a1-antitrypsin (A1AT; more mature hepatocyte 
markers) (Figure 4-17). The expression level of genes pertaining to important liver 
functions such as glycolysis/gluconeogenesis, urea cycle, fatty acid metabolism, and drug 
detoxification was also similar in D20-HLCs and EN2-HLCs (Figure 4-18). The similarity 
in transcript levels of these genes gives further credence to the notion that although the 
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endodermal cells underwent expansion, they retained undiminished differentiation 
capability to HLCs to a degree similar to that of unexpanded endodermal cells. 
4.3 Discussion 
The differentiation of PSCs toward the hepatocyte lineage raises the possibility of 
having an unlimited supply of human hepatocytes for a number of cellular applications. 
Although all protocols vary somewhat, they typically consist of treating stem cells with a 
combination of growth factors/cytokines in stages to mimic the key signaling cues 
occurring during embryonic development. However, cellular proliferation, which is 
integral during in vivo development, is typically absent or minimal in directed 
differentiations of stem cells to hepatocytes. In this study, we purposefully introduced cell 
expansion during the differentiation process between the time of commitment to DE and 
the time hepatic endoderm/hepatoblasts are being generated, with a goal to not only 
generate larger quantities of HLCs but also to more accurately mimic in vivo development 
where expansion also occurs. 
In this study, we demonstrated that hESCs, during the course of hepatocyte 
differentiation, could be expanded at an intermediate endodermal stage and continued to 
differentiate toward a hepatocyte-like phenotype. To mimic the proliferative capability of 
developing hepatic cells, we utilized the soluble factors known to induce endoderm 
differentiation and promote proliferation as a way to incorporate an expansion stage. The 
factors, BMP4 and FGF2, were chosen to mimic the signaling of the cardiogenic mesoderm 
and septum transversum mesenchyme during the transition of the foregut endoderm to the 
liver bud, a process that involves extensive cell migration, proliferation, and differentiation. 
 By providing more surface area to cells at the intermediate endodermal stage, cells 
demonstrated the ability to expand up to at least eightfold. Given that we split the cells at 
a ratio of 1:4 during the first passage, the initial EN population showed remarkable 
proliferative capability within 3 days. By the third passage, up to 15-fold increase in cell 
number was occasionally achieved, but the resulting expansion from the third passage of 
cell expansion was not as consistent. In addition, cells with a fibroblastic morphology 
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began to emerge when cells were passaged beyond the second expansion stage, suggesting 
that the expanding endodermal cells have a limited proliferative capability similar to 
developing cells in vivo. 
However, the increase in cell number during the expansion demonstrated that stem 
cell–derived endodermal cells exhibit a proliferative capability also seen with endodermal 
cells in developing embryos (103-105). The expansion in cell number was also 
accompanied by a simultaneous increase in hepatocyte transcript levels along with a drastic 
decrease in endodermal and pluripotent marker gene expression. This finding correlates 
with what happens to developing endodermal cells undergoing proliferation as they commit 
to the different endoderm lineages during liver development (103). 
Our results indicated that the DE cells were capable of simultaneous proliferation 
and differentiation. However, it is not clear whether the changes in gene expression happen 
to a larger population of cells or to only a small population. We used mass cytometry to 
examine the progression of cells at different stages of differentiation. The population of 
cells at different stages was further classified into different subpopulations to examine the 
dynamics of the cells during differentiation. In the D6, EN1, EN2, and D14 populations, 
only 50%–75% of the population were categorized as endodermal cells, hepatic 
endoderm/hepatoblasts, or hepatoblasts/hepatocytes. However, by the end of the 
differentiation, the percentage of hepatic-committed cells had increased to almost >90%. 
These results suggest that cells differentiate at different rates, giving rise to a 
heterogeneous population at different stages of differentiation. It is noted that a large 
number of the nodes in the SPADE tree were not included as the different classes of 
differentiated cells. Although the density of cells in each of those nodes was small, 
altogether they constitute a significant fraction of the total cells. It is likely that those cells 
are in a transition stage and also possible that they might include some cells that failed to 
differentiate toward the hepatic lineage. Nevertheless, the majority of the population is 
differentiating along the hepatic lineage. The decrease in endodermal and increase in 
hepatocyte markers occurred in a majority of the cells, as a large fraction of the population 
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coexpressed multiple hepatocyte markers and lost the expression of early stage markers 
simultaneously. 
Furthermore, the results demonstrate that the increased hepatic transcript level in 
EN2-HLC was not merely caused by a small subset of cells expressing extremely high 
levels of hepatocyte markers, but was attributed by a majority (>75%) of the cells 
differentiating toward the hepatic lineage. Moreover, these novel quantitative analyses of 
the differentiation of endodermal cells confirmed that the majority of cells following the 
expansion process were also capable of becoming HLCs. Indeed, the resulting EN2-HLC 
population was similar to D20-HLC: both containing a large fraction of cells expressing 
moderate to high levels of ALB, AFP, AAT, and CD44, but low levels of endodermal 
markers. The similarity between EN2-HLC and D20-HLC was further confirmed by their 
ability to secrete albumin, synthesize urea, and induce cytochrome P450 enzymes in 
response to rifampicin. 
Mass cytometry have been used to explore the heterogeneity in the hematopoietic 
system and in cancer (98, 99, 106-110). In stem cell research, it has been used to explore 
the emergence of induced PSCs from fibroblasts (111). In this study, we used mass 
cytometry to examine the population dynamics during directed differentiation of stem cells 
toward the hepatic lineage. Importantly, we took advantage of the detailed analysis at the 
single cell level provided by mass cytometry by imposing quantitative criteria for each 
marker to perform quantitative analysis of the emergence of different subpopulations at 
different stages of differentiation. The mass cytometry data demonstrate that while 
endodermal cells underwent expansion, they continued on the trajectory of differentiation 
toward the hepatocyte lineage. This was further supported through microarray analyses. 
Using PCA on the transcriptome data, we plotted the results on a PC1 versus PC2 space to 
demonstrate the similarities between each sample. All cell samples lined up in the order of 
their progression toward the hepatocyte lineage. EN1 and EN2 were positioned in between 
D6 and D10 cells, suggesting that their differentiation status is more advanced than D6, 
but not as mature as D10. Thus, during expansion, endodermal cells were proliferating 
while also differentiating toward a more hepatic endoderm/hepatoblast fate instead of 
remaining in a renewable endoderm cell stage (48).  
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In this study, hESCs were simultaneously expanded while differentiating toward 
hepatic lineage. Other studies have reported the expansion of hepatocyte progenitor cells. 
By FACS sorting, EpCAM+/c-KIT- hepatic progenitor cells from differentiating mouse 
ESCs were isolated and, subsequently, expanded on mouse embryonic feeders (92). In 
another study, human hepatoblasts were sorted from ESC progeny based on N-cadherin 
expression and, subsequently, cultured as progenitors on stromal feeder cells (48). Human 
endodermal progenitor cells have also been clonally isolated from a differentiating 
population based on expression of the surface markers CXCR4 and CD117 and expanded 
on Matrigel and feeder cells. These progenitor cells were subsequently differentiated to 
express hepatic markers. In all three studies, the cells were maintained at a ‘‘progenitor’’ 
state and did not appear to continue to differentiate until they were removed from the feeder 
and exposed to hepatocyte differentiation conditions. By contrast, in our study, the bulk of 
the starting population was expanded and differentiated simultaneously, mimicking 
embryonic liver development in which hepatic endoderm and early hepatoblast 
differentiation occurs while the size of the liver is rapidly increasing.  
In spite of the increased expression of a number of hepatic genes, both D20-HLCs 
and EN2-HLCs are not yet mature hepatocytes as transcript levels of enzymes involved in 
xenobiotic biotransformation are significantly lower in HLCs than in neonatal or adult 
hepatocytes (Data not shown). In addition, the degree of cell expansion achieved in this 
study is still limited. For potential applications in the future, a substantially larger level of 
expansion will still be more desirable. Further improvement of the protocol for hepatocyte 
differentiation from PSCs is necessary to extend cell expansion and to achieve maturity of 
HLCs. However, our findings indicate that it is possible to expand endodermal cells during 
hepatocyte differentiation, which might alleviate the time and effort in generating large 
quantities of HLCs. 
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4.4 Figures 
 
Figure 4-1. Protocol of Expansion of Endodermal Cells During Hepatocyte 
Differentiation. A) Cells were differentiated towards the endoderm stage and 
subsequently passaged using a combination of bFGF and BMP4 similar to developmental 
cues during cell expansion. The expanded cells were then further differentiated towards 
the hepatic lineage using the existing differentiation protocol.  
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Figure 4-2. Morphology of expanded endodermal cells. a) Cells after a few hours of 
plating using phase microscopy at 20x. b) Endodermal cells after 3 days of expansion at 
20x. Scale bar. 50um 
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Figure 4-3. Cell Count during Differentiation. Increasing cell number during the 
course of cell expansion and regular differentiation. All error bars are represented as SD 
(n=4). SD= standard deviation 
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Figure 4-4. Phenotype of Endodermal Cells During Expansion. Transcript level of 
marker genes A) Oct4, B) CXCR4, C)GSC, D) AFP, E) ALB in endodermal cells and 
their differentiated progenies for the dashed black line) conventional method of 
differentiation or in the expansion method.  
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Figure 4-5. Protein expression in endodermal cells over the course of differentiation 
and expansion. A) Immunostaining of endodermal markers (FOXA2 and SOX17) and 
hepatic marker (AFP) during the expansion process showing simultaneous differentiation 
and expansion. B) Immunostaining of endodermal markers (FOXA2 and SOX17) and 
53 
 
hepatic marker (AFP) during the differentiation process showing differentiation 
occurring. 
 
Figure 4-6. 3D plots of Early Markers During Expansion Using Mass Cytometry. 
Mass cytometry data is represented as a three-dimensional scatter plot with color 
representing the fourth dimension. The axes show the expression of different markers 
FOXA2, SOX17, CXCR4, DLK1, and ALB and the color gradient of each dot show the 
expression of CD44. The negative control for the markers used was hESCs which shows 
low expression for hepatic markers (DLK1 and ALB). As the cells undergo endodermal 
expansion, the endodermal genes decrease and CD44 expression increases. The presence 
of CD44 has been shown to play an important role in HGF-induced signaling by promoting 
autophosphorylation of the HGF receptor, c-MET (96). Thus, CD44 is typically used as a 
marker for a subpopulation of hepatic progenitor cells that have high growth potential in 
culture (97). The protein levels of SOX17 and CXCR4, very low in ESC (a-c), began to be 
co-expressed in a distinct population (Figure 4-6d). During the endodermal expansion, a 
DLK1 
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very large fraction of cells co-expressing SOX17 and CXCR4 gradually showed increased 
expression of CD44 (d-f). 
 
Figure 4-7. 3D plots of Late Markers During Differentiation Using Mass Cytometry. 
Mass cytometry data is represented as a three-dimensional scatter plot with color 
representing the fourth dimension. The axes show the expression of different hepatic and 
endoderm markers ALB, SOX17, CXCR4, or DLK1 and the colored dots show the 
expression of CD44. As the cells undergo endodermal expansion, the endodermal genes 
decrease and CD44 expression increases. Evaluation of the expanding D6 population 
illustrated that the bulk of the cell population expressing both ALB and CD44 also 
55 
 
simultaneously lose expression of the endodermal markers, SOX17 and CXCR4, in line 
with results from qRT-PCR and immunostaining. DLK1 has frequently been used as a 
marker for early hepatocyte committed progenitor cells that can be isolated from the 
embryonic liver in vivo(112, 113) (74, 75). Using DLK1 as a marker for hepatocyte-
committed cells, a large fraction of the expanding EN1 and EN2 population began to gain 
DLK1 expression giving credence to the assignment of early hepatic subpopulation. The 
expression of CD44 and ALB were gradually increasing along with DLK1, showing co-
expression of all three hepatoblast markers in the majority of DLK1 positive cells. The co-
expression of hepatoblast markers observed in the D20-HLCs and EN2-HLCs populations 
further illustrates that the majority of the cells are capable of differentiating towards the 
hepatocyte lineage regardless of whether or not they were subjected to endodermal 
expansion steps. Notably both D20-HLCs and EN2-HLCs showed low expression levels 
of CXCR4. 
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Figure 4-8. SPADE analysis of Mass Cytometry Data. (a-h) The expression level of 
each of 8 markers is shown in a separate tree diagram. The color represents arcsinh 
transformed intensity of each marker. Median of the intensity for a node is shown. The 
expression level of each marker is ranked as high (++), moderate (+), and low (-). The 
threshold for ++ and + is 100 and 20 for CXCR4, 100 and 10 for FOXA2, 60 and 8 for 
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SOX17, 100 and 15 for CD44, 150 and 40 for ALB, 100 and 14 for AAT, 150 and 30 for 
DLK1, and 100 and 20 for AFP, respectively. Unannotated parts of the SPADE tree for 
each marker were considered as the cells with low (-) expression of the marker.  i) K-
means clustering was performed to the 75 nodes from the SPADE analysis based on the 
median intensity of the 8 markers (green lines: nodes in subpopulation A (endodermal 
cells), blue lines: nodes in subpopulation B (hepatic endoderm/hepatoblasts), red lines: 
nodes in subpopulation C (hepatoblasts/hepatocytes), and black lines: nodes not classified 
as any subpopulation). The distance was measured with Euclidean distance. 10 of the 14 
nodes in the A subpopulation were in Cluster 1. 11 of the 16 nodes in the C 
subpopulation were in Cluster 4, revealing that majority of the nodes in A and C were 
separately clustered. The majority of the B nodes were interspersed into Clusters 2 and 3, 
with 12 and 10 of the B nodes in Clusters 2 and 3, respectively.  
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Figure 4-9. SPADE Analysis of Mass Cytometry Data of Cells Differentiating toward 
HLCs. The mass cytometry data of cells at different differentiation stages were clustered 
into 75 nodes by SPADE analysis. SPADE results for (a) D6, (b) EN1, (c) EN2, (d) D14, 
(e) D20-HLC, and (f) EN2-HLC are shown. The color and the size of a node represent 
percentage of the populations for the node in each sample. Subpopulations enclosed in A, 
B, and C are classified as endodermal cells, hepatic endoderm/hepatoblasts, and 
hepatoblasts/hepatocytes, respectively. The percentage of endodermal cells, hepatic 
endoderm/hepatoblasts, and hepatoblasts/hepatocytes for each population is shown. 
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Figure 4-10. Mass cytometry and immunostaining of hepatic and endodermal 
markers. a) Immunostaining for AFP (white) and ALB (grey) was carried out at different 
stages of the differentiation along with the percentage of cells positive for AFP (white with 
lines) and ALB (grey with lines) found during mass cytometry. b)  Immunostaining for 
FOXA2 (white) and SOX17 (grey) was carried out at different stages of the differentiation 
along with the percentage of cells positive for FOXA2 (white with lines) and SOX17 (grey 
with lines) found during mass cytometry. c) Co-staining was carried out for FOXA2 
(white) and SOX17 (grey) where the percentages of double positive (dark grey) cells were 
quantified and also compared to mass cytometry percentages (stripe bars). d) Co-staining 
was carried out for AFP (white) and ALB (grey) where the percentages of double positive 
(dark grey) cells were quantified and also compared to mass cytometry percentages (stripe 
bars). 
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Figure 4-11. Immunostaining of Albumin in HLCs. in A) HLCs and B) EN2-HLCs. 
Scale bar=50um.  
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Figure 4-12. Transcript Level of Different Hepatic Markers in HLCs. A) D20-HLCs 
and EN2-HLCs both expressed transcripts of hepatocyte markers AFP, ALB, AAT, and 
PEPCK. B) Transcript level change of CYP2A6, CYP2C8, and CYP2C9 in D20-HLCs 
and EN2-HLCs after induction with rifampicin. P values of Student’s t-test are shown. 
n=3 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
 
Figure 4-13. Functional Activity of HLCs and EN2-HLCs. A) Albumin secretion for 
D20-HLCs and EN2-HLCs B) Urea Secretion for D20-HLCs and EN2-HLCs C) Glycogen 
staining for D20-HLCs and EN2-HLCs. All error bars are represented as SD. n=3 
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Figure 4-14. Transcriptome analysis of differentiating and expanding cells. Cell 
samples at different differentiation stages from the conventional protocol (blue) and 
expanding protocol (red) align along the same PC space (PC1 vs. PC2). EN1 and EN2 
samples are in between D6 and D10 (the beginning and end of Stage 2 differentiation of 
the conventional protocol). PC, principal component. 
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Figure 4-15. Transcript dynamics of embryonic stem cell specific genes during 
directed differentiation with the original protocol or with simultaneous expansion.  
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Figure 4-16. Transcript levels of stage-specific markers. Dynamics of key a) endoderm 
markers and b) hepatoblast markers is similar in cells differentiated with the two different 
protocols (dashed = original method, solid = expansion method). 
 
 
 
 
 
 
 
 
 
 
 
 
66 
 
a 
 
b  
 
 
67 
 
c 
 
d 
 
 
68 
 
e 
 
f 
 
69 
 
g 
 
h 
 
 
70 
 
i 
 
j 
 
71 
 
k 
 
l 
 
72 
 
m 
 
n 
 
73 
 
o 
 
Figure 4-17a-o. Transcript dynamics of embryonic liver specific genes during 
directed differentiation with the original protocol or with simultaneous expansion. 
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Figure 4-18. Comparison of transcript levels of genes of different functional classes 
between D20-HLC and EN2-HLC. a) Expression levels of glycolysis/gluconeogenesis 
genes were similar between D20-HLCs and EN2-HLCs.  b) Expression levels of urea cycle 
genes were similar between D20-HLCs and EN2-HLCs.  c) Expression levels of fatty acid 
metabolism genes were similar between D20-HLCs and EN2-HLCs. d) Expression levels 
of genes in the cytochrome p450 family were similar between D20-HLCs and EN2-HLCs.  
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Chapter 5. Transcriptome Analysis of Stem Cell 
Differentiation to Hepatic Lineage 
5.1 Introduction 
 In the previous chapter, we demonstrated that hESCs can be differentiated towards 
the hepatic lineage and result in cells referred to as HLCs. These cells show remarkable 
similarities to primary hepatocytes that have the potential to be used in different clinical 
and industrial applications. They have increased hepatic-specific gene expression, protein 
expression and function similar to primary hepatocytes. However, when we compare our 
functional characterization to studies on primary hepatocytes, it is clear that directed 
differentiation from hESCs only give us immature phenotype, hence the name “hepatocyte-
like”. Although the field of developmental biology has come a long way and have 
continued to provide us with insights into different signaling pathways that have allowed 
us to develop our differentiation protocol, there is still a roadblock that is preventing us 
from achieving a primary hepatocyte state.  
 Many approaches have been explored to enhance maturation of HLCs, including 
the formation of tissue-like 3D structure (102) (114), co-culture of HLCs and endothelial 
cells (114-116), the addition of small molecules uncovered by screening (117-119) , and 
overexpression of certain transcription factors(120-122).  Using cell aggregates formed by 
co-culturing HLCs and endothelial cells for transplantation, some mature liver markers 
were seen in the transplanted cells (114).  However, despite the improvements, HLCs still 
remain functionally immature when compared to their primary counterparts in liver. The 
general lack of maturity of HLCs was also revealed in a microarray transcriptome study 
showing that HLCs derived from three different laboratories were clustered distinctively 
from primary hepatocytes (123). Through functional activities and proteomic analysis, it 
was clearly demonstrated that HLCs were closer to fetal liver hepatocytes than primary 
hepatocytes (123, 124).   
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  In this chapter, we will be trying to understand the universal roadblock that is 
preventing the immature phenotype by looking at whole gene expression analysis. This 
will be accomplished by using transcriptome analysis which is very similar to qPCR in 
concept and sample preparation except we can look at it from a whole transcriptome point 
of view. Using this approach we hope to see a more holistic view of our differentiation to 
understand what signaling pathways are missing or need to be activated. Total RNA lysate 
is obtained from the samples followed by purification of the mRNA fraction similar to 
prepping for qPCR. From this mRNA lystate, a complementary DNA is generated which 
can then be amplified using PCR and hybridized to the microarray chip. Although there 
are many technologies that are available for transcriptome analysis, we are focused on 
using microarray because of the cost and ease of data processing. In this system, we can 
look at over 47,000 probes that cover over 27,000 genes.  
 Using whole transcriptome analysis, we can identify certain genes or signaling 
pathways that are not expressed correctly compared to primary hepatocytes. Although the 
lack of maturity of HLCs has been well accepted, it is not known at which stage of 
embryonic liver development HLCs resemble. Comparison of transcriptome data of HLCs 
with those from embryonic development should allow us to identify the equivalent 
embryonic liver developmental stage for HLC. This may also lead to the identification of 
genes that behave “erratically” in HLCs differentiation compared to embryonic liver 
development. This discovery may potentially reveal the genetic roadblocks preventing 
HLCs from reaching the functional maturity of their tissue counterparts.  
Human gestation occurs over 280 days compared to 20 days in mouse. A typical 
directed stem cell differentiation process for both human and mouse PSCs lasts for about 
20 days (88).  Although these processes differ in time scales, they share similar progression 
through the different developmental stages. A key to the cross-species and cross- in vitro- 
in vivo analysis is to align all the different data onto a common “time scale”. We 
hypothesize that the transcriptome data of in vitro hepatic differentiation bear the 
characteristics of different liver embryonic stages in human and mouse. While 
transcriptome data of in vitro hPSC differentiation to HLC are publicly available, human 
in vivo data at various stages of liver development are difficult to obtain. On the other hand, 
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transcriptome data of in vivo rodent liver development are more publicly accessible. We 
hypothesized that the gene expression dynamics of embryonic liver development between 
rodents and human are highly similar, and set out to identify the equivalent stage of rodent 
embryonic liver development for human HLCs by a cross-species transcriptome meta-
analysis.  
 
Systematic variations and random errors in the transcriptome data from different 
studies can give biasing that resemble the characteristics of the sample source.  Samples 
assayed with different measurement platforms can also bear the characteristics of the 
platform. The sample source and assay platform derived-variations that can arise need to 
be removed before the transcriptome data can be combined and analyzed. The ComBat 
algorithm is an empirical Bayes method that performs a location and scale adjustment by 
pooling information across each gene in every batch and using this information to center 
the data to an overall grand mean (125). This technique can be applied to multiple batches 
of datasets and is robust for small sample size. Other methods of batch correction also have 
been described in detail such as the limma package which tends to give less “exaggerated” 
effects (126). ComBat consistently outperformed the common batch correction techniques, 
including distance-weighted discrimination (DWD) which uses a support vector machine 
based approach (127)(127), mean-centering (PAMR) which relies on gene based analysis 
of variance (128), and surrogate variable analysis (SVA) which uses a combination of 
single value decomposition and linear model analysis(129, 130).  
In this study, we employed the ComBat algorithm to integrate transcriptome data 
from in vitro differentiation of h/mPSCs and in vivo mouse embryonic liver development 
obtained from different studies and assay platforms. The batch correction allows the data 
of mouse embryonic liver development and HLCs derived from h/mPSCs to be aligned 
according to a common scale of development. Past studies have relied on the comparison 
of gene expression profile of primary hepatocytes to HLCs obtained at the end of 
differentiation to identify differentially expressed genes(124, 131)(86, 93). By placing the 
gene expression profile from the meta-data on a common developmental scale, we can use 
expression dynamics to more accurately identify genes that deviate from embryonic liver 
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development compared to in-vitro differentiation. These genes might contribute to the lack 
of maturity in HLCs differentiated from PSCs. The described meta-analysis of the highly 
heterogeneous transcriptome data from human and mouse, and in vivo and in vitro data, 
can provide clues for genetic intervention to advance directed differentiation of PSCs to 
hepatocytes, and be used for possibly other lineage differentiations.  
 
 
5.2 Approach to Transcriptome Meta-Analysis 
 Transcriptome data was collected from multiple studies to increase the validity and 
complexity of our dataset. We also included transcriptome data of our differentiation data 
from multiple cell lines from human and mouse cells to the hepatic lineage. Our focus was 
on studying the roadblocks behind our differentiation process and we incorporated other 
laboratory transcriptome data to support our approach and prove that it is robust and can 
be applied to other studies as well.  
5.2.1 Transcriptome Dataset 
The total RNA was extracted at different time points from human and mouse liver 
differentiation samples using the RNeasy Mini kit (Qiagen). Differentiating human 
embryonic stem cells (hESCs) (H9, HSF6) samples were hybridized to the Illumina HT12 
bead array v3 (Illumina Inc.), HES3 samples were hybridized to Human Genome U133 v2 
array (Affymetrix) and the mouse iPSC-derived samples were hybridized to the WG-6 v2 
(Illumina) array. Other datasets from different studies using different protocols were also 
included in this study. The source of the different human and mouse datasets is listed in 
Table 5-1 and 5-2, respectively. The human dataset included transcriptome of different 
hESCs differentiating to hepatocytes including HLCs generated using various protocols, 
two time course data from different protocols (Hu/Duncan) (79, 90, 132-134), HLCs in 
three dimensional spheroids (102), liver organoids generated through co-culture of induced 
pluripotent stem cells (iPSC)-derived HLCs and mesenchymal and endothelial cells (114), 
and iHEPs generated through direct reprogramming of fibroblasts to HLCs by hepatic 
transcription factor transduction(98) .Also included were primary human hepatocytes 
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(pooled mRNA after 1 day of culture), fetal liver (18 weeks of gestation) and adult liver. 
Transcriptome data of mouse embryonic liver development (E9.5 to post-natal) include 
CD45-Ter119- liver cells from C57/BL6/Tg mice embryos and whole livers from C57/B6 
mice embryos (114, 135).  
5.2.2 Overview of Combining Datasets 
Briefly, the raw data of Affymetrix, Illumina and Agilent array platforms were 
processed using the affy, lumi and limma packages in R respectively to obtain intensity 
expression values. Logarithmic transformed (log2) intensity from different platforms were 
corrected for depth of digital precision. The expression level of each gene is condensed by 
the median expression value of multiple specific probes. Common ENSEMBL identifiers 
were used to condense the same genes from arrays of different platforms. The cross 
platform data was then combined into a master expression dataset based on matching the 
ENSEMBL identifiers. The initial data processing until normalization was performed using 
the virtualArray package in R. Each of the human and mouse datasets were linear 
normalized. The average expression values from replicate samples were calculated and 
used for further analysis. The mouse and human datasets consisted of 16,415 genes and 
17,683 genes respectively, of which 14,333 were common based on orthologous 
ENSEMBL identifiers.  
5.2.3 Criteria for Identifying Differentially Expressed Genes 
Prior to subjecting the data to different comparison statistical to find differentially 
expressed genes, we wanted to find a way to carry out the study to find dynamically 
differentially expressed genes. In most studies, the end point of differentiation protocols, 
HLCs, are compared to primary hepatocytes but due to the complexity of development we 
wanted to take a holistic approach to look at things dynamically. Our approach was to look 
at differentially expressed genes by comparing in-vitro differentiation to the course of in-
vivo development. Thus, genes with static expression profiles in the dataset were removed. 
Only those genes changing greater than fourfold across any timewise comparison were 
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retained in the global analysis. All analysis was carried out in the statistical software, R. 
To identify orthologous genes whose time dynamic profile is different between hESC 
differentiation and mouse embryo development, the expression profile of each gene was 
expressed as a second order polynomial function of the arc that is formed after plotting the 
mouse and human dataset on a common time scale. The difference of the dynamic 
expression profiles of a pair of orthologous genes was computed in three ways: Pearson’s 
coefficient, Spearman’s coefficient and Euclidean distance.  
Further details regarding each of these statistical criteria to identify differentially 
expressed genes in a dynamic manner are described in detailed below.  
The first criteria used for identifying differentially expressed genes was to 
determine the Euclidean distance between different datasets. The formula used is 
described below:   
𝒅 = |(𝒙𝒊𝒎 − 𝒙𝒊𝒉  | = √∑ |𝒙𝒊𝒎 − 𝒙𝒊𝒉|
𝟐
𝒏
𝒊=𝟏
 
Euclidean Distance where Xij represent expression intensities for gene i and species 
j 
 
 The second criteria imposed on the different genes was to use Pearson’s 
correlation described below:  
 
𝑟 =  
∑(𝑥𝑖𝑚− 𝑥𝑖𝑚̅̅ ̅̅ ̅̅ )(𝑥𝑖ℎ−𝑥𝑖ℎ̅̅ ̅̅ ̅)
√∑(𝑥𝑖𝑚−𝑥𝑖𝑚̅̅ ̅̅ ̅̅ )
2 ∑(𝑥𝑖ℎ−𝑥𝑖ℎ̅̅ ̅̅ ̅)
2
  𝑥𝑖ℎ  is the gene in human and 𝑥𝑖𝑚 is the corresponding gene 
in mouse  
Pearson’s correlation where Xij represent expression intensities for gene i and species j  
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 The third criteria imposed on the different genes was Spearman’s’ correlation 
which is described below:  
 
𝒓 =  
∑(𝒚𝒊𝒎− 𝒚𝒊𝒎̅̅ ̅̅ ̅)(𝒚𝒊𝒉−𝒚𝒊𝒉̅̅ ̅̅ ̅)
√∑(𝒚𝒊𝒎−𝒚𝒊𝒎̅̅ ̅̅ ̅)
𝟐 ∑(𝒚𝒊𝒉−𝒚𝒊𝒉̅̅ ̅̅ ̅)
𝟐
 𝑦𝑖ℎ  is the gene in human and y is the corresponding gene in 
mouse 
Spearman’s correlation where Yij represent the ranks of gene expression intensities for 
gene i in species j 
 Genes for which the Pearson’s or Spearman’s coefficient is < -0.8 were identified 
as candidates whose expression dynamics between human in vitro differentiation and 
mouse embryo development follow opposite trends; while genes for which the Euclidean 
distance is > μ+2σ (where μ and σ are average value and standard deviation of Euclidean 
distance, respectively), were identified as candidates of dynamically differentially 
expressed genes. Genes with expression values changing fourfold or higher across any 
sample pair in either human (D5-D20) and mouse data (E9.5-15.5) were further shortlisted 
as genes represented as highly dynamically expressed different genes. 
5.2.4 Different Methods of Transcriptome Analysis 
Global analysis to elucidate trends in the data was performed using hierarchical 
clustering, principal component analysis and non-negative matrix factorization. 
Hierarchical clustering analysis was performed on the batch corrected datasets of 
human and mouse separately using the statistical software R and its hclust function. 
Euclidean distance between the expression value of all gene (i) was used as the metric for 
the distance between different pairs of samples (a and b).  
     ||a-b||2 = √∑ (𝑎𝑖 − 𝑏𝑖)2𝑖  
 
Unweighted Pair Group Method with Arithmetic Mean (UPGMA) was chosen as the 
distance metric. 
    
1
|𝐴||𝐵|
∑ ∑ 𝑑(𝑎, 𝑏)𝑏∈𝐵
 
𝑎∈𝐴       where d is the metric chosen (i.e. Euclidean 
distance) 
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Another method of whole transcriptome analysis similar to hierarchical clustering 
is to use principal component analysis (PCA). This is a multivariate statistical technique 
commonly used to reduce the dimensionality of a dataset, which was performed using the 
prcomp() function in R. Principal component calculation is based on a singular value 
decomposition (SVD) of the mean centered gene expression data (136). The transcriptome 
data of all sample was organized in a n gene x m sample matrix. Let xij be the expression 
value of gene i in sample j and A be the n x m mean centered expression matrix, where n 
is the number of genes and m is the number of samples. The elements of A are thus aij = xij 
- 𝑥?̅? 
By single value decomposition,   𝐴 = 𝑈𝐸𝑉𝑇  
Where U is the (n x m) eigenvector matrix of ATA, E is an (m x m) diagonal matrix 
and V is the (m x m) eigenvector matrix of AAT. Elements of U are referred to as eigen 
vectors and are ordered by their corresponding eigenvalues, which capture the variance of 
that element. Each eigenvector corresponds to a principal component (PC). The projection 
of the samples in the principal component space is given by  
𝑈𝑇𝐴 = 𝐸𝑉𝑇 
        
 EVT contains the coordinates or scores for the samples in the PC space, which were 
calculated using the prcomp() function in R.  If the first few PCs can capture most of the 
variance, one can visualize the coordinates of the samples defined by the first few PCs 
without losing much information. The n x m dimensions of A is therefore reduced to an m 
x v matrix, where v represents the number of PCs reflecting the largest variance in the 
dataset. In our analysis, the first two PCs captured about 90% of the variance in all datasets. 
Therefore, the multidimensional transcriptome data was reduced to m x 2 matrices, where 
m represents the number of samples in the dataset. The x and y coordinates of this matrix 
are represented by PC1 and PC2, the components which retain the most variance in the 
data. These co-ordinates were then used to visualize the ordering of the samples in the two-
dimensional PC space. 
Another common method for examining transcriptome samples based on its gene 
expression profile is non-negative matrix factorization (NMF). NMF is another dimension 
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reduction analysis method (137) used to analyze the batch corrected human or mouse 
datasets using a NMF R/Bioconductor package (138) . Briefly, A, an n x m transcriptome 
expression data  matrix of n genes of m samples was resolved as a product of two matrices 
containing only non-negative values W and H of size n x k and k x m respectively. k is the 
optimal factorization rank or the number of clusters that A can be represented by. This is a 
critical parameter whose value can usually be determined by plotting the cophenetic 
coefficient corresponding to different values of ranks, and selecting the rank at which the 
cophenetic coefficient begins to decrease (137). The samples are then assigned to the 
number of clusters determined by the cophenetic coefficient by performing several 
iterations. In the human and mouse NMF analysis, 100 iterations were used to confirm 
sample assignments.  
  The elements of matrix W are referred to as metagenes while the matrix H 
corresponds to the metagene expression profiles (138). To evaluate metagenes that 
contribute most significantly to the biological variance in the phenotypes of interest, they 
were assigned scores based on a scoring schema outlined in (139) between values 0 and 1. 
Higher values correspond to larger contributions of the gene to that cluster. A threshold 
criteria was set and genes above this threshold were designated as significant metagenes.  
5.3 Results 
5.3.1 Compilation of  Human Differentiation of Stem Cells 
 The transcriptome data involved in this study is divided into the human dataset and 
mouse dataset. This meta-analysis consisted of over 15 different studies and 100 samples 
for the comparison of in-vitro differentiation and in-vivo development. We carried out a 
differentiation protocol similar to the one described in the previous chapter on our H9 cell 
line. The H9 cells were differentiated towards the hepatic lineage using a four-stage hepatic 
differentiation protocol designed to mimic embryonic development (Figure 5-1A). The 
transcript of hepatic markers, HNF4A, AFP, ALB, CYP3A4, AAT, and TAT, all increased 
significantly by the end of the differentiation (Figure 5-1B). Immunohistochemistry reveals 
that a majority of cells were positive for endodermal marker, FOXA2, by Day 6. Hepatic 
markers, HNF4A, AAT, AFP and ALB were prominent in cells by Day 20 (Figure 5-1C). 
The high expression of AFP, which is low in primary hepatocytes, suggests the fetal liver 
nature of hHLCs derived from PSC. These samples were collected over the course of the 
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differentiation on day 6, 10, 14, and 20 (D6_H, D10_H, D14_H, D20_H, respectively) and 
will form the basis for our study and how we can find ways to improve current in-vitro 
differentiation efforts.   
The transcriptome data, along with another study of hHLC differentiation (D9_HE, 
D12_HE, HLC_H2), were augmented by data from the public domain to increase the data 
diversity as described more in detail in the previous section. One other important dataset 
was used as a dynamic comparison because it consisted of multiple time points over their 
course of differentiation from hPSC to hHLC (Duncan). While other samples are consisted 
of end point differentiation samples, hHLCs samples, obtained using various 
differentiation methods. A total of 17,683 genes were common among all the datasets based 
on ENSEMBL ID.  
5.3.2 Batch Correction of Human In-vitro Data 
 Batch correction was performed on the hHLC in vitro dataset to remove the 
systematic bias caused by the heterogeneous samples and platform sources. The effect of 
batch correction is visible after performing hierarchical clustering of the different samples 
before and after batch correction. Without batch correction, samples obtained from each 
study clustered together, as seen in Figure 5-2. After batch correction, samples based on 
their similarity in differentiation stages clustered together regardless of the study it came 
from, suggesting the removal of the batch effects (Figure 5-3A). Samples from a similar 
differentiation stage from each of the time series studies (Hu/Duncan) clustered together, 
indicating a similar progression through differentiation. However, the hHLC data from all 
sources consistently clustered separately from tissue samples of fetal and adult liver 
samples, confirming the immaturity of these cells. 
 Non-negative matrix factorization (NMF) analysis was performed to separate the 
hHLC dataset into three clusters (Figure 5-3B). The optimal number of clusters, 3, was 
determined by the highest cophenetic coefficient obtained (Figure 5-4). The smallest 
cluster consisted of mature hepatic samples from liver tissue and primary hepatocytes, and 
the other two clusters consisted of samples of early (D4-10) and late differentiation (D14-
20) stages. Only two hHLC samples (90, 102) were grouped separately in the mature 
cluster. The grouping of early and late differentiation samples was remarkably similar 
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between NMF and hierarchical clustering. Notably, samples in similar differentiation 
stages from the two differentiation time series studies (Hu/Duncan) were clustered together 
supporting their similar progression through the differentiation stages. 
 We used Database for Annotation, Visualization, and Integrated Discovery 
(DAVID) to probe the functional class of  the 967 metagenes obtained from the NMF 
analysis (Appendix Table 9-1) (140, 141). Genes associated with the clustering of early 
differentiating cell states (D4-10) were involved mainly in developmental processes, while 
those associated with late differentiation states (D14-20) were mainly involved in cell 
differentiation, adhesion, extracellular matrix reorganization, epithelial specification and 
drug response. The metagenes classifying fetal and adult liver tissue were involved in 
mature liver functions including CYP450 drug detoxification, electron carrier activity, and 
carbohydrate metabolism, among many others.  
Thus, the two unsupervised classification methods, hierarchical clustering and 
NMF, classified the batch corrected human transcriptome data into similar groups based 
on the functional relevance of gene expression patterns. This gives credence to the data 
processing method we adopted for batch correction to further carry out the meta-analysis. 
5.3.3 Alignment of Human in vitro Data along a Differentiation Scale 
 The batch corrected transcriptome data of the human dataset was subjected to 
principal component analysis (PCA) to reduce the number of dimensions of the data. Two 
principal components, PC1 and PC2, captured 90% of the data variance, suggesting that 
two components were sufficient to display the variability within the transcriptome data of 
the samples. PC1 and PC2 of each sample were then plotted on a PC1 vs. PC2 graph (Figure 
5-3C). All samples, starting from endodermal cells to HLCs were observed to 
chronologically align along an arc while primary hepatocytes and adult liver were located 
in the high PC2 region. The two time series data sets (Hu/Duncan) both aligned from left 
to right in chronological order based on the differentiation stages. Interestingly, the iHEP 
and the liver bud samples aligned with earlier differentiation samples (D10-14) of the time 
series analyses. All HLC samples, regardless of the laboratory and protocol used, aligned 
within a narrow region in the principal component space, suggesting that they all have a 
similar degree of hepatocyte maturity.  
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5.3.4 Compilation and Alignment of Mouse Fetal Liver Development   
 The data processing pipeline described for the human datasets was also used to 
process the dataset of mouse embryonic liver development. The batch corrected data from 
two studies composed of 47 samples across the development of two strains of mice during 
embryo development. After compilation, a total of 16,415 genes were common among all 
the samples. These samples were then subjected to hierarchical clustering, NMF and PCA 
as we had done before for the human in-vitro dataset. Similar to the observation made 
before, batch correction removed the bias arising from different platforms and sources 
(Figure 5-5,5-6). Clustering of the samples into two clusters gave the most optimal 
grouping compared to three or four clusters, as assessed by the cophenetic coefficient 
(Figure 5-7).  NMF classified the batch corrected dataset into two groups, early and late 
development, which was in line with the hierarchical clustering results (Figure 5-6). When 
the data was subjected to PCA, the first two principal components captured over 90% of 
the data variance. As was seen for the hPSC-HLC time series, we found that the mouse 
embryonic liver development samples were lined up chronologically in order of their 
developmental stage (Figure 5-6).  
From the NMF and PCA analysis, the samples seemed to be grouped into an early 
(E9.5-E14.5) cluster and a late (E15.5-E19.5) cluster. This classification agrees with our 
understanding of liver development, where the E14.5 stage represents a transition from 
primarily hematopoiesis to hepatocyte maturation.  Functional analysis on the 129 
metagenes obtained from the NMF grouping confirmed that genes related to liver functions 
were key in the grouping of samples (Appendix Table 9-2). 
5.3.5 Integration of Mouse in vitro Differentiation and in vivo Development Data 
 To determine whether or not it was possible to combine in-vitro data with in-vivo 
data for studying the dynamic of gene expression, we wanted to first combine datasets 
originating from the same species. Thus, transcriptome data of miPSCs differentiating to 
HLCs at different timepoints, as well as murine fibroblasts being reprogrammed to 
hepatocytes (miHeps), were integrated with the mouse embryonic development data sets 
by performing batch correction treating the in vivo and in vitro samples as two separate 
batches. Again, batch correction removed the bias of platforms, sources and in vitro/in vivo 
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contrast among the different samples. These combined data were then subjected to PCA 
like before. On a space of PC1 vs. PC2, the in vitro differentiation data and in vivo 
development data can be seen to line up along an arc based on the maturity of the samples 
(Figure 5-8). The mouse iPSC differentiation data aligned chronologically with E9.5 to 
E15.5 stages of mouse liver development, while the data points for mouse embryonic liver 
development beyond E15 continue to spread to the region with higher values of PC2. The 
results suggest that the miPSC-HLCs and miHEPS acquired a differentiation stage 
equivalent of ~E13.5-15.5 stage and still lack the maturity of further developmental stages, 
let alone fully developed prenatal E19 and postnatal liver samples. 
5.3.6 Development of Unified Time Scale Using Mouse in vivo and Human in vitro 
Dataset 
 Having shown that mouse iPSC-derived HLCs and mouse embryonic liver 
development data can be integrated using batch correction and projected onto a PC1 vs. 
PC2 plane for comparison), we next integrated the hPSC in vitro differentiation data with 
mouse in vivo embryo development data. The batch corrected mouse embryonic liver 
development (E9.5-19.5) transcriptome data was combined with batch corrected hPSC-
HLC differentiation transcriptome data. Common homologous identifiers using the 
BioMart database package found in the statistical program, R, generated a master dataset 
with 14,312 genes. Batch correction was performed on the combined dataset using the 
ComBat function in R to eliminate the batch effects from the biasing of different species 
between the human in vitro and mouse in vivo samples.  
Comparison of the expression levels of the hepatic markers, alpha-fetoprotein 
(AFP) and albumin (ALB), for mouse development and our time series of human in-vitro 
differentiation (Hu) showed consistent trends in gene expression dynamics before and after 
batch correction (Figure 5-9). After batch correction, the expression levels were slightly 
shifted down but the dynamics of the expression through the stages were preserved for each 
species.  
PCA analysis was performed on the integrated dataset of h/mPSC-HLCs and mouse 
embryonic liver development. PC1 and PC2 for each sample from both species was plotted 
onto a two dimensional PC space. The data points of mouse and human aligned along the 
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same arc, and lined up in order of their development or HLC differentiation stages 
respectively (Figure 5-10).  
From the alignment of hPSC-HLC differentiation and mouse embryonic liver 
development data, the corresponding stages of human HLC differentiation and 
development of mouse liver can be deduced. hPSC derived endodermal cells of 
differentiation were aligned with E9.5-E10.5 samples, but the majority of fully 
differentiated HLCs were aligned with E13.5-E15.5 of mouse development. These results 
strongly indicate that HLCs derived from hPSCs are more similar to the mouse ~E14-E15 
stage of in-vivo development, similar to what was observed with HLCs derived from 
mPSCs.  
5.3.7 Differentially Expressed Genes in HLCs vs Mature Cells   
 The transcriptome of all HLCs for human (hHLCs) and mouse (mHLCs) were 
separately compared to their mature state (primary hepatocytes and E19.5 liver, 
respectively) using Significance Analysis of Microarray (SAM-R) in R, where the criteria 
of q<0.05 and fold change > 4 were imposed to identify differentially expressed genes. 129 
genes were identified as differentially expressed between hHLCs and mature cells (primary 
human hepatocytes (PHHs), fetal and adult liver). Among the 129 differentially expressed 
genes, processes involved in CYP450 drug metabolism, carboxylic acid, amine and lipid 
metabolism, and complement and coagulation cascades were identified as enriched using 
the DAVID tool  (141). A similar differential expression pattern was seen when comparing 
mHLCs to E19.5. The mHLCs and E19.5 comparison identified 127 genes as significantly 
differentially expressed, of which 42 genes were common between the human and mouse 
analyses, which are shown in Figure 5-11 and listed in Appendix Table 9-3. Mature 
hepatocyte genes differentially expressed in both species included metabolic genes, such 
as G6PC and FBP1, and the cytochrome P450 enzymes, CYP3A4 and CYP2C9 indicating 
the lack of the maturity in the metabolic profile of HLCs from both species. 
5.3.8 Expression profile comparison on a Unified Developmental Time scale 
The alignment of human in vitro HLCs and mouse in vivo embryonic development data on 
a common coordinate grid presents the unique opportunity to compare the dynamics of 
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their developmental events along a common “time” scale. We treated the arc formed by 
those data points as a common developmental path. Using the first point (E9.5) as a 
reference point, the distance of a sample from the reference point along the developmental 
path can be taken as a “unified developmental time (DT)”. Using the equation shown 
below, where x corresponds to PC2 values of the samples for that dataset, DT can be 
computed for each sample, irrespective of its sample origin.  
 
where x corresponds to PC2, P(x) corresponds to the polynomial fit of the curve in the 
PC1/PC2 space and a ,b and c correspond to the coefficients of the polynomial function. 
A higher value of DT indicates a higher maturity for that sample. The PC2 
component of all the human samples along with the mouse developmental samples were 
plotted against their DT as shown in Figure 5-12. The two human HLC time series datasets 
(Hu/Duncan) both showed a progressive movement along the DT to approximately 0.4 
(equivalent to E15.5) by the end of the differentiation.  
To understand the dynamics of certain genes during development and in-vitro 
differentiation, we combined the samples of the two human time series PSC-HLC 
differentiation (Hu/Duncan) into one human in-vitro process and plotted it along with the 
mouse development data on the same DT scale. While some hepatocyte genes (e.g. AFP) 
showed similar trends between human in vitro and mouse in vivo data, others showed 
inconsistent trends. Dynamic differential expression analysis using Pearson correlation, 
Spearman’s coefficient and Euclidian distance (PSE) was performed to compare the 
dynamic between mouse development with in-vitro differentiation for each of the 14,332 
orthologous genes. The Pearson correlation coefficient measures the linear correlation, 
while the Spearman’s coefficient measures the monotonic relation between two variables. 
Briefly, the threshold criteria were set for Pearson and Spearman coefficient < -0.8 and 
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Euclidean distance > μ+2σ. The genes fulfilling the PSE criteria were plotted and visually 
inspected for both human in-vitro differentiation and mouse development (Figure 5-13).  
5.3.9 Functional Analysis and Comparative Gene Expression 
197 genes were found to be dynamically differentially expressed between PSC-
HLC differentiation and mouse embryonic liver development using the PSE criteria 
(Appendix Table 8-4), including 11 transcription factors (TFs) (Figure 5-12), 7 transporters 
and 33 other cell surface markers. The major functional classes/ pathways involved from 
the 197 genes identified by the DAVID tool, included developmental process, organ 
development, cell adhesion as shown in Figure 5-14.  
Many transcription factors regulating organ development, including HAND1, 
PITX2, ALX1, CDX2, TSHZ1 and SNAI2, were highly expressed in the early stages of 
mouse liver development and subsided after E15. However, their transcript levels in during 
PSC differentiation followed an opposite trend and remained high in HLCs (Figure 5-12). 
To confirm the dynamic of the differentially expressed TFs, we also measured the 
transcript level over the course of differentiation using qRT-PCR following the Hu 
differentiation. (Figure 5-15). ALX1 is involved in forebrain development (142), CDX2 
plays a role in lineage segregation of the inner cell mass and trophectoderm (142, 143) as 
well as intestinal fate and epithelial mesenchymal signaling (144). HAND1 regulates 
embryonic cardiac development (145), PITX2 participates in limb development (146, 147), 
SOX9 in pancreatic and bile duct development (148), SNAI2 in epithelial mesenchymal 
transition (149, 150) and TSHZ1 in pancreatic cell development and maturation (151). 
Furthermore, TGFβ signaling in conjunction with upregulation of SNAI2 are consistent 
with epithelial to mesenchymal transition (EMT), which has also been described purely as 
being abnormally expressed in HLCs compared with PHHs (149). The opposing trend of 
transcript dynamics of these TFs may be indicative of discordant gene regulation between 
mouse liver development and HLC differentiation. We also examined the TF binding sites 
in the promoter regions of the dynamically differentially expressed genes 
(http://genome.ucsc.edu/ENCODE/). The TFs that have their binding site present in the 
promoter region of a large number of differentially expressed genes are listed in Table 5-
3.   
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Several cell surface proteins also had opposite trends of transcript dynamics 
between HLC differentiation and mouse liver development including SPARC, an 
extracellular matrix secreted factor, CDH3 (P-Cadherin) and the cell surface receptors, 
Frizzled (FRZB) and TGFBR3 (for WNT and TGFβ signaling respectively). Their 
transcript levels increased during the course of differentiation, but decreased in the 
developing embryonic mouse liver by E15.5.  
Expression of GLUT2 (SLC2A2), a liver specific glucose transporter, increased in 
the developing embryonic mouse liver but not in HLCs. The transcript dynamics of GLUT2 
was plotted together with that of mature human cell types, and mouse in vivo liver 
development on the unified developmental time (Figure 5-16). While GLUT2 transcript 
levels gradually increased in mouse liver development, it remained relatively low in 
differentiating HLC. A similar contrasting expression pattern between mouse liver 
development and HLC differentiation was also seen for three other enzymes involved in 
glucose metabolism that are highly expressed in liver: aldolase B (AldoB), glucose-6-
phosphatase (G6PC) and fructose-1,6-bisphosphatase (Fbp1). The latter two are involved 
in gluconeogenesis. Using the pipeline we established to compare in vivo developmental 
data with in vitro differentiation data, we were able to clearly show that the identified 
differentially expressed enzymes that are not expressed in HLCs are characteristic of 
mature hepatocyte. 
5.4 Discussion 
In this study, we used highly heterogeneous transcriptome data from human and 
mouse PSC in vitro differentiation and mouse in vivo embryo development for meta-
analysis. Due to the heterogeneous nature of the dataset, batch correction needed to be 
performed to remove the batch effects. Previous studies have shown that the empirical 
Bayes based ComBat algorithm can be relied on in removing systems bias caused by a 
mixture of transcriptome data from different populations of cells of different sources (152-
157). Through successive data processing with increasing level of data complexity, we 
successfully integrated hPSC-HLC differentiation data from different studies with mouse 
in vivo liver development data. In each level of analysis, after batch correction, 
unsupervised clustering grouped the data by their similarity in the stage of in vitro 
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differentiation or by their embryo developmental day. The batch-correction algorithm 
employed was originally developed to deal with the effects of different sources and 
platforms. We extended its use to combine data of different species. The clustering results 
of the batch corrected data give credence to the validity of the data processing. We 
examined the identity of the metagenes used in NMF and found them to be related to 
development and liver functions, confirming the biological relevance of clustering of the 
samples. 
Two observations can be made from the PCA results: first, differentiating HLCs 
align along their differentiation progression in a PC1 vs. PC2 plot; second, the HLCs 
derived using different protocols and from various sources, for both human and mouse, all 
lined up in a region that is composed of differentiated, but still immature fetal liver cells of 
E13-15. This indicates that irrespective of the species of origin, or the protocols used, 
differentiating HLCs appear to encounter universal roadblocks preventing their maturation. 
It also suggests that there might be a fundamental block that prevents HLCs from maturing 
further. 
Because all the time series data points of both in-vitro and in-vivo samples align 
along a common trajectory in the PC space, the results also suggest that the position along 
the trajectory can be a common measurement of the developmental stage for in vitro and 
in vivo samples from both species. We called this measurement “unified developmental 
time”. 
Identification of similar stages of development across different species that have 
vastly different time scales often relies on common morphological, biochemical and 
genetic hallmarks. For example, in human embryo development day 22 and 52 are 
considered to be equivalent to mouse E9.5 and E14.5 respectively (158). In an earlier study, 
neural development events were codified and used to generate a regression model for 
predicting a translation table of times of corresponding stages across nine species(159). 
Recently, transcriptome data of nematode species were compared to morphological 
markers to establish embryo developmental milestones in different species of 
Caenorhabditis (160). In another study, different feature measurements of leaves for 
different tomato species were subjected to principal component analysis to establish a 
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developmental trajectory (161).  Similarly, an algorithm taking RNA-seq data of a species’ 
developing embryo and subjecting them to principal component analysis for alignment in 
the PC plane was reported to describe the developmental stage (162). However, in many 
cases, the maturity of HLCs is measured by comparing it to primary hepatocytes at the 
functional, proteome, and transcriptome level. To our knowledge, this is the first study to 
compare genes across species and across the in vitro/in vivo border to identify the 
developmental stage at which HLCs are stuck at. 
Our meta-analysis revealed that all HLCs, regardless of the differentiation protocol 
used or species, were closer to mid-liver development (~E14.5) than to primary adult 
hepatocytes. We aligned the transcript dynamics of human in-vitro PSC-HLC 
differentiation and mouse in-vivo development on the “unified developmental time” to 
identify genes whose expression was progressing in opposite directions. Among the genes 
that were differentially expressed between h/mHLCs and mature cells (E19.5, adult liver) 
were key CYP450 enzymes (CYP2C8, CYP2C9, CYP2E1, CYP2D6 and CYP3A4) and 
metabolic isozymes (ALDOB, GLUT2, G6PC and FBP1) that are all hallmarks of mature 
liver metabolism.   
The dynamically differentially expressed genes between hHLC differentiation and 
mouse liver embryo development encompass many hallmarks of the lack of maturity in 
HLC.  An example is the expression of genes involved in the glucose metabolism. As 
hepatocytes become more mature, a new set of transporters, enzymes and their isoforms in 
glucose metabolism are expressed to give the liver its capability in maintaining the 
homeostasis of glucose and gluconeogenesis. Notably, the increased expression of glucose 
transporter GLUT2, and aldolase B (ALDOB) seen in mouse liver development and human 
adult hepatocytes did not yet occur in HLCs (Fig S11). Not surprisingly, the increased 
expression of the gluconeogenesis enzymes, glucose 6-phosphatase (G6PC), fructose 1,6-
biphosphatase (FBP) seen in mouse development was not seen in HLCs. Furthermore, we 
observed that 100 of the dynamically differentially expressed genes were found to have the 
same dynamic in both mouse and human in-vitro differentiation (Appendix Table 8-5). 
This observation informs us that although not all genes follow the same dynamic between 
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mouse and human differentiation, this does give us an insight into the key genes that need 
to be focused on and understanding how it is contributing to the immaturity in our HLCs. 
The gene expression profile and metabolic activities has led to the notion that HLCs 
were closer to fetal than adult hepatocytes (124). Another study of comparison between 
HLCs and human hepatocytes at the transcriptome level revealed 4000 differentially 
expressed genes (123). Our study demonstrates for the first time that HLCs obtained using 
various protocols and from different sources are all equivalent to E13-15.5 of mouse 
development. We were able to pin point the stage of developmental block by developing a 
“unified developmental time” that can span across species and in vitro and in vivo samples.  
Despite the difference in the methodology used, a large fraction of genes identified as 
differently expressed in the previous studies (123, 124) were also identified as dynamically 
differentially expressed in our study (Figure 5-17). However, differences between the two 
studies are also seen. Given the different reference of comparison used, (time course of 
embryonic liver development in this study vs. primary hepatocytes (123, 124), some 
differences in the identified gene list are not surprising. Most studies conclude the maturity 
of HLCs by measuring the expression of mature markers. But a more accurate 
measurement of maturity would be to compare the dynamics to an in-vivo development 
dataset where we are not only able to look into liver markers that are not expressed high 
enough but also at certain genes that might need to be silenced or are behaving erratically.   
Interestingly, a number of common transcription factors identified as differentially 
expressed are not known to play a role in hepatocyte differentiation, but are involved in the 
development of heart (HAND1), or heart, eye, lung (PITX1). Although this may not be 
surprising, as hepatocytes are created via a mesendodermal precursor early during 
development, persistent expression of these TFs may prevent final maturation of HLCs to 
the level of primary hepatocytes.  
 This study reaffirmed that HLCs are at an immature hepatocyte cell state, and for 
the first time identifies the “corresponding state” during embryonic liver development. 
Many genes whose expression followed a different pattern from that in the developing 
embryo might contribute to this block in further maturation. Whether inhibition of mis-
expressed TFs and activation of TFs that are missing will enhance maturation of stem cell 
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derived hepatocytes remains to be determined. In addition, this meta-analysis pipeline 
should be applicable to PSC differentiation studies to other lineages if the time course 
transcriptome data for both in vitro differentiation and in vivo development are available. 
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5.5 Figures 
 
 
Figure 5-1. Differentiation of human pluripotent stem cells to hepatocyte-like–cells. 
A) The timelines for mouse and human embryonic liver development and in- vitro stem 
cell differentiations. B) Quantitative PCR results showing the expression levels of key 
hepatic markers during the course of hepatocyte differentiation depicted in A. C) 
Immunostaining of the endodermal marker, FOXA2, during the endoderm stage of 
differentiation and several hepatic markers (Hepatocyte nuclear factor 4-alpha (HNF4A), 
Alpha-1-Antitrypsin (AAT), Albumin (ALB)) at the last day of differentiation Scale bar. 
50um.  
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Figure 5-2: Hierarchical clustering of human in-vitro differentiation data before 
batch correction. Platform dependent batch effect were evident for human in-vitro 
differentiation data. The different colors indicate the different platforms for each sample. 
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Figure 5-3. Clustering of In-vitro Human Differentiation Data After Batch 
Correction. A) Hierarchical clustering of samples at different stages of differentiation. The 
colors represent different sources of data. See Table 5-1 for sample annotation. B) Non-
negative matrix factorization on human in-vitro data after batch correction. All the samples 
clustered into three distinct groups of early, mid, and late stages of differentiated cells. C) 
Principal component analysis. The samples aligned according to their differentiation status 
in the principal component space, starting with endodermal cells followed by HLCs and 
the most mature cell types to the far right. The colors represent the different stages of the 
samples and the shapes represent the different sources of the data.  
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Figure 5-4: Cophenetic plot for human samples. The cophenetic coefficient for the 
human differentiation dataset is plotted for different ranks. Since the coefficient begins to 
decrease at 3, the data was optimally clustered into three groups. 
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Figure 5-5: Platform dependent effects of mouse developmental data. The two sets of 
mouse development data where both platforms are represented in red and blue are 
illustrated. The transcriptome data were clustered largely by their sources and platforms 
without batch correction.
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Figure 5-6. Clustering of Mouse Embryonic Development Data After Batch 
Correction. A) Hierarchical clustering grouped different developmental data into early 
and late stages of development. (red): isolated CD34-Ter119- cells from fetal liver, (blue): 
cells from a whole liver . B) Non-negative matrix factorization on mouse embryonic 
development data (biological replicates from (A) were averaged) separated the mouse data 
into two groups of early and late stages of development. C) Principal Component analysis 
aligned samples (biological replicates from (A) were averaged) according to their 
developmental stage in the principal component space.   
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Figure 5-7. Cophenetic Plot for Mouse Development Samples. The cophenetic 
coefficient begins to decrease at 2 for mouse development, therefore data was optimally 
clustered into two groups 
 
 
 
 
 
 
 
 
 
103 
 
 
Figure 5-8. Principal Component Analysis on Combined Mouse In-Vitro 
Differentiation and Mouse Embryonic Liver Development Data.  
Open circles represent embryonic developmental data, blue and red indicate samples from 
two different studies (Figure 5-6).  Closed green circles represent samples from in vitro 
differentiation and X represents primary mouse hepatocytes. To confirm the robustness of 
our approach, a separate mouse in-vitro dataset was integrated with in-vivo data for 
studying the dynamic of gene expression. More specifically, transcriptome data of a time 
course analysis of miPSCs differentiating to HLCs and murine fibroblasts being 
reprogrammed to iHeps were integrated with the mouse embryonic development data sets 
by batch correction. Again, batch correction removed the bias of platforms, sources and in 
vitro/in vivo contrast. The mouse iPSC differentiation data aligned chronologically with 
E9.5 to E15.5 stages of mouse liver development, while the data points for mouse 
embryonic liver development beyond E15 continue to spread to the region with higher 
values of PC2. The results suggest that the miPSC-HLCs and miHEPS acquired a 
differentiation stage equivalent of ~E13.5-15.5 stage and still lack the maturity of fully 
developed prenatal E19 and postnatal liver.  
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Figure 5-9. Gene expression profile in mouse developmental samples before and 
after combining the human in vitro and mouse in vivo data by performing batch 
correction for species effects. A) The gene profiles for AFP and ALB for mouse 
samples (solid line) are shifted but the dynamic trend is preserved after batch correction 
(dash line). B) The gene expression profile in human differentiation samples before 
(solid line) and after (dash line) combining the human in vitro and mouse in vivo data 
by performing batch correction for species effects. C) The gene expression profile for 
AFP in mouse and human samples after batch corrections 
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Figure 5-10. Principal Component Analysis on Combined Human In-Vitro 
Differentiation and Mouse Embryonic Liver Development Data. Combined human in-
vitro and mouse in-vivo datasets were subjected to the principal component analysis. The 
blue and red circles of mouse samples represent two different studies. Human in vitro 
differentiation data are represented by color according to their differentiation state. 
Endodermal cells, hepatic progenitor cells and HLCs samples are in green, purple, and 
blue, respectively. The circles, squares and triangles correspond to samples from different 
studies described in Table 5-1. 
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Figure 5-11. Differentially Expressed Genes between HLCs and PHH. Transcript 
levels of orthologous genes of human and mouse HLC were compared to that in PHH and 
E19.5 embryo, plotted against each other. Genes consistently differentially expressed 
(upregulated by four fold or higher in E19.5) in both comparisons were highlighted. *Una.- 
Unannotated gene. 
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Figure 5-12. Alignment of Samples Along the Developmental Time and Identification 
of Dynamically Discordant Transcripts.  A) Mouse embryo development and human in 
vitro differentiation samples aligned along Unified Developmental Time (DT).  The PC2 
values for mouse and human samples are plotted against DT. The DT can be represented 
as a common measure of maturity for in vitro differentiation and in vivo development. B) 
Cross-species/Cross-in vitro-in vivo Comparison of transcript dynamics based on DT as a 
common time scale. Notable Transcription Factors are plotted along the Developmental 
Time.  
 
 
 
 
 
 
 
 
108 
 
 
 
 
109 
 
 
 
 
 
110 
 
 
 
 
 
 
L
o
g
2
(I
n
te
n
s
it
y
 V
a
lu
e
) 
111 
 
112 
 
113 
 
114 
 
115 
 
116 
 
117 
 
118 
 
119 
 
120 
 
121 
 
122 
 
123 
 
124 
 
 
125 
 
126 
 
127 
 
 
L
o
g
2
(I
n
te
n
s
it
y
 V
a
lu
e
) 
128 
 
 
Figure 5-13A-AK. Dynamically differentially expressed genes during human in 
vitro differentiation and in vivo separated based on molecular function from 
DAVID. (Black: D6_H, D10_H, D14_H, HLC_H1) and mouse development (Blue: 
E9.5, E11.5, E13.5, E15.5) A) Actin filament binding B) Amine binding C) Amino acid 
binding D) Cadmium binding E) Calcium binding F) Carbohydrate binding G) 
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Carboxylic acid binding H) Cell surface binding I) Collagen binding J) Copper ion 
binding K) Cytokine activity L) Endopeptidase inhibitor activity M) Enzyme inhibitor 
activity N) Extracellular matrix protein constituent O) Glutamate binding P) 
Glycoprotein binding Q) Glycosaminoglycan binding R) Growth factor activity S) 
Growth factor binding T) Heparin binding U) Identical protein binding V) Insulin-like 
growth factor binding W) Insulin-like growth factor I binding X) Oxidoreductase activity 
Y) Pattern binding Z) Platelet-derived growth factor binding AA) Polysaccharide 
binding AB) Protein dimerization binding AC) Protein heterodimerization activity AD) 
Protein homodimerization activity AE) SMAD binding AF) Structural molecule activity 
AG) Transcription corepressor activity AH) Transcription represssor activity AI) 
Transforming growth factor beta receptor binding AJ) Type II transforming growth 
factor beta receptor binding AK) Unannotated  
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Figure 5-14. Functionally enriched gene class in the dynamically 
differentially expressed genes. 
 
 
 
 
 
 
 
 
 
 
 
131 
 
  
Figure 5-15. Transcript Dynamics of Notable Upregulated Transcription Factors 
using qRT-PCR.   
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Figure 5-16. The gene expression profile for different metabolic genes. Four 
different genes A) aldolase B (AldoB), B) glucose transporter 2 (Glut2), C) glucose 
6-phosphatase (G6PC), D) fructose-1,6-biphosphatase 1(FBP1), in glycolysis and 
gluconeogenesis were plotted to illustrate the difference between human in vitro 
differentiation/human liver and mouse in vivo development. 
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Figure 5-17. Dynamic behavior of candidate genes found in (Godoy et al. 2015) 
were compared to our meta-analysis. Godoy et al. compared HLCs to ESCs to 
obtain 5 clusters of genes. We took the representative genes that Godoy presented and 
compared it with our dynamic data in Hu and mouse data. A check mark represents a 
similar behavior was found dynamically in either Hu or mouse time course data. A 
check mark in Cluster 1 represents a continuous increase in expression to levels 
similar to primary cells. A check mark in Cluster 2 represents a minimally induction 
of expression. A check mark in Cluster 4 represents a continuous decrease in 
expression to levels similar to primary cells. A check mark in Cluster 5 represents an 
increase in expression level from an existing high expression level. 
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Table 5-1. List of microarray transcriptome data of human HLC differentiation 
complied for this study. 
Data Platform Samples Brief Description Abbreviation of 
Samples 
GSE14897 
(Duncan) 
Affymetrix H9: D0, D20 
iPS: 
Fibroblasts, 
D20 
Hepatocyte-like cells 
from iPS and H9 
differentiation on 
D20 
HLC_D, iHLC_D 
GSE25417 
(Duncan) 
Affymetrix H9:D5, D10, 
D15, 
HNF4 
knockdown 
D20 
HNF4α knockdown 
in H9 differentiation 
D5_D, D10_D, 
D15_D 
GSE25744 Illumina H1: D0, HLC 
iPS: D0, HLC 
fibroblasts, 
fetal liver 
H1 and iPS cells 
differentiated using 2 
protocols 
HLC_A1, 
HLC_A2, 
HLC_A3, 
HLC_A4, 
HLC_A5, Fetal 
Liver 
 
 
Illumina H9: D0, D6, 
D9, D10, D12, 
D14, D20, D26 
Time-course of H9 
cells differentiation 
of HLCs 
D6_H, D9_HE, 
D10_H,D12_HE,D
14_H, 
HLC_H1,HLC_H2 
Raju et al, 
to be  
deposited 
Illumina HSF6: D0, 
D20, D32 
spheroids, 
Adult liver 
Hepatocyte-like cells 
from HSF6 cells 
differentiated to D20 
and cultured as 
spheroids as well as 
adult liver tissue 
HLC_S,HLC_SS,A
dult Liver 
Raju et al, 
To be 
deposited  
Affymetrix HES: D0, D20 Hepatocyte-like cells 
from HES3 
differentiation 
HLC_H3 
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GSE42643 Agilent Fibroblasts, 
HLCs, PHH 
Hepatocyte-like cells 
reprogrammed from 
human fibroblasts 
and primary 
hepatocytes 
iHEP,PHH 
GSE46631 Agilent Liver bud from 
iPS 
Liver bud: 
Hepatocyte-like cells 
from iPS with 
HUVECs and MSCs 
LB 
 
Table 5-2. List of mouse microarray transcriptome data compiled in this study. 
Data Platform Samples Brief 
Description 
Abbreviation of 
Samples 
GSE46631 Agilent E9.5 - 
E19.5 
Mouse liver 
development 
E9.5, E10.5, 
E11.5, E13.5, 
E15.5, E17.5, 
E19.5 
GSE13149 Affymetrix E11.5 - 
Adult 
Mouse liver 
development 
E11.5, E12.5, 
E13.5, E14.5, 
E15.6, E16.5, 
E17.5, E18.5 
www.alexaplatform.org Illumin 
HiSeq 
E8.5, 
E14.5, 
Adult 
Liver 
Mouse liver 
development 
E8.5, E14.5, 
PHH_ms 
GSE23635 Illumina MEFs, 
iHEP 
MEFs 
reprogrammed 
to hepatocytes 
iHEP1 
GSE29725 Illumina MEFs, 
iHEP 
MEFs 
reprogrammed 
to hepatocytes 
iHEP2 
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GSE48486  Affymetrix MEFS, 
iHEPSCs 
MEFS 
reprogrammed 
to hepatic 
progenitor cells 
iHEP3 
To be deposited Illumina D6, D10, 
D20, D28 
miPSCs 
differentiation 
to HLCs 
D6, D10, D20, 
D28 
 
 
Table 5-3. Transcriptional factors overrepresented in differentially expressed 
genes based on their predicted binding sites. 
Overrepresented 
TFs 
Number of Genes 
Dynamically 
Differentially Expressed  
PPARG 95 
AP4 79 
RP58 69 
ER 65 
TATA 65 
GR 64 
AHRARNT 63 
GATA 56 
CHX10 51 
IK1 50 
LYF1 49 
ZIC2 31 
GATA6 26 
CREL 23 
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Chapter 6. Metabolism Shift in Hepatocyte-like Cells  
6.1 Introduction 
 In the previous chapter, we observed significant changes in numerous genes over 
the course of the differentiation. Some of the most obvious changes that occurred were 
involved in the metabolic pathways. In some incidents, certain genes that are involved in 
mature hepatic functions that are involved with glucose metabolism, however, was found 
to never be turned on when compared to their primary hepatocytes counterpart. In this 
chapter, we dived a bit further to illustrate if our hESCs are transitioning towards a 
metabolic phenotype that mimics primary hepatocytes. The understanding of metabolism 
in mammalian cells has contributed to maximizing the capability of using cells as the major 
workhorse in the biotechnology industry and medicine field. Our increasing understanding 
on the effects of metabolism on cellular behavior has resulted in massive efforts to 
designing robust cell culture practices for reproducible production of different biologics. 
Over the past decades, as our knowledge in stem cell and developmental biology grows, 
stem cells have emerged as the next cellular candidate for revolutionizing the field of 
regenerative medicine and tissue engineering.  
 Stem cells possess the ability to self-renew and differentiate into highly specialized 
cell types found in the body. Using different growth factors and cytokines to mimic 
embryonic signaling cues, stem cells can be guided to differentiate into hepatocytes 
through different developmental stages in a manner similar to embryonic development. 
Thus, a better understanding of the different mechanisms controlling expansion and 
differentiation of stem cells is of great importance for the systematic production of cells 
for clinical and industrial applications. Various analyses have shown the resemblance of 
stem cell-derived hepatocytes (SCDHs) to primary hepatocytes on different levels, 
particularly at the global gene expression and proteomics. Although the cellular 
metabolism has been looked at extensively, the role of cellular metabolism has on 
hepatocyte differentiation is not as well established.   
Primary hepatocytes have been shown to rely primarily on mitochondrial 
respiration for bioenergetic demands. The generation of stem cell-derived functional and 
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metabolically competent hepatocytes would be a key step towards the utilization of SCDHs 
for regenerative medicine in liver applications. It is well documented that each type of cell 
has a unique metabolic profile to dictate the function or fate of that cell type. During 
differentiation, stem cells transition through several stages undergoing genetic and 
biochemical changes to fit the energetic demand of the current cell type. Stem cells and 
other fast growing cell types (e.g. CHO, cancerous cell types), have long been observed to 
rely on glycolysis for energy. In agreement with these preferences for energy demand, 
hypoxia has been shown to be beneficial in maintaining hESCs in its pluripotent state (163, 
164).  In more differentiated cell types, such as primary hepatocytes, mature mitochondria 
are typically observed with the activation of the mitochondria process of oxidative 
phosphorylation(OxPhos) for energy supply (165). Studies have shown that primary 
hepatocytes exist in a low glycolytic state with a metabolic signature representative of 
oxidative phosphorylation with moderate levels of oxygen consumption(166, 167). The 
preference between glycolysis and oxidative phosphorylation have often been used as a 
marker of differentiation status. The gene expression profile of pluripotent stem cells reveal 
slightly different metabolic signature compared to their differentiated counterpart in terms 
of glucose-dependent pathways (168).  
 While there is plenty of studies on the metabolic behavior of pluripotent stem cells 
during differentiation, the behavior of primary hepatocytes and pluripotent stem cells have 
been studied much more extensively. Pluripotent stem cells have been shown to exist in a 
high state of glycolysis with high glucose consumption and lactate production.  However, 
freshly isolated primary hepatocytes in culture are much more metabolically active capable 
of drug metabolism and gluconeogenesis. Studies have shown that primary hepatocytes 
exist in a low glycolytic state with a metabolic signature representative of oxidative 
phosphorylation with moderate levels of oxygen consumption.  
Few studies have assessed the bioenergetic changes in pluripotent energy 
metabolism during differentiation towards the hepatic lineage. Due to the dynamic nature 
of stem cells during differentiation, it is important for us to understand the bioenergetic 
changes that is occurring. During the very early stages of embryo development, cells 
experience a metabolic shift from oxidative phosphorylation to glycolysis, and reverts back 
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to oxidative phosphorylation after commitment to tissue lineage (169). For example, the 
restriction or abundance of certain amino acids can alter the metabolic behavior and lead 
to certain byproducts changing the cell’s fate and function.  
 In accordance to previous studies, our results reveal that hESCs have mitochondria 
with lower activity consistent with cells in low oxidative phosphorylation and high 
glycolytic activity. In this study, we looked at the changes occurring during differentiation 
towards the hepatic lineage and the changes in bioenergetic demands. In addition, the effect 
of glucose availability on stem cell proliferation and differentiation was examined closely 
in this work. A comprehensive analysis using transcriptome and metabolic flux model was 
used to shed some light on the mechanisms that hESCs use to maintain high levels of 
glycolysis and the changes that occurring during differentiation.  
6.2 Results 
6.2.1 Hepatocyte Differentiation from Human Embryonic Stem Cells on 
Microcarriers 
A 20-day differentiation protocol previously published before was used to 
differentiate H9 human embryonic stem cells towards hepatocyte-like cells (170). We used 
the same protocol to differentiate feeder-free H9 embryonic stem cells towards the hepatic 
lineage. As the differentiation proceeded, we assessed the level of stage-specific transcripts 
during the differentiation using qRT-PCR. Endodermal markers, goosecoid (GSC) and 
CXC motif chemokine receptor 4 (CXCR4), were both expressed in the second stage of 
hepatic differentiation as reported previously. We also observed the gradual increase in 
expression of different hepatic markers; alpha-fetoprotein (AFP), albumin (ALB), Alpha1-
antitrypsin (AAT), and hepatic nuclear factor 4 (HNF4α), reaching the highest level by the 
end of the differentiation.  
In line with the transcript levels, we also evaluated the expression of endodermal 
and hepatic genes at the protein level using immunostaining. FOXA2, a key transcription 
factor in the establishment of endodermal cells, were prominent in the second stage 
consistent with the transcript levels observed. We also observed the presence of HNF4α, a 
nuclear transcription factor expressed during liver development which regulates the 
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expression of several liver-specific genes, by the second stage of differentiation. At the end 
of the differentiation, we observed a majority of cells expressing albumin. These results 
suggest that we can successfully differentiate embryonic stem cells to hepatocytes after the 
exposure to different cytokines and growth factors over twenty days to similar reports. 
 To increase the volumetric consumption rate of nutrients and amino acids, 
microcarriers were utilized in this study to obtain higher cell concentration for measurable 
differences in metabolite concentrations between consecutive samples (Figure 6-1A). 
Numerous reports have shown the difficulty in attaching embryonic stem cells onto 
different configurations of microcarriers so we decided to use differentiating endodermal 
cells. From our previously published study, we observed that endodermal cells are capable 
of proliferating to a large extent with the capability to still differentiate towards the hepatic 
lineage. We screened different coating material on different microcarriers and found 
Matrigel™-coated Cytodex 3 microcarriers to have the highest attachment efficiency 
(Figure 6-2). Thus, we assessed the extent of differentiation for both method of 
differentiation on Cytodex 3 beads and tissue culture plates (TC). To determine the 
progression through differentiation in both methods, we investigated the presence of 
different markers using immunohistochemistry and qRT-PCR.  
Using confocal microscopy for Cytodex 3, we observed a majority of cells 
expressed the endodermal marker, FOXA2, on Cytodex 3 and tissue culture plate (TCP) 
differentiation after the endodermal induction media. Similarly, the presence of the liver 
transcription factor, HNF4α, was expressed in the second stage of differentiation 
illustrating a similar progression of differentiation for both Cytodex 3 and TCP. By the end 
of the differentiation protocol, we observed that a majority of the cells were positive for 
mature hepatic marker, albumin (ALB), on both Cytodex 3 and TCP differentiation (Figure 
6-1C and 6-3A).  
As visualized by the presence of certain stage markers, qRT-PCR using primers 
specific to different hepatic markers were used to measure the transcript level at the end of 
the 20-day protocol. In the present study, hepatic markers (ALB, AAT, ASGPR1, and 
CYP3A4) were observed to be significantly expressed by the end of the differentiation 
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process (Figure 6-1B). The transcript level revealed that the HLCs differentiated on 
Cytodex 3 and TC showed remarkably similar levels of different hepatic markers. 
Functional maturity of the hepatocyte-like cells obtained from both differentiation 
methods were also assessed by measuring albumin and urea synthesis (Figure 6-3B and 6-
3C). Both analysis showed HLCs capable of secreting albumin and urea that is typically 
observed in primary hepatocytes in the liver. The levels of secretion for both albumin and 
urea were comparable to previously reported rates as well (78, 170).  
6.2.2 Metabolic Switch During Hepatic Differentiation 
 Representative data for different metabolite (glucose, oxygen, and lactate) were 
monitored in the medium at different days of the differentiation for calculating the specific 
rates (Figure 6-4). During HLC differentiation, glucose consumption on a per cell basis 
(i.e. specific glucose consumption rate) decreased progressively over the course of the 
differentiation. Accompanied by the decrease in glucose consumption, we also observed a 
general decrease in lactate production. The maximum theoretical yield of lactate 
production from glucose consumption in glycolysis is 2.0. The molar stoichiometric ratio 
of lactate production to glucose consumption (∆L/∆G) decreased from 1.30 + 0.35 
(mol/mol) during the first stage of differentiation to 0.50 + 0.18 (mol/mol) by the second 
stage of differentiation. By the end of the differentiation, the derived hepatocyte-like cells 
exhibited a ∆L/∆G of 0.26 + 0.06 indicative of cells in a low glycolytic state (Figure 6-
5A). The consumption rate for most the amino acids decreased over the course of 
differentiation. Levels of alanine, glutamate and proline increased in the media over the 
course of the differentiation indicating secretion of these non-essential amino acids.  
Oxygen consumption increased in parallel to the decrease of glycolytic activity 
over the course of differentiation, from 1.50*10-10 mmol O2/cell/h initially to 2.29*10
-10 
mmol O2/cell/h by the end of the differentiation (Figure 6-5B). The stoichiometric ratio 
of oxygen and glucose consumption increased from 1.21 + 0.20 (mol/mol) to 3.46 + 0.41 
(mol/mol) by the end of the differentiation. The data suggests that cells adopt an 
increased OxPhos metabolism as they mature further into hepatocyte-like cells.   
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6.2.3 Metabolic State Change Reflected at Transcript Level 
 To further investigate the metabolic pathways that may be responsible for the 
metabolic switch, we looked at the transcript levels of key glycolysis genes involved in the 
regulation of glucose. Although we did not observe drastic changes in many key glycolytic 
enzymes from microarray data (Figure 6-6), we did observe the biggest changes in the 
glucose transporter (GLUT), hexokinase (HK), and pyruvate kinase (PKM). Using the 
microarray data, we further narrowed down glycolytic enzymes to the most highly 
expressed isoforms in our cells and carried out qRT-PCR to confirm our findings from the 
microarray data. We observed a substantial decrease in expression of GLUT3 for HLCs 
compared to hESCs and over 2-fold decrease in expression for GLUT1 by the second stage. 
In addition, we also saw a similar trend in gradual downregulation of PKM1/2 and HK1 
by almost 2-fold after the first stage. The collective set of genes showing a gradual decrease 
of expression over the course of differentiation suggest that there may be master regulator 
driving their behavior. Many reports have suggested that the AKT pathway can affect 
cellular growth and metabolism through the regulation of the  different glycolytic enzymes 
that were mentioned previously (75). However, no such changes were seen at the transcript 
level for the AKT gene and Western blot also revealed no changes on the protein level 
when performed on Total AKT and phosphorylated AKT (Figure 6-7). Surprisingly, we 
did see a dramatic increase in expression for mitochondria pyruvate carrier (MPC1/2) from 
the microarray data (Figure 6-8). Using qRT-PCR, we confirmed our observation by 
observing an increase of 4-fold by the second stage in expression compared to the starting 
stem cell state.  
6.2.4 Mitochondrial Morphology During Differentiation along the Hepatic 
Lineage 
 Changes in mitochondrial morphology and activity have been reported to indicate 
a preference towards cells with an oxidative phosphorylation metabolism. The observed 
transition between glycolysis and oxidative phosphorylation during the hepatocyte 
differentiation was further characterized by looking at the morphology and activity of the 
mitochondria over the course of differentiation. Using MitoTracker Green FM which stains 
the mitochondria regardless of membrane potential, we used confocal microscopy to show 
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that the mitochondrial population was much less organized and dimmer in intensity (Figure 
6-9A). However, when we looked at a differentiated population under the same imaging 
settings, we saw a brighter network of elongated mitochondria typically observed in mature 
mitochondria. The morphology in mitochondria has been frequently reported to change in 
accordance to the metabolic needs of cells [insert citation]. We assessed mitochondrial 
morphology by using a quantitative analysis measuring mitochondrial form factor and 
aspect ratio during over the course of differentiation. We showed that mitochondrial 
elongation (aspect ratio) and network formation (form factor) showed an increase by stage 
4 of differentiation consistent with the observation in increase in OxPhos (Figure 6-9B).  
6.2.5 Mitochondrial Biogenesis and Activity During Hepatocyte 
Differentiation 
 In addition to assessing the mass of mitochondria in our cells over the course of 
differentiation, we also considered mitochondria activity by using MitoTracker Red CM-
h2xros which fluoresces upon activation of membrane potential. We observed a much 
lower membrane potential as illustrated by Figure 6-10A in the beginning of 
differentiation. Cells have much more active mitochondria by the end of the differentiation 
starting in the second stage of differentiation corresponding to the increase in oxygen 
demand found previously. Due to the observation of increase in mitochondria mass and 
activity, we next analyzed the mitochondria DNA in cells over the course of differentiation. 
These results were further verified by showing an increase in mitochondria DNA levels 
over the course of differentiation (Figure 6-10B). We revealed that cells doubled their 
mtDNA levels from 0.015 + 0.002 x 10-12g/cell in the beginning to 0.034 + 0.001 x 10-
12g/cell by the end. Given that mitochondrial biogenesis is occurring, it requires the 
synthesis of many important mitochondria genes. We also assessed the expression of 
COX1, COX2, and COX3 that are essential for oxidative phosphorylation and encoded in 
the mitochondria DNA and revealed their increase in protein expression over the course of 
the differentiation (Figure 6-10C).  
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6.2.6 Amino Acid Contribution to the Energy Metabolism During Hepatocyte 
Differentiation 
In order to characterize the metabolic changes that cells undergo during hepatocyte 
differentiation, we also measured the amino acid concentration (Figure 6-11 and 6-12). All 
essential amino acids were consumed over the course of the differentiation (Figure 5A). 
However, the demand for amino acid was observed to lessen over the course of 
differentiation. Similarly, the metabolic demand for non-essential amino acid was also less 
over the course of the differentiation. Certain non-essential amino acids (e.g. alanine, 
glutamate and proline) were secreted by the cells. Alanine and glutamate have been 
frequently reported as the major amino acids that are produced by different types of stem 
cells  (171). 
 Using the specific rates of the different metabolites, a metabolic flux analysis was 
performed and the average fluxes could be mapped onto the central metabolic pathways 
(Figure 6-14). Consistent with the specific rates obtained through experiments, the 
glycolytic flux (JGLC-PYR) was twice as high in the first stage of differentiation compared to 
the last stage (Figure 6-13). Although, most of the fluxes within the TCA cycle were 
comparable throughout the differentiation but the first few pathways in the TCA cycle 
reveals a higher flux after the first stage of differentiation. The observed increase in TCA 
flux over the course of the differentiated could be attributed to the increase in (JPYRC-PYR), 
responsible for the transport of pyruvate into the mitochondria after glycolysis which is 
consistent with our previous observation with an increase expression in the enzyme 
facilitating the transport, MPC. We also observe an increase in mala-aspartate shuttle 
fluxes suggesting that oxidative phosphorylation is more active in later stages of 
differentiation.  
6.2.7 Influence of Glucose on Metabolism During Stem Cell Differentiation 
 From the previous sections, we observed that cells transition from a high to low 
glycolytic state over the course of the differentiation starting in the endodermal stage when 
cells begin to commit to the hepatic lineage. To show the importance of the metabolic 
switch, we used varying levels of glucose concentration to manipulate the metabolism state 
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of the cells during the differentiation. We observed that cells cultured in high glucose 
concentration at ~25mM consumed much larger quantities of glucose and secreted larger 
quantities of lactate (Figure 6-15). We compared differentiating hESCs at high glucose 
concentration with the conventional concentration at ~5mM and showed that the metabolic 
switch from high to low glycolytic state does not occur in the presence of high glucose 
concentration. Interestingly, the rate of glucose consumption and lactate production on a 
per cell basis was almost triple of what was observed in the high glucose differentiation 
compared to the conventional glucose concentration. Using qRT-PCR and albumin 
secretion assay, we showed that differentiation carried out at high glucose concentration 
were still capable of exhibiting hepatic phenotypes but to a lesser degree compared to a 
differentiation carried out a lower glucose levels (Figure 6-16).   
6.3 Discussion  
  Although the energetic state of hESCs have been studied extensively, the 
mechanisms and observation behind the bioenergetic changes during hepatic 
differentiation are still not completely understood. The present study assessed the 
metabolism of hESCs during the differentiation towards the hepatic lineage and how it can 
influence the way we carry out future processes for stem cell culture. Based on our findings, 
we can conclusively state that OxPhos is activated during the hepatocyte differentiation of 
hESCs. Compared to other studies documenting the bioenergetic state of undifferentiated 
and differentiated cells, our study evaluates the bioenergetics demands and mitochondria 
network at different time points over the course of hepatocyte differentiation for hESCs.  
 In this study, we explored into the metabolic mechanisms and energetic 
requirements that are occurring over the course of the differentiation. With regards to 
glycolysis, cells in the first stage of differentiation adopt a high glycolytic state where high 
glucose consumption and high lactate production was observed. This phenomenon is 
typically referred to as the Warburg Effect and has been observed in highly proliferative 
cells such as cancer cells and stem cells for decades [insert citation]. Our study reveals that 
differentiating endodermal cells also retain the pre-existing high glycolytic state. It is 
evident that the highest level of glycolysis occurs during the beginning of the 
differentiation and begins to transition towards a low glycolytic state starting after 
committing to the hepatic lineage during the second stage of differentiation. This decrease 
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in glycolytic capability is accompanied by the transition towards a OxPhos metabolism. 
We begin to observe a gradual increase in oxygen consumption starting in the second 
differentiation stage and reaching peak levels of 2.3 x 10-10 mmol/cell/h by the end of 
differentiation for SCDHs. Many studies have attempted to measure the intrinsic oxygen 
consumption rate of different primary hepatocytes and reported of similar values between 
3 x 10-10 – 3 x 10-9 mmol/cell/h (172-175).  
 It is widely accepted that differentiated and metabolically active cells such as 
primary hepatocytes have more efficient mitochondrial metabolism in favor of OxPhos. 
The plasticity in energy metabolism allows stem cells to change their metabolic phenotype 
to satisfy the different needs of self-renewal and its different lineage specification. Our 
findings suggest that when stem cells commit to the hepatic lineage there is a smaller 
dependence on glycolysis accompanied by an increase in oxygen consumption.  One 
possible explanation for the increase in oxygen consumption could be an increase in 
mitochondria biogenesis. To assess the generation of mitochondria, we measured the 
mtDNA levels on a per cell basis and found significant increase over the course of the 
differentiation. We further seek to investigate whether mitochondria network formation 
was also occurring to promote the activation of OxPhos during our hepatic differentiation. 
Typically, immature mitochondria with less defined cristae are more common among cells 
that depend more on glycolysis (176). It has frequently been reported that mature 
mitochondria is crucial and required during stem cell differentiation for cells that require 
OxPhos especially in cardiac differentiation (177-179). In addition to the increase of 
mtDNA levels over the course of hepatic differentiation, the membrane potential of the 
mitochondria was assessed using a rhodamine dye which revealed an increase in 
mitochondria activity supporting our hypothesis that OxPhos has been activated. The 
maturity of mitochondria has been shown to play a vital role in the balance between 
pluripotency and cellular differentiation(180). In this study, we further demonstrated the 
maturity of our HLCs through the established network formation. Thus, we can conclude 
that the increase in OxPhos during hepatic differentiation is due not only to mitochondria 
generation but also the maturation of mitochondria as well.  
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 The observed metabolic switch and increase in mitochondria biogenesis must also 
have a regulatory mechanism during differentiation. We used transcriptome data to look at 
glucose-related genes to give us insight into what possible regulators might be behind the 
changes in energy metabolism. Our data indicated that there may not be a master regulator 
behind the metabolic switch and decrease of glycolytic activity. Instead, we observed a 
number of different glycolytic enzymes showing decreased expression over the course of 
the differentiation. Specifically, we observed a decrease in the transporter (GLUT1 and 
GLUT3) responsible for providing intake of glucose to the cells. Interestingly, we also 
show that there is a decrease of expression in both predominant forms of hexokinase (HK1 
and HK2). Several studies have shown the elevated glucose uptake from the overexpression 
of simply either GLUT or HK or both (181, 182).  Although we observed a number of 
different glycolytic enzymes showing decreased expression in support of our metabolic 
switch, most metabolic enzymes in the TCA cycle are present at very high levels 
throughout the differentiation without any remarkable changes during differentiation. 
However, mitochondria pyruvate carrier (MPC) was expressed at very low levels until its 
induction during the second stage of differentiation corresponding to the increase in 
OxPhos activity. Recent works have shown that MPC is vital to hepatic gluconeogenesis 
and TCA cycle flux (183, 184). The loss of MPC activity was shown to impair the transport 
of pyruvate to the TCA cycle and ultimately diminishing the levels of metabolic 
intermediates found in the mitochondria. We confirmed the importance of MPC for HLCs 
generation by supplementing UK5099, a MPC inhibitor, and observed that cells were 
unable to differentiate past the second stage of the differentiation ultimately resulting in 
cell death (data not shown). This allowed us to conclude that the metabolic switch to 
OxPhos is essential to commitment to the hepatic lineage. Despite all the work conducted, 
the exact mechanism driving the switch to OxPhos to induce TCA flux has not yet been 
described.   
 In this study, we have described the bioenergetic needs of cells at different stages 
of hepatic differentiation and identified the metabolic switch that occurs which is crucial 
for making HLCs. Together, our findings provide important insights into the distinct 
regulation of bioenergetics during hepatic differentiation and the importance of the 
metabolic switch. At later stages of differentiation when hepatic cells begin to exhibit more 
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mature processes of lipid and carbohydrate metabolism, the demand for active 
mitochondria and TCA flux increases while the need for glycolysis diminishes. The work 
conducted here will be important as we move forward exploring new approaches to 
manipulate hESCs fate and lineage commitment to generating mature HLCs for new and 
important therapeutic opportunities.  
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6.4 Figures 
 
 
Figure 6-1. Characterization of HLC Differentiation. A) Cell count during hepatocyte 
differentiation on Cytodex 3 microcarriers (bold line) and on tissue culture (TC) plate 
(dashed line). Error bars are depicted as standard deviation of 3 replicates. B) Quantitative 
RT-PCR (qRT-PCR) of different hepatic markers of HLCs normalized to GAPDH 
compared to human embryonic stem cells (hESCs) for differentiation on Cytodex 3 and 
TC plates. Error bars are depicted as standard deviation of 3 replicates. C) 
Immunohistochemistry of endodermal, FOXA2, and hepatic (HNF4α, ALB) markers at 
different stages of differentiation on Cytodex 3. 
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Figure 6-2. Attachment Efficiency on Microcarriers. Different microcarriers (cytodex 
1 and 3) was examined for attachment efficiency compared to tissue culture plate (TC 
plate). Different coating using Matrigel/Collagen IV/ and Fibronectin (FN) was tested to 
give the best attachment efficiency.  
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Figure 6-3. Functional Characterization of HLC Differentiation. A) 
Immunohistochemistry of endodermal, FOXA2, and hepatic (HNF4α, ALB) markers at 
different stages of differentiation on Cytodex 3 and TC plate. Scale bar is 50um. B and C) 
Albumin and urea synthesis for HLCs differentiated on TC plate. 
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Figure 6-4. Glucose and Lactate Concentration Profile over Course of Differentiation. 
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Figure 6-5. Metabolism Profiling of Cells During HLC Differentiation. A) Glucose 
consumption and lactate production rate for cells during different stages of differentiation. 
Stoichiometric ratio of lactate:glucose was plotted in a solid red line. B)  Oxygen 
consumption was plotted along with glucose consumption for different stages. 
Stoichiometric ratio of oxygen:glucose was plotted in a solid red line. 
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Figure 6-6. Microarray Data on Different Glycolytic Isozymes During Differentiation. 
Different glycolytic enzymes were plotted along with its different isozymes. The data was 
linear normalized and each color represents an isozyme.  
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Figure 6-7 Western Blot of Total AKT and Phosphorylated AKT during 
Differentiation. 
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Figure 6-8. Microarray Data on Different TCA Cycle Isozymes During 
Differentiation. Different TCA cycle enzymes were plotted along with its different 
isozymes. The data was linear normalized and each color represents an isozyme. 
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Figure 6-9. Assessment of Mitochondria Maturation During Differentiation. A) 
Mitotracker Green FM Staining on Stage 1 and Stage 4 cells. B) Form Factor and Aspect 
Ratio quantification on Stage 1 and Stage 4 cells. 
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Figure 6-10. Mitochondria Activity and Biogenesis During Differentiation. A) 
Mitotracker Green FM and CM h2x-ros staining during differentiation. B) Quantification 
of mtDNA on cells at different days of differentiation on a per cell basis. C) Western Blot 
showing protein presence of different COX proteins during differentiation.  
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Figure 6-11. Non-essential Amino Acid Concentration Profile Over the Course of 
Hepatocyte Differentiation. A) Serine, Tyrosine, Glycine, and Asparagine. B) 
Glutamate,histidine, cysteine, proline. C) Aspartate, methionine, alanine 
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Figure 6-12. Essential Amino Acid Concentration Profile Over the Course of 
Differentiation. A) Valine, isoleucine, leucine, lysine. B) Arginine, Threonine, 
Phenylalanine, Tryptophan. C) Glutamine 
 
 
 
 
 
 
 
 
 
 
161 
 
 
Figure 6-13. Metabolic Fluxes and Consumption Profiles. A) Consumption rate of 
different essential amino acids.  B) Consumption/production rate of different non-essential 
amino acids. C) Metabolic flux (mmol/109cells/h) for different metabolic pathways 
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Figure 6-14. Metabolic Fluxes Chart. Metabolic flux (mmol/109cells/h) mapped onto 
metabolic pathway chart with the same scale for every chart. 
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Figure 6-15. Effect of Glucose Concentration on Glucose and Lactate Profile Over 
the Course of the Differentiation. Glucose consumption (black) and lactate production 
(white) were measured over the course of the differentiation using low glucose (1g/L) 
and high glucose (4.5g/L) differentiation conditions. Stoichiometric ratio of lactate: 
glucose (line graph) were plotted to illustrate the glycolytic activity during 
differentiation.   
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Figure 6-16. Effect of Glucose Concentration on Differentiation of HLCs. A) 
Transcript levels of different hepatic markers on HLCs using high and low glucose for 
differentiation B) Albumin secretion rate for differentiation carried out in high and low 
glucose levels 
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Chapter 7. Conclusions and Future Work 
 In the last few decades, large interest and research efforts have gone into harnessing 
the full potential of stem cells. With the capability to self-renew while being able to 
differentiate into any specialized cell types in response to different signaling cues, stem 
cells can become the next revolution of medicine within the next few decades. These 
intrinsic properties of stem cells provide great promise in using them to differentiate into 
hepatocyte for different applications such as drug screenings, bioartificial liver devices and 
tissue engineering. With the not too recent discovery of iPSCs, even more attention and 
funding have poured into using these particular type of stem cells to treating different 
illnesses without the potential of an immune response. Currently, there are already over 
600 clinical trials being conducted using stem cells and 30 of them are focused on treating 
different liver disorders and diseases. Hopefully, within the next few decades, the reality 
of using stem cells will have been achieved. For this potential to be realized however, 
advancements must be made in all phases of translating the laboratory practices we have 
in place to a more efficient and scalable bioprocess. Therefore, to be able to completely 
reach the full potential of stem cells, we must first be able to establish a process to be able 
to consistently and safely produce large quantities of high quality hepatocytes.  
 In this study, we utilized a systems approach to address different aspects of clinical 
translation of stem cell research. These key objectives were divided into a) increasing 
product quantity (Chapter 4) b) enhancing product quality (Chapter 5) from stem cell 
differentiation and c) understanding the metabolic effects to develop a robust and scalable 
bioprocess for large scale differentiation (Chapter 6).  
7.1 Process Improvement 
 In chapter 4, we showed that our current differentiation protocol can be optimized 
further to generate larger quantities of HLCs. We utilized the intrinsic properties of 
endodermal cells to provide large quantities without the need to culture on xenogeneic 
feeder cells or cell sorting that previous groups have shown. These cells were given the 
signaling cues of BMP4 and FGF2 with extra surface area for growth and showed the 
capability to expand up to 15-fold. These factors were chosen based on the natural 
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mesodermal signaling cues that endodermal cells are exposed to during in-vivo liver 
development. This observation of cell expansion showed a simultaneous 1000-fold 
increase in different hepatic markers and 1000-fold decrease in endodermal and pluripotent 
markers indicating the ability of cells to simultaneously expand and commit to the hepatic 
lineage similar to in-vivo embryogenesis.  To determine the efficiency of this process at a 
single cell-resolution, we utilized mass cytometry to probe the co-expression of different 
endodermal and hepatic markers at different stages of the conventional differentiation and 
the modified differentiation. We were, to the best of our knowledge, the first to use mass 
cytometry for hepatic stem cell differentiation. Using this technique, we showed that 
endodermal and hepatic genes were repressed and expressed simultaneously for a 
successful outcome. Mass cytometry allows us to do a more thorough characterization of 
our cells by being able to look at different markers without running into spectra overlap 
faced in flow cytometry. Through mass cytometry, functional analysis, and transcriptome 
analysis, we showed that the end stage HLCs obtained from the modified version were 
comparable and in some instances better than the conventional method of differentiation. 
We hypothesized that by providing extra surface area during the process to allow 
endodermal cells to proliferate it more accurately mimics what occurs in-vivo to give better 
HLCs.  
7.2 Quality Enhancement 
 In chapter 5, we discussed the functional aspect of the current efforts of hepatic 
stem cell differentiation and the current drawback faced in the field. Although our HLCs 
exhibited certain characteristics of primary hepatocytes, the levels of function and gene 
expression of HLCs still fall short compared to primary hepatocytes to be used in clinical 
settings. Through surveying recent literature and examining our own HLCs, it appears that 
all HLCs generated have the same level of immaturity and characteristics of fetal 
hepatocytes regardless of the differentiation protocol or optimization strategies used. Thus, 
we employed using a meta-analysis approach to understand the genetic roadblocks that are 
preventing stem cells from reaching the functional maturity of primary hepatocytes. Hence, 
it seemed logical to mimic embryonic liver development as stem cells were harvested 
during the blastocyst stage of development. However, transcriptome data of human in-vivo 
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development is very hard to obtain due to ethical reasons. As a result, we assumed that 
certain aspects of mammalian development are conserved between mouse and human 
development. Therefore, we succeeded in combining human in-vitro differentiation 
transcriptome data with mouse in-vivo development transcriptome data to give us insight 
into strategies for enhancing maturation.  
 We first obtained transcriptome data at different stages of our in-vitro human 
differentiation. We first examined certain families of mature hepatic genes in our cells that 
are known to be important for hepatocyte phenotype and function. These include the liver-
enriched hepatocyte nuclear factors (HNFs), Cytochrome P450 enzymes, and 
gluconeogenesis enzymes. We observed most genes were expressed at moderate levels but 
not at levels that should represent primary hepatocytes. In some instances, certain mature 
hepatic markers are not expressed at all such as FBP1 or GCK. To reinforce our assessment 
of HLCs, we combined different human in-vitro hepatic differentiation from different 
groups in the public databases. These datasets, however, originated from different assay 
platforms and sources. As a result, we needed to treat the data with a ComBat algorithm in 
order to get rid of certain batch effects that arise from compiling different datasets. This 
allowed us to perform a meta-analysis by compiling many different datasets across 
different studies in order to obtain a more comprehensive and conclusive finding. Using 
this same approach, we also incorporated in-vivo developmental data where we saw that 
all in-vitro differentiation processes fall short of primary hepatocytes. But using 
developmental data, we were able to pinpoint the exact developmental stage that our HLCs 
are stuck at and align in-vivo and in-vitro data on the same scale for direct comparison. By 
creating a uniform “developmental time”, we can now go into each gene for each process 
and observe the dynamics of the different genes. To our surprise, we observed a number of 
discordant genes that behave differently in our human in-vitro differentiation process 
compared to in-vivo development. These dynamically identified differentially expressed 
genes can provide us a way to further enhance the maturation of HLCs through certain 
genetic intervention or strategies to alter their expression dynamic.  
 The conclusion of this finding allowed us to develop a unified “developmental 
time” scale to compare different differentiation stages with its corresponding embryo 
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developmental stages. This development allowed us to conclude that most HLCs, including 
our own, are stuck at around E14.5 of development suggesting that 5 more developmental 
days of mouse signaling cues are needed to promote further maturation before achieving 
primary hepatocyte status. This analysis uncovered a pivotal gene set of about 200 genes 
that can now allow us to narrow down the number of targets we can go in with to genetic 
intervene given the recent discovery of CRISPR-CAS9 which is beyond the scope of this 
study. However, we believe this uncovering and analysis will be key in moving the field 
forward and can also be applied to other applications besides hepatic stem cell 
differentiation given that enough datasets are available.  
7.3 Process Development  
 As discussed previously, we enhanced our conventional differentiation process to 
improve cell quantity and looked into developing strategies for enhancing the cell quality. 
One of the last aspects that we attempted to address in this study was to develop a process 
that would be more scalable. We briefly explored into using different microcarriers and 
different coatings to develop a scalable manner of expanding and differentiating stem cells 
to hepatocytes. Through the development of this process, we also looked into how the 
microenvironment, specifically the presence of glucose, can affect the quality of 
hepatocytes we obtain and how that might affect our process.  
 From our previous transcriptome analysis and other reports, we know that 
gluconeogenesis is not present in our differentiation process but we did see a decrease in 
glucose consumption and glycolysis activity. We succeeded in measuring and determining 
the different metabolic demand of our cells to be able to characterize our cells. We observed 
that cells have a smaller demand for glucose and amino acids throughout the course of the 
differentiation. Without the need to proliferate and expand, the need for glucose and other 
nutrients are smaller for HLCs compared to their stem cell counterpart. We did observe a 
metabolic switch from glycolysis to oxidative phosphorylation suggesting to us that our 
HLCs do change their metabolic profile to more represent primary hepatocytes. However, 
we noticed that gluconeogenesis does not occur as a lot of the enzymes involved in 
gluconeogenesis is not expressed. Furthermore, we demonstrated that by using different 
concentrations of glucose, we can obtain different qualities of HLCs. Similar to other 
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mammalian cells that have been cultured, we observed that high presence of glucose can 
affect the glucose consumption and hence the glycolytic activity of our cells during the 
differentiation process. As a result, we found that differentiation carried out with lower 
levels of glucose gave more optimal differentiation of HLCs with higher expression of 
hepatic markers. We discovered that although glucose consumption and a number of 
different glycolytic enzymes were repressed over the course of the differentiation, the TCA 
activity and flux seemed to be going up over the course of the differentiation. From our 
metabolic flux analysis, we revealed that the gene, MPC, is responsible for the influx of 
carbons into the TCA cycle. Although, there is lower levels of glucose consumption, the 
sudden expression in MPC allows cells to more effectively channel pyruvate into the TCA 
cycle for mitochondria respiration reflected by the increase in oxygen consumption over 
the course of the differentiation. This information will allow us to fully define the metabolic 
demands of our cells at different stages of the differentiation to prevent overfeeding of 
certain nutrients where we showed glucose can be detrimental.  
7.4 Future Work 
 This thesis work provides a thorough understanding of the current status of hepatic 
stem cell differentiation and the development of a process to translate laboratory stem cell 
practices into a stem cell technology. The availability of a renewable source of hepatocytes 
will have profound impact not only in the clinical settings but also in the industrial settings. 
HLCs have already been shown to be effective in the industrial setting as a platform for 
drug toxicity screenings. By relying on human HLCs, clinicians expect a more accurate 
screening using human cells that can represent human physiology instead of relying on 
animal models. However, in the future, cellular therapy and all the different applications 
will require high-quality, functionally mature hepatocytes in large quantities.  
 With the discovery of iPSCs, the discussion of personalized medicine for 
individuals or selective populations have transpired and picked up steam. Current work 
have already shown the capability of generating HLCs from ESCs or iPSCs using the same 
differentiation process. However, as we discussed in this thesis, the current field needs to 
address the ability to generate HLCs in a robust manner representative of primary 
hepatocytes.  
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 The lack of functional maturity in HLCs were addressed in Chapter 5 where a 
thorough transcriptome analysis was conducted to show that there is a universal gap that is 
faced by all research groups regardless of differentiation strategy. This functional 
immaturity is a big concern and represents one of the biggest bottleneck that the field of 
stem cells is facing. In our study, we conducted a meta-analysis to identify certain genes 
and their regulators that might be key in enhancing functional maturity of HLCs. 
Additionally, it was revealed in this study that HLCs are blocked at a developmental stage 
corresponding to E14.5 in mouse development. Typically, HLCs are transplanted into 
animal models to show rescue of liver failure or restoration of liver function. However, we 
believe that HLCs are not at the maturity level to show any real progress by transplanting 
into adult livers of different models. We propose an alternative strategy to transplant HLCs 
into the embryonic livers of mice at E14. This approach will rely on the environmental 
cues of an E14 mice to further enhance the maturity of HLCs. By using a comparative 
transcriptome and proteomic analysis of both cells transplanted and without transplanted, 
we can then begin to understand the critical developmental cues that we are missing in our 
in-vitro systems.  
 Lastly, a final consideration that must be addressed for transplantation and different 
applications is determining what process can be robust enough to generate large quantities 
of HLCs. We showed that it is capable of differentiating HLCs in defined conditions 
without the use of serum that are not only suitable for laboratory practices but also for 
manufacturing and clinical applications. For most applications using adherent cells, 
microcarriers is a common matrix to support cell growth and adherence especially in the 
manufacturing of viral vaccines in large scale. We were able to show that microcarriers can 
also support stem cell growth and differentiation for facilitating large quantities of HLCs. 
However, more test will need to be conducted to determine the effect of mechanical stress 
on cells in large tank reactors. But we showed that using gene expression analysis we 
identified metabolic changes ESCs undergo as they transition towards HLCs. Using this 
knowledge, we identified that cells have different metabolic demands over the course of 
the differentiation and that certain overfeeding can hinder the differentiation process. For 
safety reasons and process development, we established a robust process capable of 
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differentiating endodermal cells on microcarriers in a scalable manner that can be utilized 
in large tank bioreactors.  
 With the recent advancements in developmental biology, it is an exciting time in 
the stem cell field as we continue to understand the control of cell fate. However, hopefully 
stem cells, in the next decade, will be key in realizing the potential impact of using stem 
cells as a technology in different clinical and industrial applications. This will require the 
collaborative efforts of researchers from academia and industry from different fields of 
study in order to establish this technology. Hopefully as we demonstrated in this study, the 
innovations and discovery being put into the area of stem cells will one day make 
regenerative medicine a reality in the not too distant future.  
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Chapter 9. Appendix 
 Table 9-1. Metagenes Identified from Human In-vitro NMF Analysis 
Gene ID Metagene 
ENSG00000154277 1 
ENSG00000138829 1 
ENSG00000158270 1 
ENSG00000043355 1 
ENSG00000198467 1 
ENSG00000131914 1 
ENSG00000213120 1 
ENSG00000187772 1 
ENSG00000130294 1 
ENSG00000104332 1 
ENSG00000163629 1 
ENSG00000163508 1 
ENSG00000175928 1 
ENSG00000006118 1 
ENSG00000137285 1 
ENSG00000121966 1 
ENSG00000156925 1 
ENSG00000106278 1 
ENSG00000170373 1 
ENSG00000090530 1 
ENSG00000171208 1 
ENSG00000151640 1 
ENSG00000116729 1 
ENSG00000095596 1 
ENSG00000184867 1 
ENSG00000268151 1 
ENSG00000174469 1 
ENSG00000105270 1 
ENSG00000158246 1 
ENSG00000123560 1 
ENSG00000136943 1 
ENSG00000143768 1 
ENSG00000164434 1 
ENSG00000168280 1 
ENSG00000262907 1 
ENSG00000067445 1 
ENSG00000082497 1 
188 
 
ENSG00000088756 1 
ENSG00000177519 1 
ENSG00000184261 1 
ENSG00000026025 1 
ENSG00000111716 1 
ENSG00000141971 1 
ENSG00000166503 1 
ENSG00000178531 1 
ENSG00000213190 1 
ENSG00000176887 1 
ENSG00000092445 1 
ENSG00000243709 1 
ENSG00000167157 1 
ENSG00000121570 1 
ENSG00000166086 1 
ENSG00000128045 1 
ENSG00000125285 1 
ENSG00000169169 1 
ENSG00000143320 1 
ENSG00000050165 1 
ENSG00000075213 1 
ENSG00000114854 1 
ENSG00000198211 1 
ENSG00000258947 1 
ENSG00000106631 1 
ENSG00000131711 1 
ENSG00000104728 1 
ENSG00000168268 1 
ENSG00000138650 1 
ENSG00000076716 1 
ENSG00000082397 1 
ENSG00000179046 1 
ENSG00000132688 1 
ENSG00000149591 1 
ENSG00000184304 1 
ENSG00000196368 1 
ENSG00000269203 1 
ENSG00000041982 1 
ENSG00000148143 1 
ENSG00000109089 1 
ENSG00000109705 1 
ENSG00000147869 1 
ENSG00000138180 1 
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ENSG00000046653 1 
ENSG00000114948 1 
ENSG00000105655 1 
ENSG00000165349 1 
ENSG00000162551 1 
ENSG00000133636 1 
ENSG00000181449 1 
ENSG00000165588 1 
ENSG00000134775 1 
ENSG00000152377 1 
ENSG00000196526 1 
ENSG00000103449 1 
ENSG00000164659 1 
ENSG00000144339 1 
ENSG00000113758 1 
ENSG00000144834 1 
ENSG00000165495 1 
ENSG00000149201 1 
ENSG00000240694 1 
ENSG00000074047 1 
ENSG00000136231 1 
ENSG00000139946 1 
ENSG00000124766 1 
ENSG00000272398 1 
ENSG00000126878 1 
ENSG00000088882 1 
ENSG00000019144 1 
ENSG00000267867 1 
ENSG00000184613 1 
ENSG00000134531 1 
ENSG00000172348 1 
ENSG00000061337 1 
ENSG00000026559 1 
ENSG00000204335 1 
ENSG00000183145 1 
ENSG00000143632 1 
ENSG00000104722 1 
ENSG00000240563 1 
ENSG00000128683 1 
ENSG00000159167 1 
ENSG00000138795 1 
ENSG00000109255 1 
ENSG00000166426 1 
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ENSG00000134323 1 
ENSG00000198795 1 
ENSG00000137821 1 
ENSG00000204711 1 
ENSG00000033170 1 
ENSG00000196376 1 
ENSG00000150551 1 
ENSG00000161249 1 
ENSG00000157827 1 
ENSG00000101144 1 
ENSG00000153707 1 
ENSG00000144810 1 
ENSG00000128596 1 
ENSG00000122861 1 
ENSG00000169992 1 
ENSG00000179431 1 
ENSG00000154188 1 
ENSG00000160326 1 
ENSG00000261768 1 
ENSG00000128567 1 
ENSG00000167657 1 
ENSG00000145321 2 
ENSG00000136872 2 
ENSG00000117601 2 
ENSG00000187758 2 
ENSG00000118520 2 
ENSG00000106927 2 
ENSG00000122194 2 
ENSG00000091583 2 
ENSG00000099937 2 
ENSG00000229314 2 
ENSG00000113889 2 
ENSG00000101981 2 
ENSG00000123561 2 
ENSG00000110245 2 
ENSG00000135744 2 
ENSG00000138207 2 
ENSG00000171557 2 
ENSG00000145192 2 
ENSG00000091513 2 
ENSG00000163631 2 
ENSG00000197249 2 
ENSG00000171560 2 
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ENSG00000086696 2 
ENSG00000080618 2 
ENSG00000156096 2 
ENSG00000180432 2 
ENSG00000151655 2 
ENSG00000261701 2 
ENSG00000198099 2 
ENSG00000163581 2 
ENSG00000110169 2 
ENSG00000079557 2 
ENSG00000090512 2 
ENSG00000036473 2 
ENSG00000088926 2 
ENSG00000105398 2 
ENSG00000205364 2 
ENSG00000211452 2 
ENSG00000172482 2 
ENSG00000151224 2 
ENSG00000114771 2 
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ENSG00000131482 2 
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ENSG00000249948 2 
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ENSG00000168509 2 
ENSG00000265970 2 
ENSG00000164344 2 
ENSG00000166035 2 
ENSG00000136881 2 
ENSG00000106258 2 
ENSG00000130173 2 
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ENSG00000134240 2 
ENSG00000002933 2 
ENSG00000132703 2 
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ENSG00000118514 2 
ENSG00000105697 2 
ENSG00000165471 2 
ENSG00000145826 2 
ENSG00000100652 2 
ENSG00000161944 2 
ENSG00000162267 2 
ENSG00000055957 2 
ENSG00000039537 2 
ENSG00000160870 2 
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ENSG00000178772 2 
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ENSG00000248144 2 
ENSG00000084110 2 
ENSG00000153086 2 
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ENSG00000177575 2 
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ENSG00000141485 2 
ENSG00000179761 2 
ENSG00000133488 2 
ENSG00000009724 2 
ENSG00000173369 2 
ENSG00000151790 2 
ENSG00000262635 2 
ENSG00000172955 2 
ENSG00000170099 2 
ENSG00000132840 2 
ENSG00000139344 2 
ENSG00000166278 2 
ENSG00000204364 2 
ENSG00000206372 2 
ENSG00000226560 2 
ENSG00000231543 2 
ENSG00000235017 2 
ENSG00000235696 2 
ENSG00000166816 2 
ENSG00000165828 2 
ENSG00000204359 2 
ENSG00000239754 2 
ENSG00000241253 2 
ENSG00000241534 2 
ENSG00000242335 2 
ENSG00000243570 2 
ENSG00000243649 2 
ENSG00000125730 2 
ENSG00000047457 2 
ENSG00000139194 2 
ENSG00000204287 2 
ENSG00000226260 2 
ENSG00000228987 2 
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ENSG00000230726 2 
ENSG00000234794 2 
ENSG00000227993 2 
ENSG00000206308 2 
ENSG00000109758 2 
ENSG00000134365 2 
ENSG00000108242 2 
ENSG00000114200 2 
ENSG00000115718 2 
ENSG00000138823 2 
ENSG00000137491 2 
ENSG00000116882 2 
ENSG00000172497 2 
ENSG00000129151 2 
ENSG00000135423 2 
ENSG00000123838 2 
ENSG00000176919 2 
ENSG00000163959 2 
ENSG00000110243 2 
ENSG00000069535 2 
ENSG00000166840 2 
ENSG00000000971 2 
ENSG00000143278 2 
ENSG00000148702 2 
ENSG00000188582 2 
ENSG00000143546 2 
ENSG00000130988 2 
ENSG00000270349 2 
ENSG00000171236 2 
ENSG00000162365 2 
ENSG00000187048 2 
ENSG00000146678 2 
ENSG00000159189 2 
ENSG00000163825 2 
ENSG00000131187 2 
ENSG00000154262 2 
ENSG00000021826 2 
ENSG00000140284 2 
ENSG00000157103 2 
ENSG00000169562 2 
ENSG00000123843 2 
ENSG00000138075 2 
ENSG00000111249 2 
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ENSG00000175899 2 
ENSG00000198610 2 
ENSG00000266359 2 
ENSG00000077420 2 
ENSG00000011600 2 
ENSG00000023839 2 
ENSG00000144908 2 
ENSG00000100665 2 
ENSG00000144891 2 
ENSG00000134716 2 
ENSG00000137204 2 
ENSG00000109511 2 
ENSG00000196136 2 
ENSG00000273259 2 
ENSG00000138115 2 
ENSG00000198670 2 
ENSG00000135447 2 
ENSG00000126231 2 
ENSG00000166927 2 
ENSG00000103569 2 
ENSG00000100024 2 
ENSG00000122862 2 
ENSG00000117707 2 
ENSG00000139547 2 
ENSG00000136305 2 
ENSG00000169856 2 
ENSG00000158874 2 
ENSG00000245848 2 
ENSG00000144837 2 
ENSG00000019169 2 
ENSG00000131910 2 
ENSG00000112299 2 
ENSG00000149124 2 
ENSG00000005471 2 
ENSG00000111181 2 
ENSG00000198300 2 
ENSG00000160282 2 
ENSG00000142748 2 
ENSG00000120915 2 
ENSG00000108924 2 
ENSG00000198692 2 
ENSG00000113600 2 
ENSG00000196620 2 
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ENSG00000258085 2 
ENSG00000214274 2 
ENSG00000186204 2 
ENSG00000198417 2 
ENSG00000113905 2 
ENSG00000073734 2 
ENSG00000263298 2 
ENSG00000124568 2 
ENSG00000138030 2 
ENSG00000116791 2 
ENSG00000060566 2 
ENSG00000132855 2 
ENSG00000204099 2 
ENSG00000187045 2 
ENSG00000124713 2 
ENSG00000131781 2 
ENSG00000266748 2 
ENSG00000148346 2 
ENSG00000174990 2 
ENSG00000205403 2 
ENSG00000143819 2 
ENSG00000165682 2 
ENSG00000025423 2 
ENSG00000009950 2 
ENSG00000262077 2 
ENSG00000170439 2 
ENSG00000215644 2 
ENSG00000169174 2 
ENSG00000171903 2 
ENSG00000182902 2 
ENSG00000163687 2 
ENSG00000110077 2 
ENSG00000120054 2 
ENSG00000124253 2 
ENSG00000083807 2 
ENSG00000250799 2 
ENSG00000135218 2 
ENSG00000141505 2 
ENSG00000266964 2 
ENSG00000144035 2 
ENSG00000132437 2 
ENSG00000182326 2 
ENSG00000269882 2 
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ENSG00000087237 2 
ENSG00000163347 2 
ENSG00000132541 2 
ENSG00000126218 2 
ENSG00000186115 2 
ENSG00000196660 2 
ENSG00000175003 2 
ENSG00000160868 2 
ENSG00000130208 2 
ENSG00000138308 2 
ENSG00000108515 2 
ENSG00000196139 2 
ENSG00000265685 2 
ENSG00000187193 2 
ENSG00000159423 2 
ENSG00000117009 2 
ENSG00000213424 2 
ENSG00000264058 2 
ENSG00000113790 2 
ENSG00000169877 2 
ENSG00000151365 2 
ENSG00000111796 2 
ENSG00000197444 2 
ENSG00000196600 2 
ENSG00000121858 2 
ENSG00000109819 2 
ENSG00000167798 2 
ENSG00000140107 2 
ENSG00000152804 2 
ENSG00000168384 2 
ENSG00000206291 2 
ENSG00000224103 2 
ENSG00000228163 2 
ENSG00000229685 2 
ENSG00000231389 2 
ENSG00000235844 2 
ENSG00000236177 2 
ENSG00000161573 2 
ENSG00000183549 2 
ENSG00000115919 2 
ENSG00000134538 2 
ENSG00000141293 2 
ENSG00000171840 2 
198 
 
ENSG00000149742 2 
ENSG00000117594 2 
ENSG00000154274 2 
ENSG00000100197 2 
ENSG00000272000 2 
ENSG00000272532 2 
ENSG00000125246 2 
ENSG00000106804 2 
ENSG00000160255 2 
ENSG00000133574 2 
ENSG00000134709 2 
ENSG00000157873 2 
ENSG00000136011 2 
ENSG00000171747 2 
ENSG00000021488 2 
ENSG00000204444 2 
ENSG00000206409 2 
ENSG00000224290 2 
ENSG00000226215 2 
ENSG00000227567 2 
ENSG00000231974 2 
ENSG00000235754 2 
ENSG00000062282 2 
ENSG00000121691 2 
ENSG00000146233 2 
ENSG00000241935 2 
ENSG00000106538 2 
ENSG00000187017 2 
ENSG00000084734 2 
ENSG00000143845 2 
ENSG00000139144 2 
ENSG00000189221 2 
ENSG00000151726 2 
ENSG00000106327 2 
ENSG00000118513 2 
ENSG00000244067 2 
ENSG00000145850 2 
ENSG00000162817 2 
ENSG00000258818 2 
ENSG00000259171 2 
ENSG00000170608 2 
ENSG00000110887 2 
ENSG00000127951 2 
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ENSG00000155659 2 
ENSG00000129596 2 
ENSG00000204291 3 
ENSG00000198759 3 
ENSG00000139329 3 
ENSG00000113083 3 
ENSG00000087303 3 
ENSG00000113196 3 
ENSG00000118271 3 
ENSG00000164266 3 
ENSG00000081051 3 
ENSG00000174498 3 
ENSG00000171564 3 
ENSG00000173391 3 
ENSG00000079112 3 
ENSG00000134258 3 
ENSG00000164294 3 
ENSG00000170290 3 
ENSG00000040731 3 
ENSG00000140937 3 
ENSG00000130635 3 
ENSG00000164764 3 
ENSG00000125872 3 
ENSG00000107165 3 
ENSG00000115380 3 
ENSG00000128591 3 
ENSG00000185559 3 
ENSG00000164825 3 
ENSG00000162998 3 
ENSG00000261258 3 
ENSG00000141756 3 
ENSG00000069011 3 
ENSG00000118495 3 
ENSG00000169116 3 
ENSG00000157005 3 
ENSG00000168743 3 
ENSG00000114251 3 
ENSG00000110811 3 
ENSG00000268828 3 
ENSG00000019549 3 
ENSG00000167874 3 
ENSG00000139055 3 
ENSG00000138119 3 
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ENSG00000112818 3 
ENSG00000164484 3 
ENSG00000113657 3 
ENSG00000183160 3 
ENSG00000164125 3 
ENSG00000104415 3 
ENSG00000270132 3 
ENSG00000135919 3 
ENSG00000145147 3 
ENSG00000182752 3 
ENSG00000126016 3 
ENSG00000084636 3 
ENSG00000138615 3 
ENSG00000148677 3 
ENSG00000203857 3 
ENSG00000164692 3 
ENSG00000104368 3 
ENSG00000163520 3 
ENSG00000168952 3 
ENSG00000011465 3 
ENSG00000135046 3 
ENSG00000163359 3 
ENSG00000129757 3 
ENSG00000007062 3 
ENSG00000103241 3 
ENSG00000143125 3 
ENSG00000159212 3 
ENSG00000171004 3 
ENSG00000060718 3 
ENSG00000132031 3 
ENSG00000171345 3 
ENSG00000163430 3 
ENSG00000180340 3 
ENSG00000110244 3 
ENSG00000170955 3 
ENSG00000168542 3 
ENSG00000105825 3 
ENSG00000149090 3 
ENSG00000099960 3 
ENSG00000166147 3 
ENSG00000173068 3 
ENSG00000135480 3 
ENSG00000145824 3 
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ENSG00000174807 3 
ENSG00000218336 3 
ENSG00000073756 3 
ENSG00000154856 3 
ENSG00000077942 3 
ENSG00000169129 3 
ENSG00000162493 3 
ENSG00000108821 3 
ENSG00000113739 3 
ENSG00000086991 3 
ENSG00000077616 3 
ENSG00000111319 3 
ENSG00000136193 3 
ENSG00000198796 3 
ENSG00000170425 3 
ENSG00000164116 3 
ENSG00000037965 3 
ENSG00000197614 3 
ENSG00000125384 3 
ENSG00000152661 3 
ENSG00000120937 3 
ENSG00000188176 3 
ENSG00000167617 3 
ENSG00000261931 3 
ENSG00000263030 3 
ENSG00000270365 3 
ENSG00000167434 3 
ENSG00000133110 3 
ENSG00000137573 3 
ENSG00000141526 3 
ENSG00000130176 3 
ENSG00000067057 3 
ENSG00000102359 3 
ENSG00000150556 3 
ENSG00000110660 3 
ENSG00000163132 3 
ENSG00000144645 3 
ENSG00000168386 3 
ENSG00000163624 3 
ENSG00000164093 3 
ENSG00000171033 3 
ENSG00000101198 3 
ENSG00000103196 3 
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ENSG00000100739 3 
ENSG00000260225 3 
ENSG00000112852 3 
ENSG00000165556 3 
ENSG00000071282 3 
ENSG00000130508 3 
ENSG00000141696 3 
ENSG00000261163 3 
ENSG00000176788 3 
ENSG00000167755 3 
ENSG00000120068 3 
ENSG00000260027 3 
ENSG00000171729 3 
ENSG00000143867 3 
ENSG00000162576 3 
ENSG00000148344 3 
ENSG00000173376 3 
ENSG00000062038 3 
ENSG00000105894 3 
ENSG00000166250 3 
ENSG00000171951 3 
ENSG00000107485 3 
ENSG00000122176 3 
ENSG00000155465 3 
ENSG00000133519 3 
ENSG00000168824 3 
ENSG00000070019 3 
ENSG00000109099 3 
ENSG00000172638 3 
ENSG00000113140 3 
ENSG00000013588 3 
ENSG00000079215 3 
ENSG00000138193 3 
ENSG00000145681 3 
ENSG00000104435 3 
ENSG00000134871 3 
ENSG00000172458 3 
ENSG00000117525 3 
ENSG00000136859 3 
ENSG00000159251 3 
ENSG00000118971 3 
ENSG00000006747 3 
ENSG00000117152 3 
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ENSG00000020181 3 
ENSG00000140945 3 
ENSG00000038427 3 
ENSG00000197406 3 
ENSG00000106031 3 
ENSG00000153822 3 
ENSG00000177875 3 
ENSG00000154127 3 
ENSG00000166482 3 
ENSG00000150630 3 
ENSG00000143036 3 
ENSG00000079931 3 
ENSG00000089472 3 
ENSG00000114270 3 
ENSG00000099256 3 
ENSG00000166173 3 
ENSG00000129038 3 
ENSG00000139174 3 
ENSG00000164932 3 
ENSG00000111799 3 
ENSG00000180318 3 
ENSG00000150687 3 
ENSG00000116774 3 
ENSG00000145287 3 
ENSG00000163947 3 
ENSG00000146197 3 
ENSG00000146250 3 
ENSG00000124107 3 
ENSG00000078098 3 
ENSG00000183036 3 
ENSG00000100079 3 
ENSG00000101680 3 
ENSG00000147655 3 
ENSG00000204381 3 
ENSG00000164251 3 
ENSG00000120820 3 
ENSG00000184515 3 
ENSG00000269503 3 
ENSG00000132854 3 
ENSG00000166165 3 
ENSG00000137269 3 
ENSG00000132698 3 
ENSG00000147883 3 
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ENSG00000163171 3 
ENSG00000134369 3 
ENSG00000130224 3 
ENSG00000268417 3 
ENSG00000079689 3 
ENSG00000198108 3 
ENSG00000179178 3 
ENSG00000187123 3 
ENSG00000123700 3 
ENSG00000050555 3 
ENSG00000197635 3 
ENSG00000154734 3 
ENSG00000137507 3 
ENSG00000010932 3 
ENSG00000064692 3 
ENSG00000129116 3 
ENSG00000100196 3 
ENSG00000165794 3 
ENSG00000169583 3 
ENSG00000121297 3 
ENSG00000133661 3 
ENSG00000104723 3 
ENSG00000168461 3 
ENSG00000164106 3 
ENSG00000184347 3 
ENSG00000069702 3 
ENSG00000091986 3 
ENSG00000112964 3 
ENSG00000169594 3 
ENSG00000091136 3 
ENSG00000101955 3 
ENSG00000145555 3 
ENSG00000167642 3 
ENSG00000126947 3 
ENSG00000269801 3 
ENSG00000150938 3 
ENSG00000261899 3 
ENSG00000146374 3 
ENSG00000164946 3 
ENSG00000132915 3 
ENSG00000138772 3 
ENSG00000103064 3 
ENSG00000198648 3 
205 
 
ENSG00000104044 3 
ENSG00000109846 3 
ENSG00000263007 3 
ENSG00000125266 3 
ENSG00000163637 3 
ENSG00000118407 3 
ENSG00000198832 3 
ENSG00000046604 3 
ENSG00000135549 3 
ENSG00000100842 3 
ENSG00000079257 3 
ENSG00000167528 3 
ENSG00000242779 3 
ENSG00000152049 3 
ENSG00000144619 3 
ENSG00000166863 3 
ENSG00000140682 3 
ENSG00000174099 3 
ENSG00000146674 3 
ENSG00000164107 3 
ENSG00000102034 3 
ENSG00000164683 3 
ENSG00000119888 3 
ENSG00000163638 3 
ENSG00000184005 3 
ENSG00000165868 3 
ENSG00000263052 3 
ENSG00000122691 3 
ENSG00000103175 3 
ENSG00000206538 3 
ENSG00000005884 3 
ENSG00000099994 3 
ENSG00000120149 3 
ENSG00000015413 3 
ENSG00000077943 3 
ENSG00000189334 3 
ENSG00000135736 3 
ENSG00000163191 3 
ENSG00000151612 3 
ENSG00000125398 3 
ENSG00000115604 3 
ENSG00000139278 3 
ENSG00000163288 3 
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ENSG00000166963 3 
ENSG00000095752 3 
ENSG00000101825 3 
ENSG00000183876 3 
ENSG00000142156 3 
ENSG00000135052 3 
ENSG00000116991 3 
ENSG00000125850 3 
ENSG00000163993 3 
ENSG00000115602 3 
ENSG00000161896 3 
ENSG00000112655 3 
ENSG00000184697 3 
ENSG00000163017 3 
ENSG00000115008 3 
ENSG00000102243 3 
ENSG00000197702 3 
ENSG00000108244 3 
ENSG00000263309 3 
ENSG00000182534 3 
ENSG00000119630 3 
ENSG00000143839 3 
ENSG00000106348 3 
ENSG00000114113 3 
ENSG00000166923 3 
ENSG00000131459 3 
ENSG00000119900 3 
ENSG00000151693 3 
ENSG00000157502 3 
ENSG00000137809 3 
ENSG00000188153 3 
ENSG00000182718 3 
ENSG00000109472 3 
ENSG00000065911 3 
ENSG00000168615 3 
ENSG00000142552 3 
ENSG00000132205 3 
ENSG00000111339 3 
ENSG00000141744 3 
ENSG00000084207 3 
ENSG00000158258 3 
ENSG00000124102 3 
ENSG00000140465 3 
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ENSG00000107317 3 
ENSG00000172380 3 
ENSG00000103888 3 
ENSG00000125787 3 
ENSG00000152137 3 
ENSG00000104213 3 
ENSG00000186377 3 
ENSG00000167695 3 
ENSG00000197380 3 
ENSG00000078401 3 
ENSG00000070404 3 
ENSG00000171812 3 
ENSG00000167644 3 
ENSG00000197712 3 
ENSG00000164124 3 
ENSG00000198768 3 
ENSG00000166394 3 
ENSG00000153558 3 
ENSG00000147003 3 
ENSG00000144642 3 
ENSG00000177984 3 
ENSG00000081479 3 
ENSG00000165379 3 
ENSG00000052344 3 
ENSG00000103742 3 
ENSG00000198121 3 
ENSG00000239474 3 
ENSG00000240583 3 
ENSG00000166145 3 
ENSG00000175315 3 
ENSG00000183722 3 
ENSG00000142173 3 
ENSG00000145730 3 
ENSG00000165124 3 
ENSG00000134668 3 
ENSG00000133135 3 
ENSG00000243978 3 
ENSG00000182636 3 
ENSG00000148942 3 
ENSG00000129514 3 
ENSG00000118503 3 
ENSG00000118849 3 
ENSG00000112175 3 
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ENSG00000146072 3 
ENSG00000166900 3 
ENSG00000105928 3 
ENSG00000122585 3 
ENSG00000174307 3 
ENSG00000184838 3 
ENSG00000173715 3 
ENSG00000111913 3 
ENSG00000118137 3 
ENSG00000251493 3 
ENSG00000204262 3 
ENSG00000127472 3 
ENSG00000142583 3 
ENSG00000164318 3 
ENSG00000160207 3 
ENSG00000136026 3 
ENSG00000132386 3 
ENSG00000165105 3 
ENSG00000050438 3 
ENSG00000173559 3 
ENSG00000170190 3 
ENSG00000120708 3 
ENSG00000181264 3 
ENSG00000123096 3 
ENSG00000152268 3 
ENSG00000262655 3 
ENSG00000183853 3 
ENSG00000116017 3 
ENSG00000182985 3 
ENSG00000118194 3 
ENSG00000001626 3 
ENSG00000185565 3 
ENSG00000135750 3 
ENSG00000007384 3 
ENSG00000049130 3 
ENSG00000164120 3 
ENSG00000147257 3 
ENSG00000173546 3 
ENSG00000108797 3 
ENSG00000086548 3 
ENSG00000272939 3 
ENSG00000166920 3 
ENSG00000130812 3 
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ENSG00000174482 3 
ENSG00000139926 3 
ENSG00000108947 3 
ENSG00000179921 3 
ENSG00000187498 3 
ENSG00000110195 3 
ENSG00000163362 3 
ENSG00000156711 3 
ENSG00000140545 3 
ENSG00000183844 3 
ENSG00000167535 3 
ENSG00000181541 3 
ENSG00000112562 3 
ENSG00000156510 3 
ENSG00000105989 3 
ENSG00000142227 3 
ENSG00000211448 3 
ENSG00000129270 3 
ENSG00000271447 3 
ENSG00000185222 3 
ENSG00000180447 3 
ENSG00000116157 3 
ENSG00000121440 3 
ENSG00000168032 3 
ENSG00000106366 3 
ENSG00000176907 3 
ENSG00000121361 3 
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Table 9-2. Metagenes Identified from Mouse In-vivo NMF Analysis. 
Gene ID Metagene 
ENSMUSG00000026368 1 
ENSMUSG00000031645 1 
ENSMUSG00000038656 1 
ENSMUSG00000054630 1 
ENSMUSG00000029656 1 
ENSMUSG00000029445 1 
ENSMUSG00000070704 1 
ENSMUSG00000040134 1 
ENSMUSG00000022445 1 
ENSMUSG00000062410 1 
ENSMUSG00000037798 1 
ENSMUSG00000027870 1 
ENSMUSG00000030382 1 
ENSMUSG00000026365 1 
ENSMUSG00000028186 1 
ENSMUSG00000069805 1 
ENSMUSG00000031640 1 
ENSMUSG00000027048 1 
ENSMUSG00000060407 1 
ENSMUSG00000025991 1 
ENSMUSG00000022871 1 
ENSMUSG00000074264 1 
ENSMUSG00000074336 1 
ENSMUSG00000026542 1 
ENSMUSG00000030236 1 
ENSMUSG00000022512 1 
ENSMUSG00000057037 1 
ENSMUSG00000030111 1 
ENSMUSG00000002588 1 
ENSMUSG00000056035 1 
ENSMUSG00000021210 1 
ENSMUSG00000056973 1 
ENSMUSG00000031271 1 
ENSMUSG00000026822 1 
ENSMUSG00000038641 1 
ENSMUSG00000037942 1 
ENSMUSG00000033715 1 
ENSMUSG00000027261 1 
ENSMUSG00000024863 1 
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ENSMUSG00000031722 1 
ENSMUSG00000070811 1 
ENSMUSG00000034528 1 
ENSMUSG00000052974 1 
ENSMUSG00000074207 1 
ENSMUSG00000020072 1 
ENSMUSG00000020010 1 
ENSMUSG00000054417 1 
ENSMUSG00000052131 1 
ENSMUSG00000029273 1 
ENSMUSG00000037053 1 
ENSMUSG00000057400 1 
ENSMUSG00000030413 1 
ENSMUSG00000064294 1 
ENSMUSG00000010601 1 
ENSMUSG00000015970 1 
ENSMUSG00000025911 1 
ENSMUSG00000019232 1 
ENSMUSG00000021135 1 
ENSMUSG00000029630 1 
ENSMUSG00000029727 1 
ENSMUSG00000003617 1 
ENSMUSG00000040809 1 
ENSMUSG00000020884 1 
ENSMUSG00000025479 1 
ENSMUSG00000020641 1 
ENSMUSG00000025934 1 
ENSMUSG00000031594 1 
ENSMUSG00000058207 1 
ENSMUSG00000036216 1 
ENSMUSG00000033533 1 
ENSMUSG00000055782 1 
ENSMUSG00000028715 1 
ENSMUSG00000019987 1 
ENSMUSG00000025003 1 
ENSMUSG00000041828 1 
ENSMUSG00000087107 1 
ENSMUSG00000034435 1 
ENSMUSG00000036381 1 
ENSMUSG00000052595 1 
ENSMUSG00000030909 1 
ENSMUSG00000022868 1 
ENSMUSG00000021390 1 
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ENSMUSG00000078650 1 
ENSMUSG00000021922 1 
ENSMUSG00000031138 1 
ENSMUSG00000029556 1 
ENSMUSG00000031173 1 
ENSMUSG00000000049 1 
ENSMUSG00000044749 1 
ENSMUSG00000028553 1 
ENSMUSG00000028262 1 
ENSMUSG00000030359 1 
ENSMUSG00000054072 1 
ENSMUSG00000048217 1 
ENSMUSG00000072601 1 
ENSMUSG00000027761 1 
ENSMUSG00000030244 1 
ENSMUSG00000040017 1 
ENSMUSG00000096852 1 
ENSMUSG00000021091 1 
ENSMUSG00000057425 1 
ENSMUSG00000039438 1 
ENSMUSG00000032081 1 
ENSMUSG00000070594 1 
ENSMUSG00000035540 1 
ENSMUSG00000025194 1 
ENSMUSG00000029368 1 
ENSMUSG00000020264 1 
ENSMUSG00000060317 1 
ENSMUSG00000021999 1 
ENSMUSG00000041660 1 
ENSMUSG00000003053 1 
ENSMUSG00000042118 1 
ENSMUSG00000032291 2 
ENSMUSG00000045179 2 
ENSMUSG00000004885 2 
ENSMUSG00000043668 2 
ENSMUSG00000021506 2 
ENSMUSG00000039476 2 
ENSMUSG00000021508 2 
ENSMUSG00000074637 2 
ENSMUSG00000079012 2 
ENSMUSG00000044206 2 
ENSMUSG00000025478 2 
ENSMUSG00000075334 2 
213 
 
ENSMUSG00000038624 2 
ENSMUSG00000048001 2 
ENSMUSG00000086503 2 
ENSMUSG00000033737 2 
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Table 9-3. Differentially Expressed Genes Identified from mHLCs vs E19.5. 
Gene Name Fold Change q-value(%) 
ARG1 19.47648 0 
ADH1A 17.695 0 
APCS 17.03517 0 
GC 15.79147 0 
FETUB 14.36397 0 
ADH1C 14.03646 0 
AZGP1 14.03505 0 
CYP2C9 13.92966 0 
HPR 13.09532 0 
ITIH4 12.98748 0 
F9 12.69693 0 
HAMP 12.49579 0 
ITIH3 12.13291 0 
RARRES2 11.82974 0 
CYP2C9 11.72359 0 
CYP2C9 11.56773 0 
FBP1 11.26727 0 
CYP8B1 11.09845 0 
KLKB1 10.8902 0 
CFHR2 10.69348 0 
SLCO1B1 10.69292 0 
CYP2C9 10.24091 0 
HAO1 10.19456 0 
G6PC 10.07402 0 
BAAT 9.990331 0 
C4BPA 9.951422 0 
F11 9.822402 0 
CYP3A4 9.787597 0 
LRG1 9.353939 0 
SLCO1B3 8.983395 0 
C3 8.711476 0 
CYP3A5 8.647951 0 
CRP 8.603505 0 
CYP3A4 8.586851 0 
SEC14L4 8.462595 0 
MT1G 8.398134 0 
C8A 8.368593 0 
C8G 8.150217 0 
AKR1C4 7.982445 0 
CYP3A4 7.796432 0 
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AQP9 7.760693 0 
AKR1C4 7.699717 0 
BHMT2 7.66797 0 
MBL2 7.667351 0 
ETNPPL 7.637466 0 
CYP2C19 7.593378 0 
CYP3A4 7.584423 0 
THRSP 7.560952 0 
SLC2A2 7.54792 0 
CPB2 7.517397 0 
UGT2B15 7.491674 0 
CYP4A22 7.332241 0 
CYP4A11 7.332241 0 
AGXT 7.318679 0 
HFE2 7.294192 0 
CYP2D6 6.980419 0 
F12 6.977067 0 
AKR1C4 6.830319 0 
CYP2C19 6.818073 0 
MT1M 6.80367 0 
RDH16 6.790065 0 
SLC27A5 6.593052 0 
CYP4A22 6.47747 0 
CYP4A11 6.47747 0 
PAH 6.451182 0 
MT1F 6.419835 0 
IGFALS 6.37437 0 
CYP2C19 6.368176 0 
AKR1C1 6.160139 0 
CYP2D6 6.125002 0 
UGT2B15 5.996523 0 
CYP4A11 5.921239 0 
CYP4A22 5.921239 0 
CYP2C19 5.913506 0 
AKR1C1 5.910363 0 
IGFBP1 5.869926 0 
HAO2 5.860457 0 
ABCG5 5.85733 0 
UPB1 5.678749 0 
CYP2D6 5.615751 0 
LDHD 5.594874 0 
CYP2D6 5.585391 0 
APOA5 5.571442 0 
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AOX1 5.552244 0 
CYP2J2 5.533126 0 
MASP2 5.468354 0 
NAT8 5.398458 0 
SLC17A2 5.348241 0 
UGT2B15 5.26995 0 
AKR1C4 5.187966 0 
NR1I2 5.174316 0 
UGT2B15 5.170655 0 
CYP4F2 5.163166 0 
CYP2C8 5.15697 0 
HGFAC 5.052705 0 
LPA 5.042815 0 
ONECUT1 5.036339 0 
CYP4F12 5.031971 0 
CYP2D6 4.941497 0 
ABCA6 4.918435 0 
AKR1C1 4.880393 0 
GLS2 4.847726 0 
UGT2B15 4.846635 0 
HABP2 4.836134 0 
UGT2B15 4.793784 0 
C2 4.735973 0 
AKR1C4 4.712947 0 
CYP4F2 4.710266 0 
TAT 4.703243 0 
ABCB11 4.691866 0 
VNN1 4.607717 0 
F13B 4.571373 0 
ONECUT2 4.554322 0 
CYP2C8 4.519439 0 
RTP3 4.491045 0 
CYP4F12 4.488012 0 
RDH16 4.441499 0 
PEMT 4.402901 0 
CYP2C8 4.338335 0 
CSTA 4.308267 0 
CD14 4.262732 0 
SLC25A47 4.228052 0 
ACOT12 4.156665 0 
CYP39A1 4.145899 0 
MLXIPL 4.130333 0 
SDS 4.105943 0 
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PAQR9 4.014396 0 
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Table 9-4. Dynamically Differentially Expressed Genes Identified Between hHLCs 
and In-vivo Mouse Development. 
Gene 
Name 
spearman 
coeff 
pearson 
coeff euclidean 
Foldchange 
human 
Foldchange 
mouse 
TPD52L1 -1 -0.99998 8.202735 3.287442 2.42286 
SOX9 -1 -0.96806 6.470891 3.673472 2.691969 
CA4 -1 -0.99363 12.76903 5.023663 2.934446 
COL1A1 -1 -0.99799 10.52601 5.878911 1.165311 
FOXM1 -1 -0.96139 6.176861 2.561048 0.105252 
RIN2 -1 -0.99932 7.199617 2.972658 1.446347 
LAMB1 -1 -0.98367 8.43345 3.265966 2.529975 
INMT-
FAM188B -0.88264 -0.90333 8.721384 3.390595 0.190508 
INMT -0.88264 -0.90333 8.721384 3.390595 0.190508 
ANGPTL2 -0.9952 -0.97192 6.669714 4.644773 1.990356 
CLEC11A -1 -0.99259 6.607506 2.787634 0.737749 
MAPK13 -1 -0.99952 7.057298 2.113425 1.629894 
WISP1 -1 -0.99999 7.103779 4.687063 1.852809 
SPC25 -1 -0.97999 6.566221 2.608397 0.991307 
SLC1A3 -1 -0.99898 6.147721 2.936563 2.013546 
TYRP1 -1 -0.99885 10.5835 4.493249 0.642752 
FBLN1 -1 -0.99926 9.118421 1.821108 3.43929 
SCUBE2 -1 -0.98805 7.176644 3.651059 1.537498 
TLE1 -1 -0.9997 6.542244 2.191705 0.648269 
RAB25 -1 -0.9995 9.011451 2.633916 3.262243 
ODC1 -1 -0.99905 8.152495 2.951116 0.571813 
GATA5 -1 -0.95235 8.659841 3.400776 1.18373 
BIRC5 -1 -0.99532 5.884918 2.165832 0.503302 
MMP9 -1 -0.98558 7.253185 2.603546 0.970577 
GPX3 -1 -0.99299 7.088938 3.202002 2.977199 
CLDN7 -0.99789 -0.99353 7.635152 2.7394 2.987019 
SPARC -1 -0.98394 9.983665 6.048512 1.121165 
P4HA2 -1 -0.99275 7.009518 2.837876 1.699379 
E2F2 -1 -0.98456 6.313519 2.48639 2.249367 
DPEP1 -1 -0.99968 8.169601 2.502557 2.235288 
SOCS2 -0.93133 -0.90123 9.100238 2.578425 1.060604 
IGF1 -1 -0.99121 6.01632 2.829677 1.577037 
IGFBP3 -1 -0.99083 11.78145 7.476728 2.054755 
MTHFD1 -1 -0.97191 8.034054 1.581466 2.406489 
MSX2 -0.93133 -0.8851 6.676606 3.935041 2.888799 
CXCL14 -1 -0.99855 6.8103 6.909237 3.966255 
VCAN -0.88264 -0.91007 6.073209 2.971706 1.744054 
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NID2 -1 -0.9947 9.804529 7.742699 1.517822 
WNT5A -1 -0.99715 8.458978 3.831782 2.970028 
LCP1 -1 -0.99149 17.44107 5.717766 1.476532 
GPC5 -1 -0.99631 7.514748 4.469395 0.45908 
CTNND2 -1 -0.99652 6.886003 2.16132 2.122937 
ZFPM2 -1 -0.99994 6.433396 2.97006 2.000771 
ANGPT1 -1 -0.99666 7.687757 3.271078 2.445031 
CDH10 -1 -0.99725 9.986773 5.275753 1.360325 
COL2A1 -1 -0.97266 6.112505 2.43766 4.138637 
PPP1R1A -1 -0.99688 6.177531 3.719291 2.619232 
DGAT1 -1 -0.99811 7.963457 2.405352 0.449161 
ARC -1 -0.98125 6.23039 0.718595 2.144159 
SNAI2 -1 -0.99993 11.54102 5.39566 3.316863 
PROS1 -1 -0.97454 9.90243 3.815411 1.108385 
CLIC6 -1 -0.99905 7.546699 3.349008 2.775784 
RCAN1 -1 -0.99644 6.985294 2.497737 1.162306 
SMOC2 -1 -0.97742 5.756148 3.828843 1.806198 
CBS -1 -1 6.806959 3.699452 2.540984 
EPB41L3 -1 -0.99894 6.68763 2.424304 2.302699 
ANKS1A -1 -0.99574 5.626824 3.292288 0.491621 
BAMBI -0.94094 -0.91258 7.815337 2.692172 1.648303 
SYT4 -1 -0.99943 7.897645 4.126923 1.209736 
BIN1 -1 -0.99905 5.915923 2.698904 1.554763 
SNCAIP -1 -0.99984 7.299104 4.133323 1.46805 
PPIC -1 -0.98817 6.57819 2.855431 1.555656 
ASRGL1 -1 -0.9768 5.948578 2.782423 1.639415 
SLC1A1 -1 -0.97201 5.639671 2.737276 0.604882 
HSPA12A -1 -0.98903 6.379916 2.270736 1.029907 
BNC1 -1 -0.99934 5.736315 3.709759 1.794152 
PSTPIP2 -1 -0.98109 6.241606 2.436976 0.941142 
TK1 -1 -0.99993 6.948543 2.809313 1.23098 
COL3A1 -1 -0.97662 16.61379 7.134201 1.788591 
IGFBP5 -1 -0.98632 8.864169 4.590883 4.055705 
RGS1 -1 -0.98933 5.666029 2.867679 0.460585 
RGS2 -0.94958 -0.95763 7.162765 3.418134 1.389152 
KIFAP3 -1 -0.99948 7.615188 2.139961 2.056832 
FRZB -1 -0.99192 10.56679 3.121508 2.94741 
PAMR1 -0.93133 -0.91952 5.721357 5.799499 3.246058 
MDK -1 -0.99438 7.171142 1.836701 3.296871 
SPINT1 -1 -0.99904 8.263304 2.241655 2.977843 
BMP2 -1 -0.99857 9.248287 2.995835 0.169777 
CD93 -1 -0.99244 7.169902 2.578764 1.234445 
PKIA -1 -0.99594 7.832302 3.785553 2.247848 
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POSTN -1 -0.98873 9.225436 4.444603 3.342483 
SERPINI1 -1 -1 5.693185 2.218662 1.623499 
FAM198B -1 -0.98209 9.50968 3.783681 2.424531 
CCDC109B -1 -0.99142 7.50031 2.350011 2.384037 
TDO2 -1 -0.99771 8.91894 4.859247 1.872948 
PDGFC -1 -0.99708 7.619929 3.268998 3.122205 
PITX2 -1 -0.98387 11.57107 4.543715 3.106901 
F3 -1 -0.99305 7.140429 3.964018 2.137135 
COL15A1 -1 -0.99993 10.7584 9.604504 1.286437 
ALDH4A1 -1 -0.99651 7.549047 1.174329 2.871219 
SEMA3C -1 -0.99344 7.557414 2.411146 2.100976 
PCDH7 -1 -0.99805 6.056629 2.391598 1.863397 
Una. -1 -0.99988 5.914584 3.745275 2.438067 
CDX2 -1 -0.9971 7.904824 3.482707 2.92062 
COL1A2 -1 -0.98409 11.00918 6.08499 1.52914 
AASS -1 -0.99866 8.450191 1.215457 3.420273 
ADD2 -1 -0.99979 6.627112 1.916887 2.374459 
SLCO2B1 -1 -0.98626 11.4765 5.186084 1.200618 
TSC22D3 -1 -0.9959 8.455545 3.045552 1.354535 
GPR124 -1 -0.984 6.75361 5.63952 2.42959 
VEGFC -1 -0.99946 8.449825 4.848861 2.020543 
PLAT -1 -0.99529 7.554406 6.14278 3.220333 
SLIT2 -1 -0.97949 9.463614 3.435444 2.839977 
SCRG1 -1 -0.9995 11.93331 5.435314 1.028461 
KLKB1 -1 -0.99457 9.584776 3.622454 3.756616 
CDH11 -0.85143 -0.90562 10.08777 5.175973 2.01917 
MT1X -1 -0.99958 14.69135 3.97352 5.361478 
MT1M -1 -0.99181 10.15712 4.699498 4.710045 
MT1E -1 -0.99001 11.40912 3.520225 4.581416 
MT1G -1 -0.99984 12.87808 3.050806 4.880415 
MT1F -1 -0.99975 11.62271 3.417577 4.523986 
MT1H -1 -0.99544 9.078276 2.501644 4.216505 
CRISPLD2 -1 -0.99808 9.640576 5.248432 4.158231 
CDH13 -1 -0.9912 5.85786 5.24851 0.446286 
PDGFD -1 -0.99941 5.637534 2.570399 1.776597 
THY1 -1 -0.9998 5.898586 2.943447 1.972785 
CADM1 -1 -0.99126 5.666782 2.323375 2.465708 
APOA4 -1 -0.9905 19.40484 7.492938 2.460919 
MNS1 -1 -0.98452 7.064168 2.397407 0.835902 
DNAJA4 -1 -0.99992 6.344101 0.936862 2.376461 
TSPAN3 -1 -0.99951 6.062608 1.538401 2.214344 
LOXL1 -0.99673 -0.97118 6.863864 3.662788 1.71054 
PLOD2 -1 -0.99999 6.69004 4.37611 2.075458 
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IGDCC3 -0.92077 -0.87152 8.968043 3.941408 3.504619 
SLCO2A1 -1 -0.99894 6.527005 4.086047 2.784743 
SBSPON -1 -0.92368 6.908534 5.484962 1.188689 
RASGRP2 -1 -0.9936 6.149767 0.681514 2.034262 
CST1 -1 -0.99627 7.394144 8.047238 1.132582 
PRSS35 -0.99328 -0.97129 11.29819 4.156408 2.396574 
UCP2 -1 -0.99942 8.215212 1.930647 2.590443 
DIO1 -1 -0.96993 14.54904 6.130609 0.679016 
PARM1 -1 -0.9977 12.20437 4.260447 2.812948 
KANK4 -1 -1 9.194998 4.579135 1.766136 
FOXA1 -1 -0.99185 8.920911 4.634631 1.352117 
TGFBI -1 -0.99385 13.99386 6.888526 4.47516 
SLC51A -1 -0.99976 11.17642 4.114251 2.0838 
PRTG -1 -0.99459 7.032647 2.896586 3.573539 
SOSTDC1 -1 -0.96966 7.064512 2.513585 2.79548 
ALX1 -1 -0.99942 8.59478 1.798566 2.726357 
NODAL -1 -0.99778 5.878139 3.996051 1.314737 
HAND1 -1 -0.99924 14.10207 6.999903 4.126651 
CDKN1C -1 -0.96259 11.07485 3.927051 1.347614 
CPE -1 -0.99788 6.760178 2.924181 1.529346 
SPON1 -1 -0.94975 7.059034 3.713748 1.894611 
SLC19A3 -1 -0.99826 5.850146 2.924093 0.624851 
RGS4 -0.81513 -0.90034 6.579283 4.283272 1.601526 
LEFTY2 -1 -0.99985 10.5707 7.257231 3.448976 
LEFTY1 -1 -0.99918 12.09782 6.497584 3.566699 
ECHDC3 -1 -0.99237 6.323923 1.652374 2.591008 
TGFB2 -1 -0.99998 5.715218 2.724041 2.147273 
PRSS23 -1 -1 7.360117 5.920373 1.979309 
CITED2 -1 -0.99871 5.875684 1.816708 2.169233 
GPR176 -1 -0.9713 7.38363 1.459685 3.040128 
NPNT -1 -0.99812 8.876435 4.837207 1.820217 
FBXO2 -1 -0.9987 5.900228 3.106349 2.368491 
AMOT -1 -0.97965 9.637363 4.032142 2.364655 
KCNJ2 -1 -0.98704 6.847413 3.717141 1.297968 
S100A10 -1 -0.99657 8.964101 3.160094 1.51785 
SLC35F2 -1 -0.98804 6.085977 2.16187 2.704036 
MFAP4 -1 -0.99958 9.761389 7.621643 1.672373 
MUM1L1 -1 -0.99995 11.21239 3.725983 2.428555 
CXXC4 -1 -0.99765 7.163809 2.69722 0.993399 
SHISA2 -1 -0.96374 5.762676 4.010679 3.477351 
TMEM88 -1 -0.9962 8.281414 4.204806 1.685703 
EPCAM -1 -0.99605 8.012674 1.421146 3.699162 
TSHZ1 -1 -0.99768 5.76684 3.549243 2.490843 
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OSR1 -1 -0.99864 5.911354 4.89944 3.034315 
NDNF -1 -0.99573 7.755868 4.959952 2.273667 
FAM110B -0.99971 -0.9615 5.893586 2.858926 2.0205 
TMEM200A -1 -0.98677 6.609809 4.54988 2.471675 
FLRT3 -1 -0.99992 11.71001 2.857839 3.323295 
RSPO2 -1 -0.98042 5.719607 4.603523 2.394453 
REEP1 -1 -0.99862 9.033056 4.04275 0.852762 
CTHRC1 -1 -0.99862 8.530364 4.270829 2.735034 
TMEM119 -1 -0.99976 7.568417 5.020092 3.16296 
HBZ -1 -0.99451 7.102326 2.841429 4.268472 
SLIT3 -1 -0.9889 6.504 3.136287 2.459745 
CD248 -1 -0.97829 7.223254 6.151601 2.975828 
MAB21L2 -1 -0.99982 8.168393 2.870649 2.087563 
GPC6 -1 -0.99985 6.087021 3.077187 1.868578 
DSC3 -1 -0.98015 7.702813 2.949513 1.052887 
IFITM1 -1 -0.98948 6.026868 4.574779 1.737948 
CDH3 -1 -0.99443 6.323749 3.145868 2.18805 
MYL4 -1 -0.98138 7.870759 2.461171 3.26288 
AKR1B10 -1 -0.99588 7.158083 2.770126 1.387845 
HS6ST2 -1 -0.99254 6.006891 3.113056 2.3427 
CYTL1 -1 -0.99661 6.758688 3.667129 0.915346 
CDC42EP5 -1 -0.99727 6.718535 6.34062 1.102656 
IFITM1 -1 -0.99015 6.506348 4.55697 1.63668 
S1PR3 -0.95736 -0.93724 6.881802 2.458088 2.214965 
TMEM100 -1 -0.99171 5.963785 3.954433 2.495345 
CLDN3 -1 -0.98888 8.725134 2.710618 1.899637 
THBD -1 -0.99986 11.04372 3.036152 0.803528 
SERPINA3 -0.9805 -0.94329 5.634335 3.146055 2.260811 
TNNC1 -1 -0.99895 5.767938 3.582013 3.104565 
KCTD12 -0.94094 -0.93558 8.172536 3.826093 2.355453 
TGFBR3 -0.92077 -0.89025 5.029718 6.453567 1.868401 
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Table 9-5. Identified Dynamically Differentially Expressed Genes that Retain the 
Same Dynamics in hHLCs and mHLCs 
Gene Name 
ADD2 
ALDH4A1 
ANGPT1 
ANKS1A 
APOA4 
ARC 
BIN1 
BIRC5 
BNC1 
CCDC109B 
CDC42EP5 
CDH11 
CDH13 
CDH3 
CDX2 
CITED2 
CLEC11A 
COL15A1 
COL1A1 
COL3A1 
CPE 
CRISPLD2 
CXCL14 
CXXC4 
DGAT1 
DIO1 
DPEP1 
DSC3 
E2F2 
ECHDC3 
FAM110B 
FAM198B 
FBLN1 
FBXO2 
FLRT3 
FOXM1 
GATA5 
GPX3 
HAND1 
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HSPA12A 
IGF1 
INMT 
KANK4 
LAMB1 
LCP1 
LEFTY1 
LEFTY2 
MAPK13 
MDK 
MNS1 
MTHFD1 
MYL4 
NDNF 
NODAL 
OSR1 
P4HA2 
PARM1 
PDGFC 
PDGFD 
PKIA 
PLAT 
PROS1 
RGS1 
RGS4 
RIN2 
RSPO2 
S1PR3 
SBSPON 
SCUBE2 
SEMA3C 
SERPINA3 
SERPINI1 
SHISA2 
SLC1A1 
SLC1A3 
SLC51A 
SLCO2B1 
SLIT2 
SNAI2 
SOCS2 
SOSTDC1 
SOX9 
225 
 
SPARC 
SPC25 
SPINT1 
SPON1 
SYT4 
THY1 
TK1 
TMEM100 
TMEM119 
TNNC1 
TSC22D3 
TSHZ1 
TSPAN3 
UCP2 
VCAN 
VEGFC 
WNT5A 
 
